

Cochrane Database of Systematic Reviews

Nitrous oxide-based techniques versus nitrous oxide-free techniques for general anaesthesia (Review)

Sun R, Jia WQ, Zhang P, Yang K, Tian JH, Ma B, Liu Y, Jia RH, Luo XF, Kuriyama A

Sun R, Jia WQ, Zhang P, Yang K, Tian JH, Ma B, Liu Y, Jia RH, Luo XF, Kuriyama A. Nitrous oxide-based techniques versus nitrous oxide-free techniques for general anaesthesia. *Cochrane Database of Systematic Reviews* 2015, Issue 11. Art. No.: CD008984. DOI: 10.1002/14651858.CD008984.pub2.

www.cochranelibrary.com



TABLE OF CONTENTS

| ABSTRACT |
|--|
| PLAIN LANGUAGE SUMMARY |
| SUMMARY OF FINDINGS |
| BACKGROUND |
| DBJECTIVES |
| METHODS |
| RESULTS |
| Figure 1 |
| Figure 2 |
| Figure 3 |
| Figure 4 |
| DISCUSSION |
| AUTHORS' CONCLUSIONS |
| ACKNOWLEDGEMENTS |
| REFERENCES |
| CHARACTERISTICS OF STUDIES |
| DATA AND ANALYSES |
| Analysis 1.1. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 1 Inhospital case fatality rate |
| Analysis 1.2. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 2 Pneumonia |
| Analysis 1.3. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 3 Pulmonary atelectasis |
| Analysis 1.4. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 4 Myocardial infarction |
| Analysis 1.5. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 5 Stroke. |
| Analysis 1.6. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 6 Severe nausea and vomiting |
| Analysis 1.7. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 7 Venous thromboembolism |
| Analysis 1.8. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 8 Wound infection rate. |
| Analysis 1.9. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 9 Length of hospital stay. |
| Analysis 1.10. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 10 Inhospital case fatality rate: type of 8 surgery. |
| Analysis 1.11. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 11 Pneumonia: type of surgery |
| Analysis 1.12. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 12 Pulmonary atelectasis: type of surgery. |
| Analysis 1.13. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 13 Myocardial infarction: type of surgery. |
| Analysis 1.14. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 14 Stroke: type of surgery |
| Analysis 1.15. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 15 Severe nausea and vomiting: type of surgery. |
| Analysis 1.16. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 16 Wound infection rate: type of surgery. |
| Analysis 1.17. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 17 Length of hospital stay: type of surgery. |
| Analysis 1.18. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 18 Inhospital case fatality rate: 8 concentrations of inhaled nitrous oxide. |
| Analysis 1.19. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 19 Stroke: concentrations of inhaled 9 nitrous oxide. |
| Analysis 1.20. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 20 Severe nausea and vomiting: 9 concentrations of inhaled nitrous oxide. |
| Analysis 1.21. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 21 Length of hospital stay: concentrations 9 of inhaled nitrous oxide. |
| Analysis 1.22. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 22 Inhospital case fatality rate: techniques used in the nitrous oxide-free group. |
| Analysis 1.23. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 23 Pneumonia: techniques used in the 9 nitrous oxide-free group. |
| Analysis 1.24. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 24 Pulmonary atelectasis: techniques used in the nitrous oxide-free group. |



| Analysis 1.25. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 25 Myocardial infarction: techniques used in the nitrous oxide-free group. | 94 |
|--|-----|
| Analysis 1.26. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 26 Stroke: techniques used in the nitrous oxide-free group. | 94 |
| Analysis 1.27. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 27 Severe nausea and vomiting: techniques used in the nitrous oxide-free group. | 95 |
| Analysis 1.28. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 28 Wound infection rate: techniques used in the nitrous oxide-free group. | 96 |
| Analysis 1.29. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 29 Length of hospital stay: techniques used in the nitrous oxide-free group. | 96 |
| APPENDICES | 97 |
| CONTRIBUTIONS OF AUTHORS | 102 |
| DECLARATIONS OF INTEREST | 103 |
| SOURCES OF SUPPORT | 103 |
| DIFFERENCES BETWEEN PROTOCOL AND REVIEW | 103 |
| INDEX TERMS | 104 |

[Intervention Review]

Nitrous oxide-based techniques versus nitrous oxide-free techniques for general anaesthesia

Rao Sun¹, Wen Qin Jia², Peng Zhang³, KeHu Yang⁴, Jin Hui Tian¹, Bin Ma¹, Yali Liu¹, Run H Jia⁵, Xiao F Luo⁶, Akira Kuriyama⁷

¹Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou City, China. ²Department of Anesthesia, Gansu Provincial Hospital, Lanzhou City, China. ³Department of Pediatric Surgery, Nanyang Central Hospital, Nanyang, China. ⁴Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province, Lanzhou University, Lanzhou City, China. ⁵Department of Radiology, Chinese Medicine Hospital in Gansu Province, Lanzhou City, China. ⁶Epidemiology and Health Statistics Institution of School of Public Health, Lanzhou University, Lanzhou City, China. ⁷Department of General Medicine, Kurashiki Central Hospital, Kurashiki, Japan

Contact: KeHu Yang, Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province, Lanzhou University, No. 199, Donggang West Road, Lanzhou City, Gansu, 730000, China. yangkh@lzu.edu.cn, Yangkh2006@163.com.

Editorial group: Cochrane Anaesthesia Group. **Publication status and date:** New, published in Issue 11, 2015.

Citation: Sun R, Jia WQ, Zhang P, Yang K, Tian JH, Ma B, Liu Y, Jia RH, Luo XF, Kuriyama A. Nitrous oxide-based techniques versus nitrous oxide-free techniques for general anaesthesia. *Cochrane Database of Systematic Reviews* 2015, Issue 11. Art. No.: CD008984. DOI: 10.1002/14651858.CD008984.pub2.

Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Nitrous oxide has been used for over 160 years for the induction and maintenance of general anaesthesia. It has been used as a sole agent but is most often employed as part of a technique using other anaesthetic gases, intravenous agents, or both. Its low tissue solubility (and therefore rapid kinetics), low cost, and low rate of cardiorespiratory complications have made nitrous oxide by far the most commonly used general anaesthetic. The accumulating evidence regarding adverse effects of nitrous oxide administration has led many anaesthetists to question its continued routine use in a variety of operating room settings. Adverse events may result from both the biological actions of nitrous oxide and the fact that to deliver an effective dose, nitrous oxide, which is a relatively weak anaesthetic agent, needs to be given in high concentrations that restrict oxygen delivery (for example, a common mixture is 30% oxygen with 70% nitrous oxide). As well as the risk of low blood oxygen levels, concerns have also been raised regarding the risk of compromising the immune system, impaired cognition, postoperative cardiovascular complications, bowel obstruction from distention, and possible respiratory compromise.

Objectives

To determine if nitrous oxide-based anaesthesia results in similar outcomes to nitrous oxide-free anaesthesia in adults undergoing surgery.

Search methods

We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2014 Issue 10); MEDLINE (1966 to 17 October 2014); EMBASE (1974 to 17 October 2014); and ISI Web of Science (1974 to 17 October 2014). We also searched the reference lists of relevant articles, conference proceedings, and ongoing trials up to 17 October 2014 on specific websites (http://clinicaltrials.gov/, http://controlled-trials.com/, and http://www.centerwatch.com).

Selection criteria

We included randomized controlled trials (RCTs) comparing general anaesthesia where nitrous oxide was part of the anaesthetic technique used for the induction or maintenance of general anaesthesia (or both) with any general anaesthesia using a volatile anaesthetic or propofol-based maintenance of anaesthesia but no nitrous oxide for adults undergoing surgery. Our primary outcome was inhospital case fatality rate. Secondary outcomes were complications and length of stay.



Data collection and analysis

Two review authors independently assessed trial quality and extracted the outcome data. We used meta-analysis for data synthesis. Heterogeneity was examined with the Chi² test and by calculating the l² statistic. We used a fixed-effect model if the measure of inconsistency was low for all comparisons (l² statistic < 50%); otherwise we used a random-effects model for measures with high inconsistency. We undertook subgroup analyses to explore inconsistency and sensitivity analyses to evaluate whether the results were robust. We assessed the quality of evidence of the main outcomes using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system.

Main results

We included 35 trials (13,872 adult participants). Seven included studies were at low risk of bias. We identified eight studies as awaiting classification since we could not obtain the full texts, and had insufficient information to include or exclude them. We included data from 24 trials for quantitative synthesis. The results of meta-analyses showed that nitrous oxide-based techniques increased the incidence of pulmonary atelectasis (odds ratio (OR) 1.57, 95% confidence interval (CI) 1.18 to 2.10, P = 0.002), but had no effects on the inhospital case fatality rate, the incidence of pneumonia, myocardial infarction, stroke, severe nausea and vomiting, venous thromboembolism, wound infection, or the length of hospital stay. The sensitivity analyses suggested that the results of the meta-analyses were all robust except for the outcomes of pneumonia, and severe nausea and vomiting. Two trials reported length of intensive care unit (ICU) stay but the data were skewed so were not pooled. Both trials reported that nitrous oxide-based techniques had no effects on the length of ICU stay. We rated the quality of evidence for two outcomes (pulmonary atelectasis, myocardial infarction) as high, four outcomes (inhospital case fatality rate, stroke, venous thromboembolism, length of hospital stay) as moderate, and three (pneumonia, severe nausea and vomiting, wound infection rate) as low.

Authors' conclusions

Given the evidence from this Cochrane review, the avoidance of nitrous oxide may be reasonable in participants with pre-existing poor pulmonary function or at high risk of postoperative nausea and vomiting. Since there are eight studies awaiting classification, selection bias may exist in our systematic review.

PLAIN LANGUAGE SUMMARY

Nitrous oxide (laughing gas)-based techniques versus nitrous oxide-free techniques for general anaesthesia

Review question

We reviewed the evidence about the harmful effects of nitrous oxide on people undergoing general anaesthesia.

Background

Nitrous oxide is an anaesthetic gas which has been used for more than 160 years for inducing anaesthesia and keeping patients anaesthetized throughout an operation. It is also known as 'laughing gas'. It is a colourless non-flammable gas with a pleasant, faint sweet odour and taste. Its low cost and low toxicity have made nitrous oxide by far the most commonly used general anaesthetic. However, some studies have reported that adding nitrous oxide may lead to harmful effects. This has led many anaesthetists to question its continued routine use in a variety of operating room settings.

We wanted to discover whether using nitrous oxide in general anaesthesia was better or worse than not using nitrous oxide.

Study characteristics

We examined the evidence available up to 17 October 2014. We included 35 trials involving 13,872 adult participants, all of whom were randomized to either receive nitrous oxide or no nitrous oxide. The trials covered a variety of situations during general anaesthesia.

Key results

We found that general anaesthesia with nitrous oxide increased the risk of pulmonary atelectasis (i.e. failure of the lungs to expand fully). When we restricted the results to the highest quality studies only, we found evidence that nitrous oxide may potentially increase the risk of pneumonia and severe nausea and vomiting. However, nitrous oxide had no effect on the patients' survival, the incidence of heart attack, stroke, wound infection, the occurrence of blood clots within veins, the length of hospital stay, or the length of intensive care unit stay.

Quality of the evidence

The evidence related to survival of participants was of moderate quality because we did not have enough data. The evidence related to some harmful effects, such as failure of the lungs to expand fully and heart attack, was of high quality, while for other harmful effects, such as stroke and the occurrence of blood clots within veins, the evidence was of moderate quality. For others, such as pneumonia, severe nausea and vomiting, and wound infection, the evidence was of low quality. The evidence related to the length of time spend in hospital was of moderate quality.



Authors conclusions

The avoidance of nitrous oxide may be reasonable in participants with pre-existing poor pulmonary function or at high risk of postoperative nausea and vomiting.

Nitrous oxide-based techniques versus nitrous oxide-free techniques for general anaesthesia (Review) Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. SUMMARY OF FINDINGS

Summary of findings for the main comparison. Summary of findings' table 1

Nitrous oxide-based compared to nitrous oxide-free for general anaesthesia

Patient or population: adult patients 18 years and above undergoing standard general anaesthesia Settings: operating room

Intervention: nitrous oxide-based techniques **Comparison:** nitrous oxide-free techniques

| Outcomes | Illustrative comparat | tive risks* (95% CI) | Relative effect | No of partici- pants | Quality of the | Comments |
|-----------------|-----------------------|------------------------------------|-----------------------------------|-------------------------|--------------------|---|
| | Assumed risk | Corresponding risk | - (55% CI) | (studies) | (GRADE) | |
| | nitrous oxide-free | Nitrous oxide-based | | | | |
| Inhospital case | Study population | | OR 0.87 | 10148 (8 studies) | ⊕⊕⊕⊝ modorato 1 | _ |
| | 12 per 1000 | 11 per 1000 (8 to 16) | (0.01 (0 1.20) | (0 studies) | nouerate - | |
| | Moderate | | | | | |
| | 0 per 1000 | 0 per 1000 (0 to 0) | | | | |
| Pneumonia | Study population | | OR 1.68 | 2699 (8 studies) | ⊕⊕©© Iow 2.3 | The sensitivi- |
| | 17 per 1000 | 27 per 1000 (17 to 45) | (1 to 2.01) (0 statics) (0 | | | gested that the results of meta- analysis was |
| | Moderate | | | | | not robust. |
| | 11 per 1000 | 18 per 1000 (11 to 30) | | | | |
| Pulmonary at- | Study population | | OR 1.57 | 2400 (5 studies) | ⊕⊕⊕⊕ hiah | _ |
| electasis | 79 per 1000 | 119 per 1000 (92 to 153) | (1.10 (0 2.1) | (5 studies) | ingn | |
| | Moderate | | | | | |



| | 50 per 1000 | 76 per 1000 (58 to 100) | | | | |
|------------------------------|------------------|--|------------------|-----------------------|-------------------------------|---|
| Myocardial in- | Study population | | OR 1.01 | 9246 (6 studies) | ⊕⊕⊕⊕ hiah | _ |
| | 51 per 1000 | 51 per 1000 (43 to 61) | - (0.04 (0 1.22) | (o studies) | ingn | |
| | Moderate | | | | | |
| | 65 per 1000 | 66 per 1000 (55 to 78) | | | | |
| Stroke | Study population | | OR 1.47 | 9142 (4 studies) | ⊕⊕⊕⊝ modorato 3 | _ |
| | 5 per 1000 | 7 per 1000 (4 to 12) | - (0.00 to 2.00) | (+ studies) | moderate ^o | |
| | Moderate | | | | | |
| | 3 per 1000 | 4 per 1000 (3 to 8) | | | | |
| Severe nausea | Study population | | OR 1.44 | 11045 (10 studios) | ⊕⊕⊝⊝ Low 4 5 | The sensitivi- |
| | 95 per 1000 | 131 per 1000 (92 to 184) | - (0.97 to 2.13) | (10 studies) | IOM 1,0 | gested that the results of meta- analysis was |
| | Moderate | | | | | not robust. |
| | 108 per 1000 | 148 per 1000 (105 to 207) | | | | |
| Length of hos- pital stay | | The mean length of hospital stay in the interven- tion groups was 0.36 higher (0.69 lower to 1.4 higher) | | 1103 (6 studies) | ⊕⊕⊕⊝ moderate ⁵ | _ |

Cl: confidence interval; OR: odds ratio.

GRADE Working Group grades of evidence

High quality: further research is very unlikely to change our confidence in the estimate of effect.

ы

Cochrane Database of Systematic Reviews

Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low quality:** further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low quality:** we are very uncertain about the estimate.

¹Serious imprecision: 95% CI of OR includes both 1.0 and 0.75/1.25. Downgraded by one level.

²Serious risk of bias: all studies were described as randomized but details were only provided by three; four studies described allocation concealment. Two studies blinded participants and personnel; six studies blinded outcome assessors. Downgraded by one level.

³Serious imprecision: 95% CI of OR includes both 1.0 and 1.25. Downgraded by one level.

⁴Serious risk of bias: all studies were described as randomized but details were only provided by three; four studies described allocation concealment. Four studies blinded participants and personnel; seven studies blinded outcome assessors. Downgraded by one level.

⁵Serious inconsistency: substantial heterogeneity with I² statistic > 50%. Downgraded by one level.

Summary of findings 2. 'Summary of findings' table 2

Nitrous oxide-based compared to nitrous oxide-free for general anaesthesia

Patient or population: adult patients 18 years and above undergoing standard general anaesthesia

Settings: operating room

Intervention: nitrous oxide-based techniques

Comparison: nitrous oxide-free techniques

| Outcomes | Illustrative comparative ri | Relative effect | No of partici- pants | Quality of the evidence | Comments | |
|-----------------------------|-----------------------------|------------------------------------|-------------------------------|-------------------------|--------------------|---|
| | Assumed risk | Corresponding risk | Corresponding risk | | (GRADE) | |
| | nitrous oxide-free | Nitrous oxide-based | | | | |
| Venous throm- boembolism | s throm- Study population | | OR 0.73 (0.45 to 1.2) | 9004 (2 studies) | ⊕⊕⊕⊝ modorato 1 | _ |
| | 8 per 1000 | 6 per 1000 (4 to 10) | (0.10 (0 112) | (| moderate | |
| | Moderate | | | | | |
| | 11 per 1000 | 8 per 1000 (5 to 13) | | | | |
| Wound infec- tion rate | nfec- Study population | | OR 1.22 (0.84 to 1.78) | 9789 (6 studies) | ⊕⊕⊝⊝ Low 2 3 | _ |
| | 88 per 1000 | 106 per 1000 (75 to 147) | (| (| | |

Cochrane Database of Systematic Reviews

Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

techniques versus nitrous oxide-free techniques for general anaesthesia (Review)

Nitrous oxide-based

| Moderate | | |
|-------------|-----------------------------------|--|
| 83 per 1000 | 99 per 1000 (71 to 139) | |

*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **CI:** Confidence interval; **OR:** Odds ratio.

GRADE Working Group grades of evidence

High quality: further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: we are very uncertain about the estimate.

 $^1\!Serious$ imprecision: 95% CI of OR includes both 1.0 and 0.75. Downgraded by one level.

²Serious inconsistency: substantial heterogeneity with I² statistic > 50%. Downgraded by one level.

³Serious imprecision: 95% CI of OR includes both 1.0 and 1.25. Downgraded by one level.

Cochrane

Trusted evidence. Informed decisions. Better health.



BACKGROUND

Description of the condition

Nitrous oxide, also known as laughing gas, is a colourless nonflammable gas with a pleasant, faintly sweet odour and taste. The gas has been in use for more than 160 years for the induction and maintenance of general anaesthesia. It has been used as a sole agent but is most often employed as part of a technique using other anaesthetic gases, intravenous agents, or both. Its low tissue solubility (and therefore rapid kinetics), low cost, and low rate of cardiorespiratory complications have made nitrous oxide by far the most commonly used general anaesthetic. Worldwide, it is given to more than one billion surgical patients annually (Fleischmann 2005).

The accumulating evidence regarding adverse effects of nitrous oxide administration has led many anaesthetists to question its continued routine use in a variety of operating room settings. Adverse events may result from both the biological actions of nitrous oxide and the fact that to deliver an effective dose, nitrous oxide, which is a relatively weak anaesthetic agent, needs to be given in high concentrations that restrict oxygen delivery (for example, a common mixture is 30% oxygen with 70% nitrous oxide).

The disadvantages of nitrous oxide have been reported. Concerns have been raised regarding the risk of compromising the immune system (Parbrook 1967), low blood oxygen levels (Cheney 2007), impaired cognition (mental ability) (Culley 2007; Linde 1969), postoperative cardiovascular complications (Myles 2008b), as well as bowel obstruction from distention and possible respiratory compromise (Eger 1965). In addition, nitrous oxide may increase the risk of developing brain damage from reduced cerebral blood flow (Lehmberg 2008; Pasternak 2009). Finally, nitrous oxide is a proven risk factor for nausea and vomiting (Apfel 2004).

Description of the intervention

As a weak anaesthetic, nitrous oxide is generally not used alone in general anaesthesia. Although there is considerable variation in how this drug is used, a typical scenario would be the maintenance of surgical anaesthesia, for whatever period required, by the administration of 69% nitrous oxide, 29% oxygen, and 2% of a potent volatile anaesthetic agent such as sevoflurane. Alternatively, an intravenous drug could be continuously infused while the patient breathes 70% nitrous oxide and 30% oxygen. The effect of nitrous oxide is to reduce the dose of either a volatile or intravenous anaesthetic that is required to maintain an appropriate level of anaesthesia.

How the intervention might work

As is the case with other gaseous anaesthetic agents, the exact mechanism of action of nitrous oxide is not completely understood. Theories include antagonism at both the N-methyl-D-aspartate (NMDA) excitatory receptors and central nicotinic receptors; and a similar inhibitory effect at the two-pore K⁺ channel TWIK-related potassium channel-1 (TREK-1), a potassium channel involved in polymodal pain perception, to display analgesic, anxiolytic, and amnesic properties (Gruss 2004; Jevtović-Todorović 1998; Yamakura 2000).

As suggested above, nitrous oxide is often used as one component of a balanced anaesthetic approach. This has several potential advantages including a reduction in the requirements for other agents, and consequently a reduced incidence and severity of any adverse effects of those agents, a rapid onset of anaesthetic effect, and a more rapid recovery of consciousness once the anaesthesia is discontinued (Becker 2008). These advantages need to be balanced against the potential disadvantages of nitrous oxide. Mechanistically, many of the adverse effects of nitrous oxide are ascribed to the inactivation of the cobalamin form of vitamin B12, by oxidation, thereby inhibiting the action of methionine synthase, folate metabolism, and deoxyribonucleic acid synthesis. All of these are important for protein production and DNA synthesis (Guirguis 1990; Perry 1983; Rowland 1995). Moreover, nitrous oxide depresses some white cells' ability to respond to various stimuli and reduces the growth of other white cell elements (mononucleocytes) (Kripke 1987).

Why it is important to do this review

As nitrous oxide administration brings both advantages and disadvantages, a systematic review will assist the individual anaesthetist in making the most appropriate choice of anaesthetic technique on an individual patient basis. The balance of risk versus benefit is likely to depend on many factors. The aim of this Cochrane review was to quantitatively evaluate if nitrous oxide was responsible for clinically significant adverse events following general anaesthesia that could be safely avoided by the use of alternative agents. This may have a wide impact on the conduct of general anaesthesia.

OBJECTIVES

To determine if nitrous oxide-based anaesthesia results in similar outcomes to nitrous oxide-free anaesthesia in adults undergoing surgery.

METHODS

Criteria for considering studies for this review

Types of studies

We included only randomized controlled trials (RCTs).

Types of participants

We included participants, aged 18 years and older, undergoing surgery with standard general anaesthesia.

Types of interventions

Intervention:

General anaesthesia where nitrous oxide was part of the anaesthetic technique used for the induction or maintenance of general anaesthesia, or both.

Control:

General anaesthesia using a volatile anaesthetic or propofol-based maintenance of anaesthesia but no nitrous oxide.

Types of outcome measures

Primary outcomes

1. Inhospital case fatality rate (number or proportion of deceased participants after a defined period following anaesthesia).



Secondary outcomes

1. Pulmonary complications:

1.1 Pneumonia: We accepted any definition used by the authors of included papers;

1.2 Pulmonary atelectasis: We accepted any definition used by the authors of included papers.

2. Heart complications:

2.1 Myocardial infarction: We accepted any definition of myocardial infarction used by the authors of included papers.

3. Neurological complications:

3.1 Stroke: We accepted any definition of stroke used by the authors of included papers. Where there was no definition, we accepted in the outcome any participant with new neurological signs (paralysis, weakness or speech difficulties) that persisted for 24 hours or leaded to early death.

4. Other complications:

4.1 Severe nausea and vomiting: We accepted any definition of severe nausea and vomiting made by the authors of included trials. Where there was no definition, we accepted into the outcome any participant with at least two episodes of vomiting or who required at least three doses of antiemetic medication within 24 hours of surgery;

4.2 Venous thromboembolism: We accepted any definition of deep venous thrombosis or pulmonary embolism used by the authors of included papers;

4.3 Wound infection rate: We accepted any definition of wound infection made by the authors of included trials.

5. Length of stay:

5.1 Length of hospital stay: We accepted any definition of length of hospital stay made by the authors of included trials;

5.2 Length of intensive care unit (ICU) stay: We accepted any definition of length of ICU stay made by the authors of included trials.

Search methods for identification of studies

Electronic searches

We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2014 Issue 10); MEDLINE (1966 to 17 October 2014); EMBASE (1974 to 17 October 2014); and ISI Web of Science (1974 to 17 October 2014).

We developed a specific strategy for each database (Appendix 1 for CENTRAL; Appendix 2 for MEDLINE; Appendix 3 for EMBASE; and Appendix 4 for ISI Web of Science).

Searching other resources

Two review authors (RS, WQJ) examined the reference lists of any retrieved articles for additional relevant publications. In addition, two review authors (BM, YL) manually searched conference proceedings and review articles for relevant studies. We contacted relevant trial authors to identify any additional or ongoing studies. We also searched for relevant trials on specific websites: http://clinicaltrials.gov/; http://controlled-trials.com/; and http:// www.centerwatch.com. We did not apply any language restrictions.

Data collection and analysis

Two review authors (RS, WQJ) developed and used a standardized data extraction form in accordance with the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011). Two review authors (RS, XFL) independently checked and entered data into RevMan 5.3 for statistical analysis.

Selection of studies

One review author (WQJ) scanned the titles and abstracts of articles retrieved by the search and removed those that did not meet our inclusion criteria. Three review authors (JHT, WQJ, RS) retrieved the full text of all potentially eligible studies. Two review authors (RS, WQJ) independently examined the full text articles for compliance with the inclusion criteria and selected studies eligible for inclusion in the review. We resolved any disagreement as to study eligibility by discussion with a third review author (KHY).

Data extraction and management

We extracted data from eligible studies using a data form we had designed and pilot-tested (Appendix 5). When a study either overlapped or was a duplicate of another study, WQ Jia and P Zhang contacted the study authors for clarification and, if confirmed, used the publication with the more detailed data for this systematic review and combined the additional data. Two review authors (RS, PZ) contacted the original study authors for additional data for included outcomes that were not published in the study. Two review authors (WQJ, RS) independently extracted the data and resolved any disagreement by consulting a third review author (KHY).

We extracted the following information:

- Study design (RCT).
- Participants (number, age, gender, American Society of Anesthesiologists (ASA) physical status classification, disease, type of surgery).
- Intervention (concentration of nitrous oxide, mixed inhaled anaesthetic, concentration of oxygen, duration of inhaled nitrous oxide).
- Quality assessment (sequence generation, allocation concealment, blinding, incomplete outcome data, other issues).
- Outcome (primary and secondary outcomes, methods used to assess outcomes, time of follow-up).

Assessment of risk of bias in included studies

Two review authors (RS, BM) independently assessed the quality of the studies by constructing a 'Risk of bias' table for each study which included sequence generation, allocation concealment, blinding, incomplete outcome data, selective reporting, and other bias (Higgins 2011). Any disagreements were resolved by discussion between the two review authors.

We assessed the quality factors of each study separately. These were classified as either 'low', 'high', or 'unclear' risk of bias.

Measures of treatment effect

Considering dichotomous variables, we expressed the difference in the number of events in the nitrous oxide-based group and the nitrous oxide-free group as an odds ratio (OR) for complications and Peto odds ratio (Peto OR) for the inhospital case fatality rate.



For length of stay, we only pooled the data expressed as mean and standard deviation (SD). The effect size for length of stay was the mean difference (MD). We presented 95% confidence intervals (CIs) for all outcomes.

Unit of analysis issues

Non-standard design RCTs can present statistical problems. Whilst we did not anticipate including crossover or cluster randomized designs in this Cochrane review, we expected multiple intervention groups. We took care to avoid 'unit of analysis' errors when analysing these types of trials (Higgins 2011).

Dealing with missing data

In the event of missing data, two review authors (WQJ, RS) tried to contact the authors of the original studies in order to obtain the necessary information. Two review authors (XFL, RS) analysed the data on an intention-to-treat (ITT) basis as far as possible.

Assessment of heterogeneity

We considered whether the clinical and methodological characteristics of the included studies were sufficiently similar for meta-analysis to provide a meaningful summary. Statistically, we examined heterogeneity with the Chi² test and by calculating the I² statistic. We considered heterogeneity to be substantial when the I² statistic > 50% and carefully considered the data before reporting any pooled results (Higgins 2002). If substantial heterogeneity was detected, we explored possible explanations in subgroup analyses.

Assessment of reporting biases

We conducted a comprehensive search for eligible studies. If there were 10 or more studies in an analysis, we used a funnel plot to explore the possibility of publication bias and other reporting biases. In the analyses for dichotomous outcomes we also assessed publication bias statistically with the use of Egger's test (Egger 1997) performed with Stata 11.0. We based evidence of asymmetry on P < 0.05.

Data synthesis

We used meta-analysis for data synthesis. We used a fixed-effect model if the measure of inconsistency was low for all comparisons (l^2 statistic < 50%); otherwise we used a random-effects model for measures with high inconsistency. Where we did not conduct meta-analysis, we described the findings of the included studies qualitatively.

We included the following outcomes in the 'Summary of findings' tables:

- Inhospital case fatality rate.
- Pneumonia.
- Pulmonary atelectasis.

- Myocardial infarction.
- Stroke.
- Severe nausea and vomiting.
- Length of hospital stay.
- Venous thromboembolism.
- Wound infection rate.

We rated the quality of evidence for each outcome following the guidelines of Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach (Schünemann 2009) and based on the following five downgrade factors: risk of bias, inconsistency, indirectness, imprecision, and publication bias. For each downgrade factor, a judgment of 'no', 'serious (downgrade the quality of evidence by one level)', or 'very serious (downgrade the quality of evidence by two levels)' was assigned. At the very beginning, we classified all the outcomes as at 'high' quality by default, and after rating, each outcome could receive a grade of either 'high', 'moderate', 'low', or 'very low' quality.

Subgroup analysis and investigation of heterogeneity

We undertook subgroup analyses as follows, as stated in the Cochrane protocol (Yang 2011):

- 1. Type of surgery (day-case procedures/examinations versus intra-abdominal surgery versus neurosurgery versus vascular surgery versus ophthalmic surgery versus breast surgery).
- 2. Different concentrations of inhaled nitrous oxide (high concentration [higher than 50%] versus low concentration [equal to or lower than 50%]).
- 3. Different intervention in the nitrous oxide-free group (propofolbased maintenance of anaesthesia versus volatile anaestheticbased maintenance of anaesthesia).

Sensitivity analysis

To evaluate whether the results of the systematic review were robust, we conducted sensitivity analyses based on the methodological quality (high quality versus low quality) and the percentages of withdrawals (above 10% versus below 10%) of the included RCTs.

RESULTS

Description of studies

See: Characteristics of included studies; Characteristics of excluded studies; and Characteristics of studies awaiting classification sections.

Results of the search

The number of potential RCTs screened for inclusion in this Cochrane review is outlined in the study flow diagram (Figure 1).

Figure 1. Study flow diagram.



Nitrous oxide-based techniques versus nitrous oxide-free techniques for general anaesthesia (Review) Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Figure 1. (Continued)



We identified a total of 2906 references through searches of electronic databases and a further 229 through other resources. After removing the duplicates, we screened 2127 unique references. We excluded 2040 records based on titles and abstracts, and a further eight studies are awaiting classification (see Characteristics of studies awaiting classification) as we were unable to obtain their full texts from either our university library, the Danish National Library, or Cochrane Anaesthesia, Critical and Emergency Care Group members. We assessed 79 full text papers, of which 38 reports (consisting of 35 trials) were eligible for inclusion in this Cochrane review.

Included studies

We included 35 trials in this Cochrane review; see Characteristics of included studies.

Four studies included participants who had undergone day-case procedures or examinations (Arellano 2000; Sengupta 1988; Short 1985; Van Hemelrijck 1991); 14 studies included participants who had undergone intra-abdominal surgery (Akca 2004; Brodsky 2005; Chen 2013; Fleischmann 2005; Jensen 1992; Jensen 1993a; Jensen 1993b; Krogh 1994; Lee 2005; Lonie 1986; Mraovic 2008; Paredi 1994; Pedersen 1993; Sukhani 1994); three studies included participants who had undergone neurosurgery (Lampe 1990; Singh 2011; Todd 1993); two studies included participants who had undergone vascular surgery (Badner 2000; Kozmary 1990); one study included participants who had undergone ophthalmic surgery (Deleu 2000); one study included participants who had undergone breast surgery (Vanacker 1999); one study included participants who had undergone orthopedic surgery (Alhashemi 1997); and one study included participants who had undergone thoracic surgery (Yoshimura 2014). Eight studies included participants who had undergone different types of surgery (Bloomfield 1988; Eger 1990; ENIGMA II trial 2014; ENIGMA trial 2007; Gilani 2008; Larsen 2000; Leung 2006; Myles 2008a).

Twenty-six studies used high concentrations of nitrous oxide in the nitrous oxide-based group (Akca 2004; Alhashemi 1997; Arellano 2000; Badner 2000; Chen 2013; Eger 1990; ENIGMA II trial 2014; ENIGMA trial 2007; Fleischmann 2005; Gilani 2008; Jensen 1992; Jensen 1993a; Jensen 1993b; Kozmary 1990; Krogh 1994; Lampe 1990; Larsen 2000; Lee 2005; Lonie 1986; Myles 2008a; Pedersen 1993; Short 1985; Singh 2011; Todd 1993; Van Hemelrijck 1991; Sukhani 1994); three studies used low concentrations of nitrous oxide (Brodsky 2005; Mraovic 2008; Yoshimura 2014); and one study used both low and high concentrations of nitrous oxide (Sengupta 1988). Five studies did not report the concentration of nitrous oxide (Bloomfield 1988; Deleu 2000; Leung 2006; Paredi 1994; Vanacker 1999).

Ten studies used propofol-based maintenance of anaesthesia in the nitrous oxide-free group (Alhashemi 1997; Arellano 2000; Deleu 2000; Jensen 1992; Jensen 1993b; Larsen 2000; Krogh 1994; Sukhani 1994; Todd 1993; Yoshimura 2014); 22 studies used volatile anaesthetic-based maintenance of anaesthesia in the nitrous oxide-free group (Akca 2004; Badner 2000; Bloomfield 1988; Brodsky 2005; Chen 2013; Eger 1990; Fleischmann 2005; Gilani 2008; Jensen 1993a; Kozmary 1990; Lampe 1990; Lee 2005; Leung 2006; Lonie 1986; Mraovic 2008; Paredi 1994; Pedersen 1993; Sengupta 1988; Short 1985; Singh 2011; Vanacker 1999; Van Hemelrijck 1991). Three studies used different techniques of anaesthesia in the nitrous oxide-free group (ENIGMA II trial 2014; ENIGMA trial 2007; Myles 2008a).

Of the 35 included trials, 24 trials reported outcomes identified as of interest for this review (Arellano 2000; Chen 2013; Deleu 2000; Eger 1990; ENIGMA II trial 2014; ENIGMA trial 2007; Fleischmann 2005; Jensen 1992; Jensen 1993a; Jensen 1993b; Kozmary 1990; Krogh 1994; Lampe 1990; Leung 2006; Mraovic 2008; Myles 2008a; Paredi 1994; Pedersen 1993; Sengupta 1988; Short 1985; Singh 2011; Todd 1993; Vanacker 1999; Van Hemelrijck 1991). Of the 11 trials excluded from the quantitative analysis, three reported quality of recovery (Brodsky 2005; Larsen 2000; Sukhani 1994); two reported non-severe nausea and vomiting (Bloomfield 1988; Lonie 1986); one reported myocardial ischaemia (Badner 2000); one reported bowel distension (Akca 2004); one reported costs of anaesthesia and postoperative care (Alhashemi 1997); one reported postoperative pioid consumption (Lee 2005); and one reported lung collapse score (Yoshimura 2014).

Excluded studies

We excluded 41 studies after full text assessment. We excluded six of those studies because they were not RCTs (Antonini 1994; Barr 1999; Divatia 1996; Dover 1994; Morimoto 1997; Wesner 2005); 11 for including participants aged lower than 18 years (Jastak 1973; Johnson 1997; Lim 1992; Losasso 1992; Nightingale 1992; Ogg 1983; Rocca 2000; Saïssy 2000; Taki 2003; Towey 1979; Van den Berg 1995); six for including participants not undergoing general anaesthesia (Atanassoff 1994; Castéra 2001; Haraguchi 1995; Heath 1996; Kryshtalskyj 1990; Masood 2002); and 18 for using nitrous oxide in the control group (Atassi 2005; Bronco 2010; Cheong 2000; Einarsson 1997; Fredman 1998; Gozdemir 2007; Haessler 1993; Holst 1993; Ishii 1994; Jellish 1996; Nishiyama 1998; Simpson 1977; Sinha 2006; Smith 1993; Vari 2010; Yamakage 2001; Yang 2004; Zuurmond 1986). See Characteristics of excluded studies.

Studies awaiting classification

Eight studies are awaiting classification (Adams 1994; Miralles Pardo 1991; Moussa 1995; Rashchupkin 2011; Röpcke 2001; Schaffranietz 2000; Segatto 1993; Shulunov 2002). We were unable to obtain full text articles of these eight publications from our university library, the Danish National Library, and Cochrane Anaesthesia, Critical and Emergency Care Group members. Of these eight studies, seven were published in non-English languages (three studies were in German, two studies were in Russian,

Cochrane Database of Systematic Reviews



one study was in Italian, and one study was in Spanish). See Characteristics of studies awaiting classification.

Ongoing studies

We did not identify any ongoing studies.

Risk of bias in included studies

We have summarized our 'Risk of bias' assessments for each included study in Figure 2 and as percentages across all studies in Figure 3. The details and reasons for each assessment are listed in the Characteristics of included studies section. Seven studies were at low risk of bias (Akca 2004; Arellano 2000; ENIGMA II trial 2014; ENIGMA trial 2007; Fleischmann 2005; Lee 2005; Leung 2006).



| Aleo 2004 | Random sequence generation (selection bias) | Allocation concealment (selection bias) | Blinding of participants and personnel (performance bias) | Blinding of outcome assessment (detection bias): Inhospital case fatality rate/len | Blinding of outcome assessment (detection bias): Complications | Incomplete outcome data (attrition bias) | Selective reporting (reporting bias) | • Other bias |
|---|---|---|---|--|--|--|--------------------------------------|----------------------------|
| Akca 2004 Albachemi 1997 | • | • | • | ? | | • | • | |
| Arellano 2000 | • | | • | ? | • | • | | |
| Badner 2000 | • | ? | ? | ? | • | • | • | • |
| Bloomfield 1988 | | 2 | ? | ? | • | • | • | • |
| Dioonniela 1300 | | · • | | | | _ | | i I |
| Brodsky 2005 | • | ? | ? | ? | • | • | • | • |
| Brodsky 2005 Chen 2013 | • | • ? • | ? ? | ? • | • | • | • | • |
| Brodsky 2005 Chen 2013 Deleu 2000 | • • • • • | • ? • ? | ? ? ? | ? • ? | • | • • • | • | • |
| Brodsky 2005 Chen 2013 Deleu 2000 Eger 1990 | • • • ? | ? • ? ? | ? ? ? ? | ? • ? | • • ? | • • ? ? | • • • | • |
| Brodsky 2005 Chen 2013 Deleu 2000 Eger 1990 ENIGMA II trial 2014 | • • ? ? • | • ? ? ? ? | ? ? ? ? | ? ? ? | • • ? • | • • ? ? | • • • | • • • • |
| Brodsky 2005 Chen 2013 Deleu 2000 Eger 1990 ENIGMA II trial 2014 ENIGMA trial 2007 | • • ? ? • | ? ? ? ? | ? ? ? * | ? ? ? * | • • • • | • • ? • • | • • • • | |
| Brodsky 2005 Chen 2013 Deleu 2000 Eger 1990 ENIGMA II trial 2014 ENIGMA trial 2007 Fleischmann 2005 | • • ? ? • • | • • • • • | ? ? ? • | ? ? ? ? ? | • • • • • | • • ? • • | • • • • • | • • • • • • |

Figure 2. 'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study.



Figure 2. (Continued)

| Jensen 1992 | ? | • | ? | • | ? | • | • | • |
|---------------------|---|---|---|---|---|---|---|---|
| Jensen 1993a | ? | ? | ? | • | • | • | • | • |
| Jensen 1993b | ? | ? | ? | ? | • | • | • | • |
| Kozmary 1990 | ? | ? | ? | ? | • | • | • | • |
| Krogh 1994 | ? | ? | ? | + | ? | + | • | • |
| Lampe 1990 | ? | ? | ? | + | • | ÷ | • | • |
| Larsen 2000 | ? | ? | • | ? | • | • | • | • |
| Lee 2005 | • | • | ? | ? | • | • | • | • |
| Leung 2006 | • | • | ? | • | ? | • | • | • |
| Lonie 1986 | ? | ? | ? | ? | • | ÷ | • | • |
| Mraovic 2008 | • | ? | ? | ? | • | • | • | • |
| Myles 2008a | • | • | • | • | ? | • | • | • |
| Paredi 1994 | ? | ? | | ? | • | • | • | • |
| Pedersen 1993 | ? | ? | • | ? | • | ? | • | |
| Sengupta 1988 | ? | ? | ? | ? | ? | ? | • | • |
| Short 1985 | ? | ? | ? | ? | • | ? | • | • |
| Singh 2011 | • | ? | • | • | • | • | • | • |
| Sukhani 1994 | ? | ? | | ? | • | • | • | • |
| Todd 1993 | ? | • | ? | • | ? | • | • | • |
| Vanacker 1999 | ? | • | ? | ? | ? | • | • | • |
| Van Hemelrijck 1991 | ? | ? | | ? | • | • | • | • |
| Yoshimura 2014 | • | ? | ? | ? | • | • | • | • |

Figure 3. 'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies.



Allocation

All included studies mentioned randomization in the methodology, but only 16 trials stated the actual method used for randomization (Akca 2004; Alhashemi 1997; Arellano 2000; Badner 2000; Bloomfield 1988; Brodsky 2005; Chen 2013; ENIGMA II trial 2014; ENIGMA trial 2007; Fleischmann 2005; Lee 2005; Leung 2006; Mraovic 2008; Myles 2008a; Singh 2011; Yoshimura 2014).

In 23 studies, the trial authors did not give the details of the method of concealment of allocation, and we categorized these studies as 'unclear'. Concealment was adequate in 12 studies (Akca 2004; Arellano 2000; Chen 2013; ENIGMA II trial 2014; ENIGMA trial 2007; Fleischmann 2005; Jensen 1992; Lee 2005; Leung 2006; Myles 2008a; Todd 1993; Vanacker 1999).

Blinding

Participants and personnel were blinded in eight studies (Akca 2004; Arellano 2000; ENIGMA II trial 2014; ENIGMA trial 2007; Fleischmann 2005; Myles 2008a; Pedersen 1993; Singh 2011); four studies were not blinded (Larsen 2000; Paredi 1994; Sukhani 1994; Van Hemelrijck 1991); and the remaining studies were unclear.

We have separated 'blinding of outcome assessment (detection bias)' by type of outcome as the impact of outcome assessor knowledge of allocation may vary across different outcomes.

We assessed the 13 studies reporting clinical endpoints of inhospital case fatality rate or length of stay as being at a low risk of detection bias, since the outcome measurements were unlikely to have been influenced by lack of blinding (Chen 2013; Eger 1990; ENIGMA II trial 2014; ENIGMA trial 2007; Fleischmann 2005; Jensen 1992; Jensen 1993a; Krogh 1994; Lampe 1990; Leung 2006; Myles 2008a; Singh 2011; Todd 1993). Of the 32 studies reporting clinical endpoints of complications, the outcome assessors were blinded in 25 studies (Akca 2004; Alhashemi 1997; Arellano 2000; Badner 2000; Bloomfield 1988; Brodsky 2005; Chen 2013; Eger 1990; ENIGMA II trial 2014; ENIGMA trial 2007; Fleischmann 2005; Jensen 1993a; Jensen 1993b; Kozmary 1990; Lampe 1990; Larsen 2000; Lee 2005; Lonie 1986; Mraovic 2008; Paredi 1994; Pedersen 1993; Singh 2011; Sukhani 1994; Van Hemelrijck 1991; Yoshimura 2014); outcome assessors were not blinded in one study (Short 1985); and the remaining studies were unclear (Deleu 2000; Gilani 2008; Jensen 1992; Sengupta 1988; Todd 1993; Vanacker 1999).

Incomplete outcome data

The number of participants entering the trials and the number subjected to analysis, as mentioned in the results, were the same in 21 studies (Akca 2004; Alhashemi 1997; Bloomfield 1988; Brodsky 2005; Gilani 2008; Jensen 1992; Jensen 1993b; Kozmary 1990; Krogh 1994; Lampe 1990; Larsen 2000; Lee 2005; Leung 2006; Lonie 1986; Myles 2008a; Paredi 1994; Sukhani 1994; Todd 1993; Vanacker 1999; Van Hemelrijck 1991; Yoshimura 2014). Of the 14 studies that had withdrawals, the missing outcome data was balanced in numbers across the intervention groups. Nine trials gave similar reasons for missing data across groups (Arellano 2000; Badner 2000; Chen 2013; ENIGMA II trial 2014; ENIGMA trial 2007; Fleischmann 2005; Jensen 1993a; Mraovic 2008; Singh 2011). The remaining five studies had insufficient information to enable us to form a judgment (Deleu 2000; Eger 1990; Pedersen 1993; Sengupta 1988; Short 1985).

Selective reporting

Two studies, ENIGMA II trial 2014 and ENIGMA trial 2007, were registered on ClinicalTrials.gov (NCT00430989 and NCT00164047, respectively). The study protocols were available and all of the pre-specified (primary and secondary) outcomes that were of interest in the review were reported in the pre-specified way. Of the 33 studies that had no protocol, one study had not reported all the pre-specified primary outcomes (Myles 2008a); and the remaining studies reported all the outcomes described in their method sections.

Other potential sources of bias

Given the outcomes of interest in this Cochrane review, such as inhospital death and complications, were at low incidence, most of the included trials were underpowered for these outcomes. We assessed this item as high risk in studies that reported the outcomes of inhospital death or complications, but had fewer than 50 participants per arm (Chaparro 2013). Therefore we assessed 13 studies as at high risk of bias (Chen 2013; Deleu 2000; Jensen 1992; Jensen 1993a; Jensen 1993b; Kozmary 1990; Lampe 1990; Pedersen 1993; Sengupta 1988; Short 1985; Singh 2011; Vanacker 1999; Van Hemelrijck 1991).



Effects of interventions

See: Summary of findings for the main comparison Summary of findings' table 1; Summary of findings 2 'Summary of findings' table 2

See: Summary of findings for the main comparison and Summary of findings 2.

Primary outcomes

1. Inhospital case fatality rate (number or proportion of deceased participants after a defined period following anaesthesia)

Eight studies reported inhospital case fatality rate and together included 10,148 participants, 73.2% of the total number of participants included in this Cochrane review (Chen 2013; Eger 1990; ENIGMA II trial 2014; ENIGMA trial 2007; Fleischmann 2005; Lampe 1990; Leung 2006; Todd 1993). Of the included participants, 5076 (50%) were randomized to a nitrous oxide-based technique and 5072 (50%) to a nitrous oxide-free technique. Fifty-five participants died in the nitrous oxide group (1.1%), versus 63 in the nitrous oxide-free group (1.2%). Pooling of the data showed this small difference was not statistically significant. The Peto OR for the outcome of inhospital case fatality rate was 0.87 (95% CI 0.61 to 1.26; P = 0.47) when nitrous oxide was compared with control (Analysis 1.1). As the 95% CI of Peto OR included both 1.0 and 0.75/1.25, we downgraded the quality of the evidence for this outcome from high to moderate quality due to 'imprecision'.

We performed subgroup analyses using the prespecified subgroups, and did not detect any significant differences for the following subgroup analyses: type of surgery (Analysis 1.10), test for subgroup differences: Chi² test = 1.02, df = 1 (P value = 0.31); intervention in the nitrous oxide-free group (Analysis 1.22), test for subgroup differences: Chi² test = 0.37, df = 1 (P value = 0.54). The test for subgroup differences was not applicable when we performed subgroup analysis by concentration of inhaled nitrous oxide. The results showed no significant difference between high-concentration nitrous oxide-based group and nitrous oxide-free group on inhospital case fatality rate (Peto OR 0.86, 95% CI 0.60 to 1.24, l^2 statistic = 34%, P value = 0.42; seven studies, 9920 participants; Analysis 1.18).

The sensitivity analysis performed just including the studies at low risk of bias (ENIGMA II trial 2014; ENIGMA trial 2007; Fleischmann 2005; Leung 2006) suggested that the results of meta-analysis were robust.

As all eight studies had < 10% withdrawals, we did not conduct a sensitivity analysis excluding studies with > 10% withdrawals.

Secondary outcomes

1. Pulmonary complications

1.1 Pneumonia

Eight studies reported pneumonia and together included 2699 participants, 19.5% of the total number of participants included in this review (Chen 2013; Eger 1990; Jensen 1992; Jensen 1993a; Lampe 1990; ENIGMA trial 2007; Singh 2011; Todd 1993). Of the included participants, 1368 (50.7%) were randomized to a nitrous oxide-based technique and 1331 (49.3%) to a nitrous oxide-free technique. Thirty-seven participants caught pneumonia in the

nitrous oxide group (2.7%), versus 22 in the nitrous oxide-free group (1.7%). Pooling of the data showed this small difference was not statistically significant. The OR for the outcome of pneumonia was 1.68 (95% CI 1.00 to 2.81; P = 0.05) when nitrous oxide was compared with control (Analysis 1.2). As the serious risk of bias existed among included studies, and the 95% CI of the OR included both 1.0 and 1.25, we downgraded the quality of the evidence for this outcome from high to low quality due to 'risk of bias' and 'imprecision'.

We conducted subgroup analyses using the prespecified subgroups, but could not perform a subgroup analysis of concentration of inhaled nitrous oxide, as all included studies in this analysis used a high concentration. No significant differences were detected for the following subgroup analyses: type of surgery (Analysis 1.11), test for subgroup differences: Chi² test = 0.15, df = 1, P = 0.70; intervention in the nitrous oxide-free group (Analysis 1.23), test for subgroup differences: Chi² test = 0.84, df = 1, P = 0.36).

We performed a sensitivity analysis including only the studies at low risk of bias (ENIGMA trial 2007), which suggested that the results of meta-analysis were not robust. The results changed from OR 1.68 (95% CI 1.00 to 2.81) to OR 1.99 (95% CI 1.07 to 3.73).

The sensitivity analysis excluding studies with more than 10% withdrawals (Singh 2011) suggested that the results of metaanalysis were robust.

1.2 Pulmonary atelectasis

Five studies reported pulmonary atelectasis and together included 2400 participants, 17.3% of the total number of participants included in this review (Eger 1990; Jensen 1993b; Jensen 1992; Lampe 1990; ENIGMA trial 2007). Of these included participants, 1222 (50.9%) were randomized to a nitrous oxide-based technique and 1178 (49.1%) to a nitrous oxide-free technique. One hundred and fifty participants developed pulmonary atelectasis in the nitrous oxide group (12.3%), versus 93 in the nitrous oxide-free group (7.9%). Pooling of the data showed this difference was statistically significant. The odds of pulmonary atelectasis were significantly increased in the nitrous oxide-based group (OR 1.57, 95% Cl 1.18 to 2.10, l² statistic = 48%, P = 0.002; five studies, 2400 participants; Analysis 1.3). We rated the quality of the evidence for this outcome as high.

We ran subgroup analyses using the prespecified subgroups, but could not perform a subgroup analysis by concentration of inhaled nitrous oxide, as all included studies in this analysis used a high concentration. No significant differences were detected for the subgroup analyses by intervention in the nitrous oxide-free group (Analysis 1.24), test for subgroup differences: Ch^2 test = 1.24, df = 1, P = 0.27). The test for subgroup differences was not applicable when we performed subgroup analysis by type of surgery. The results showed no significant difference between the two groups for intraabdominal surgery (OR 0.16, 95% CI 0.02 to 1.06, I² statistic = 0%, P value = 0.06; two studies, 102 participants). The subgroup analysis for neurosurgery was not applicable as no pulmonary atelectasis was reported in either the nitrous oxide-based or nitrous oxide-free group (Analysis 1.12).

We performed a sensitivity analysis including only the studies of low risk of bias (ENIGMA trial 2007), which suggested that the results of meta-analysis were robust.

As all the five studies had < 10% withdrawals, we did not conduct a sensitivity analysis excluding studies with > 10% withdrawals.

2. Heart complications

2.1 Myocardial infarction

Six studies reported myocardial infarction and together included 9246 participants, 66.7% of the total number of participants included in this review (Chen 2013; Eger 1990; Kozmary 1990; ENIGMA II trial 2014; ENIGMA trial 2007; Singh 2011). Of the included participants, 4602 (49.8%) were randomized to a nitrous oxide-based technique and 4644 (50.2%) to a nitrous oxide-free technique. Two hundred and thirty-five participants developed myocardial infarction in the nitrous oxide group (5.1%), versus 236 in the nitrous oxide-free group (5.1%). Pooling of the data showed no significant difference in the outcome between groups. The OR for the outcome of myocardial infarction was 1.01 (95% CI 0.84 to 1.22, P = 0.88) when nitrous oxide was compared with control (Analysis 1.4). The quality of the evidence for this outcome was high.

We conducted subgroup analyses using the prespecified subgroups, but could not perform a subgroup analysis by concentration of inhaled nitrous oxide, as all included studies in this analysis used a high concentration. No significant differences were detected for the subgroup analyses by type of surgery (Analysis 1.13), test for subgroup differences: Chi² test = 2.55, df = 2, P = 0.28, I² statistic = 21.5%. The test for subgroup differences was not applicable when we performed subgroup analysis by interventions in the nitrous oxide-free group. The results showed no significant difference between nitrous oxide-based group and volatile anaesthetic-based group on myocardial infarction (OR 0.96, 95% CI 0.37 to 2.53, I² statistic = 17%, P value = 0.94; four studies, 242 participants; Analysis 1.25).

We performed a sensitivity analysis including only studies at low risk of bias (ENIGMA II trial 2014; ENIGMA trial 2007), which suggested that the results of meta-analysis were robust.

The sensitivity analysis excluding studies with more than 10% withdrawals (Singh 2011) suggested that the results of metaanalysis were robust.

3. Neurological complications

3.1 Stroke

Four studies reported stroke and together included 9142 participants, 65.9% of the total number of participants included in this review (Deleu 2000; ENIGMA II trial 2014; ENIGMA trial 2007; Singh 2011). Regarding randomization, 4565 (49.9%) were randomized to a nitrous oxide-based technique and 4577 (50.1%) to a nitrous oxide-free technique. Thirty-two participants developed stroke in the nitrous oxide group (0.7%), versus 22 in the nitrous oxide-free group (0.5%). Pooling of the data showed this small difference was not statistically significant. The OR for the outcome of stroke was 1.47 (95% CI 0.86 to 2.53, P = 0.16) when nitrous oxide was compared with control, with four studies consisting of 9142 participants being analysed (Analysis 1.5). As the 95% CI of OR included both 1.0 and 1.25, we downgraded the quality of the evidence for this outcome from high to moderate quality due to 'imprecision'.

We performed subgroup analyses using the prespecified subgroups, and no significant differences were detected for the

following subgroup analyses: type of surgery (Analysis 1.14), test for subgroup differences: Chi² test = 0.36, df = 1, P = 0.55; intervention in the nitrous oxide-free group (Analysis 1.26), test for subgroup differences: Chi² test = 0.36, df = 1, P value = 0.55. The test for subgroup differences was not applicable when we performed subgroup analysis by concentrations of inhaled nitrous oxide. The results showed no significant difference between highconcentration nitrous oxide-based group and nitrous oxide-free group on stroke (OR 1.39, 95% CI 0.80 to 2.42; I² statistic = 0%, P value = 0.24; three studies, 9091 participants; Analysis 1.19).

The sensitivity analysis just including the studies of low risk of bias (ENIGMA II trial 2014; ENIGMA trial 2007) suggested that the results of meta-analysis were robust.

The sensitivity analysis excluding studies with more than 10% withdrawals (Deleu 2000; Singh 2011) suggested that the results of meta-analysis were robust.

4. Other complications

4.1 Severe nausea and vomiting

Ten studies reported severe nausea and vomiting and together included 11,045 participants, 79.6% of the total number of participants included in this Cochrane review (Arellano 2000; Mraovic 2008; ENIGMA II trial 2014; ENIGMA trial 2007; Paredi 1994; Pedersen 1993; Sengupta 1988; Short 1985; Vanacker 1999; Van Hemelrijck 1991). Of the included participants, 5579 (50.5%) were randomized to a nitrous oxide-based technique and 5466 (49.5%) to a nitrous oxide-free technique. Seven hundred and ninety participants had severe nausea and vomiting in the nitrous oxide group (14.2%), versus 518 in the nitrous oxide-free group (9.5%). Pooling of the data showed this small difference was not statistically significant. The OR for the outcome of severe nausea and vomiting was 1.44 (95% CI 0.97 to 2.15, P = 0.07) when nitrous oxide was compared with control (Analysis 1.6). As serious risk of bias and substantial heterogeneity existed among included studies, we downgraded the quality of the evidence for this outcome from high to low quality due to 'risk of bias' and 'inconsistency'.

We ran subgroup analyses using the prespecified subgroups, and no significant differences were detected for the following subgroup analyses: type of surgery (Analysis 1.15), test for subgroup differences: Chi² test = 2.94, df = 2, P = 0.23); concentration of inhaled nitrous oxide (Analysis 1.20), test for subgroup differences: Chi² test = 0.01, df = 1, P = 0.94); intervention in the nitrous oxidefree group (Analysis 1.27), test for subgroup differences: Chi² test = 0.22, df = 1, P = 0.64).

The sensitivity analysis just including the studies of low risk of bias (Arellano 2000; ENIGMA II trial 2014; ENIGMA trial 2007) suggested that the results of meta-analysis were not robust. The results changed from OR 1.44 (95% CI 0.97 to 2.15) to OR 1.86 (95% CI 1.10 to 3.16).

The sensitivity analysis excluding studies with more than 10% withdrawals (Pedersen 1993; Sengupta 1988; Short 1985) suggested that the results of meta-analysis were not robust. The results changed from OR 1.44 (95% CI 0.97 to 2.15) to OR 1.54 (95% CI 1.02 to 2.33).

Substantial heterogeneity was found in the outcome (Chi² test = 26.68, df = 9; P = 0.002, I^2 statistic = 66%) and seemed largely



attributable to type of surgery and techniques used in the nitrous oxide-free group.

As the outcome included 10 studies, we generated a funnel plot. The visual inspection of the funnel plot (Figure 4) did not show asymmetry. Egger's test was not statistically significant (P = 0.64).

Figure 4. Funnel plot of comparison: 1 Nitrous oxide-based versus nitrous oxide-free, outcome: 1.6 Severe nausea and vomiting.



4.2 Venous thromboembolism

Two studies reported venous thromboembolism and together included 9004 participants, 64.9% of the total number of participants included in this review (ENIGMA II trial 2014; ENIGMA trial 2007). Of the included participants, 4498 (50%) were randomized to a nitrous oxide-based technique and 4506 (50%) to a nitrous oxide-free technique. Twenty-eight participants developed venous thromboembolism in the nitrous oxide group (0.6%), versus 38 in the nitrous oxide-free group (0.8%). Pooling of the data showed this small difference was not statistically significant. The OR for the outcome of venous thromboembolism was 0.73 (95% CI 0.45 to 1.20, P=0.21) when nitrous oxide was compared with control (Analysis 1.7). As the 95% CI of OR included both 1.0 and 0.75, we downgraded the quality of the evidence for this outcome from high to moderate quality for 'imprecision'.

We could not perform subgroup analyses by type of surgery or intervention in the nitrous oxide-free group, as these were not reported in the studies. Nor could we perform subgroup analysis by concentrations of inhaled nitrous oxide, as all included studies in this analysis used a high concentration.

As all the two studies were of high quality and had < 10% withdrawals, we did not conduct the sensitivity analysis.

4.3 Wound infection rate

Six studies reported wound infection rate and together included 9789 participants, 70.6% of the total number of participants included in this review (Chen 2013; Eger 1990; Fleischmann 2005; Lampe 1990; ENIGMA II trial 2014; ENIGMA trial 2007). Of these participants, 4874 (49.8%) were randomized to a nitrous oxide-based technique and 4915 (50.2%) to a nitrous oxide-free technique. Regarding wound infection, 471 participants developed wound infection in the nitrous oxide group (9.7%), versus 434 in the nitrous oxide-free group (8.8%). Pooling of the data showed this small difference was not statistically significant. The OR for the outcome of wound infection rate was 1.22 (95% CI 0.84 to 1.78, P = 0.30) when nitrous oxide was compared with control (Analysis 1.8). As the 95% CI of OR included both 1.0 and 0.75 as well as substantial heterogeneity existed among included studies, we downgraded the quality of the evidence for this outcome from high to low quality for 'imprecision' and 'inconsistency'.

We ran subgroup analyses using the prespecified subgroups, but could not conduct a subgroup analysis by concentration of inhaled nitrous oxide, as all included studies in this analysis used a high concentration. The test for subgroup differences was not applicable when we performed subgroup analysis by type of surgery or interventions in the nitrous oxide-free group. The



subgroup analysis by types of surgery showed no significant difference between the two groups for intra-abdominal surgery (OR 1.63, 95% CI 0.28 to 9.33, I² statistic = 87%, P = 0.58; two studies, 499 participants). The subgroup analysis for neurosurgery was not applicable for no wound infection being reported in either nitrous oxide-based or nitrous oxide-free group (Analysis 1.16). The subgroup analysis by interventions in the nitrous oxide-free group showed no significant difference between nitrous oxide-based group and volatile anaesthetic-based group (OR 2.13, 95% CI 0.44 to 10.22; I² statistic = 80%, P = 0.34; four studies, 785 participants; Analysis 1.28).

We performed sensitivity analysis including only the studies at low risk of bias (ENIGMA II trial 2014; ENIGMA trial 2007; Fleischmann 2005), which suggested that the results of meta-analysis were robust.

As all six studies had less than 10% withdrawals, we did not conduct the sensitivity analysis excluding studies with more than 10% withdrawals.

We found substantial heterogeneity in the trials that reported this outcome (Chi² test = 12.49, df = 4; P = 0.01, I² statistic = 68%), which did not seem to be attributable to type of surgery, concentrations of inhaled nitrous oxide, intervention in the nitrous oxide-free group, or methodological quality of the included studies.

5. Length of stay

5.1 Length of hospital stay

Thirteen studies reported length of hospital stay (Chen 2013; Eger 1990; Fleischmann 2005; Jensen 1992; Jensen 1993a; Krogh 1994; Lampe 1990; Leung 2006; ENIGMA II trial 2014; ENIGMA trial 2007; Myles 2008a; Singh 2011; Todd 1993). Five studies reported the data as median (interquartile range) (ENIGMA II trial 2014; ENIGMA trial 2007; Jensen 1993a; Krogh 1994; Todd 1993) and two studies reported it as a median (range) value (Jensen 1992; Singh 2011). Only six studies reported the data as mean (SD), and together included 1103 participants, 8.0% of the total number of participants included in this review (Chen 2013; Eger 1990; Fleischmann 2005; Lampe 1990; Leung 2006; Myles 2008a). Of these participants, 546 (49.5%) were randomized to a nitrous oxide-based technique and 557 (50.5%) to a nitrous oxide-free technique. Pooling of the data showed no significant difference in the outcome between groups. The MD for the outcome of length of hospital stay was 0.36 days (95% CI -0.69 to 1.40 days, P = 0.50) when nitrous oxide was compared with control (Analysis 1.9). Due to the substantial heterogeneity between included studies, we downgraded the quality of the evidence for this outcome from high to moderate quality for 'inconsistency'.

We conducted subgroup analyses using the prespecified subgroups, and no significant differences were detected for the subgroup analysis by type of surgery, test for subgroup differences: Chi^2 test = 1.46, df = 1, P = 0.23). The test for subgroup differences was not applicable when we performed subgroup analysis by concentration of inhaled nitrous oxide and interventions in the nitrous oxide-free group. The subgroup analysis by concentrations of inhaled nitrous oxide-based group and nitrous oxide-free group (MD 0.45 days, 95% CI -1.03 to 1.93 days; I² statistic = 59%, P = 0.55; six studies, 875 participants; Analysis 1.21). The subgroup analysis by interventions in the nitrous oxide-free group showed

no significant difference between nitrous oxide-based group and volatile anaesthetic-based group (MD 0.20 days, 95% CI -0.36 to 0.75 days, I^2 statistic = 31%, P = 0.49; five studies, 1013 participants; Analysis 1.29).

The sensitivity analysis including only the studies of low risk of bias (Fleischmann 2005; Leung 2006) suggested that the results of metaanalysis were robust.

As all the six studies had less than 10% withdrawals, we did not conduct sensitivity analysis excluding studies with more than 10% withdrawals.

We observed substantial heterogeneity for this outcome (Chi² test = 13.43, df = 6; P value = 0.04, l² statistic = 55%) which seemed largely attributable to type of surgery and techniques used in the nitrous oxide-free group.

5.2. Length of ICU stay

Two studies reported length of ICU stay (ENIGMA trial 2007; Singh 2011). ENIGMA trial 2007 provided only the medians of the ICU stay, but no interquartile ranges. We contacted the study authors via email but found the data were skewed. Singh 2011 reported the data of the ICU stay as median (range) values. Therefore, we did not pool the data. Both trials reported no significant difference in the length of ICU stay between nitrous oxide-based group and nitrous oxide-free group.

DISCUSSION

Summary of main results

We included a total of 35 trials; seven of which were of low risk of bias (Akca 2004; Arellano 2000; ENIGMA II trial 2014; ENIGMA trial 2007; Fleischmann 2005; Lee 2005; Leung 2006). The meta-analyses revealed that nitrous oxide-based techniques, compared with nitrous oxide-free techniques, increased the incidence of pulmonary atelectasis but showed no difference in the inhospital case fatality rate, the incidence of pneumonia, myocardial infarction, stroke, severe nausea and vomiting, venous thromboembolism, wound infection, or the length of hospital stay. Compared with nitrous oxide-free techniques, high-concentration nitrous oxide-based techniques increased the incidence of pulmonary atelectasis. Compared with either propofol-based or volatile anaesthetic-based anaesthesia, nitrous oxide-based techniques had no significant effects on the inhospital case fatality rate, complications, or length of stay. The sensitivity analyses suggested that the results of meta-analyses were all robust except for the outcomes of pneumonia and severe nausea and vomiting.

Overall completeness and applicability of evidence

We included 13,872 adult participants, who were of different ASA status undergoing different surgeries. We compared different concentrations of nitrous oxide with nitrous oxide-free anaesthesia, and also compared nitrous oxide-based anaesthesia with either propofol-based maintenance of anaesthesia or volatile anaesthetic-based maintenance of anaesthesia. We paid more attention to endpoints and patient-important outcomes in addressing the question as to whether nitrous oxide was responsible for clinically significant adverse events following general anaesthesia. The meta-analyses results suggest that nitrous oxide results in more complications. Since the use of nitrous

oxide in patients undergoing surgery remains near-routine (de Vasconcellos 2013), this systematic review may have a wide impact on the conduct of general anaesthesia.

Quality of the evidence

We included 35 RCTs, of which only 16 trials described the methods for randomization and only 12 concealed the allocation sequence. Regarding blinding, eight trials reported they blinded participants and personnel, while 25 trials reported they blinded the outcome assessors. Only seven of the 35 included trials were at low risk of bias.

We identified substantial heterogeneity in the outcomes of severe nausea and vomiting, wound infection rate, and hospital stay, so we downgraded the quality of evidence for inconsistency.

As the 95% CIs of ORs were wide for the outcomes of inhospital case fatality rate, pneumonia, stroke, venous thromboembolism, and wound infection rate, we downgraded the quality of evidence for these outcomes due to imprecision.

Finally, the quality of the evidence for two outcomes (pulmonary atelectasis, myocardial infarction) was rated as high, four outcomes (inhospital case fatality rate, stroke, venous thromboembolism, and length of hospital stay) as moderate, and three (pneumonia, severe nausea and vomiting, wound infection rate) as low; see Summary of findings for the main comparison and Summary of findings 2.

Potential biases in the review process

We conducted this Cochrane review following the guidelines recommended in the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011) to minimize bias. However, there are two issues that should be of concern. Firstly, we were unable to obtain the full texts of eight publications through either our university library, the Danish National Library, or Cochrane Anaesthesia, Critical or Emergency Care Group members, so we may have missed potential eligible studies. Therefore selection bias may exist in our systematic review. Secondly, substantial heterogeneity was found in the outcome 'wound infection rate', which was not explained by either subgroup analyses or sensitivity analyses. The heterogeneity seemed inexplicable, and we pooled the data using a random-effects model, which downgraded our confidence in this result.

Agreements and disagreements with other studies or reviews

In this Cochrane review we compared nitrous oxide-based techniques with nitrous oxide-free techniques on adult surgical participants, to determine whether nitrous oxide was responsible for clinically significant adverse events following general anaesthesia and whether nitrous oxide could be avoided. There are also three systematic reviews comparing general anaesthesia techniques with or without nitrous oxide but they focus on postoperative nausea and vomiting and intraoperative awareness. Two of these systematic reviews were published in 1996 (Divatia 1996; Tramèr 1996). Tramèr 1996 analysed the data on 2,478 participants from 24 studies and concluded that omitting nitrous oxide from general anaesthetics significantly decreased the incidence of postoperative vomiting for patients at high risk of vomiting preoperatively, but had no effect on the incidence of

nausea. They also found that omitting nitrous oxide increased the risk of intraoperative awareness. Divatia 1996 included 26 trials and reported that omission of nitrous oxide reduced the odds of postoperative nausea and vomiting by 37%, a reduction in risk of 28%. Fernández-Guisasola 2010 is another systematic review, and unlike the former systematic reviews, Fernández-Guisasola 2010 excluded paediatric reports. The authors included 30 studies with 4598 adult participants, and concluded that avoiding nitrous oxide reduces the risk of postoperative nausea and vomiting, especially in women, but the overall impact was modest. In this Cochrane review we also evaluated the effects of nitrous oxide on postoperative nausea and vomiting. However, we focused on the incidence of severe nausea and vomiting. We found that avoiding nitrous oxide may have no effects on the incidence of severe nausea and vomiting, but the sensitivity analysis suggested that the result was not robust. Imberger 2014 conducted a systematic review with meta-analysis and trial sequential analysis, focusing on the effects of nitrous oxide on mortality and cardiovascular morbidity. The authors analysed the data of 13 trials and found that nitrous oxide did not affect either short term (within 30 days after operation) or long term (starting from 30 days after operation) mortality. However, trial sequential analysis demonstrated that the data were far too sparse to make any conclusions. They did not perform meta-analysis for cardiovascular complications (i.e. stroke, myocardial infarct, pulmonary embolus, cardiac arrest) due to insufficient data. Consistent with Imberger 2014, we also found that nitrous oxide-based anaesthesia resulted in similar inhospital mortality compared with nitrous oxide-free anaesthesia. Moreover, we pooled the data of cardiovascular complications (i.e. myocardial infarction). The results showed no significant difference in the outcome between groups. The beneficial effects were also explored by several studies. When used as one component of general anaesthesia, nitrous oxide enables a reduction in the requirements for other agents, which are usually more expensive and could have other side effects (Becker 2008). Moreover, a follow-up study showed that nitrous oxide reduced the risk of persistent pain after surgery (Chan 2011). These outcomes were not assessed in our Cochrane review but should be taken into consideration in clinical practice.

AUTHORS' CONCLUSIONS

Implications for practice

This Cochrane review shows that adding nitrous oxide in general anaesthesia increases the risk of pulmonary atelectasis and may potentially increase the incidence of pneumonia and severe nausea and vomiting. However, it also reveals that nitrous oxide neither increases the risk of death, myocardial infarction, stroke, venous thromboembolism, wound infection, nor prolongs the hospital stay. Given the evidence from this review, avoidance of nitrous oxide may be reasonable in participants with pre-existing poor pulmonary function or at high risk of postoperative nausea and vomiting.

Implications for research

Most of the included studies did not report the methods for randomization, allocation concealment, or blinding, which made it difficult for us to determine their methodological quality. Future studies would benefit from improved reporting, and we strongly recommend that future studies be reported according to the

CONSORT statement (Consolidated Standards of Reporting Trials) (www.consort-statement.org).

To improve research transparency and ultimately strengthen the validity and value of the scientific evidence base, study authors are encouraged to register their clinical trials in the registry platform. However in this systematic review, only two included trials were registered (ENIGMA II trial 2014; ENIGMA trial 2007). This should be improved in any future studies.

In this systematic review we focused on endpoints and patientimportant outcomes, but some studies did not report them, and so we excluded them from quantitative synthesis. Outcome reporting is another concern in future studies.

Many outcomes we focused on had a low incidence and were downgraded for 'imprecision'. Large-scale, multicentre studies are still needed to enable us to draw a reliable conclusion. Another approach of study design may be to establish prospective registries or a multi-database for a large cohort (Khan 2013).

Another suggestion for future studies is that they should pay more attention to the outcome of economic factors, such as total costs of hospitalization and costs of nursing after discharge. It could answer the question whether adding nitrous oxide reduces the total costs of hospitalization or not.

ACKNOWLEDGEMENTS

We thank the following people:

- All the participants and clinical researchers who were involved in the publications mentioned in this Cochrane review.
- The Cochrane Anaesthesia, Critical and Emergency Care Group for the support that they have provided, especially Jane Cracknell for her enthusiastic support from the very beginning and her careful and constructive advice throughout.
- Mike Bennett (content editor), Cathal Walsh (statistical editor), Mark D Neuman, Kate Leslie (peer reviewers), and Robert Wyllie (consumer referee) for their help and editorial advice during the preparation of this systematic review.
- Alejandro Gonzalez Garay, Anna Lee, Anthony Messina, Brenda NG Silva, Cristina Martinelli, Davide Chiumello, Ingrid Arévalo Rodriguez, Marc Van de Velde, Massimo Lamperti, Melissa Giraldo Duque, Michael Holzer, Miguel Coral Pabon, Mukadder Orhan Sungur, Rintaro Mori, Stephan Kettner, and Yuu Tanaka for providing full-text papers.
- Bernard Coronel, Brenda NG Silva, Christian Byhann, Federico Bilotta, Martin Hellmich, Massimo Lamperti, Mukadder Orhan Sungur, Nicola Petrucci, Patrick Brass, Souhayl Dahmani, Hongliang Tian, and Wenyu Zhao for help in abstracting data from papers.
- Professor Paul Myles for providing additional data from the ENIGMA trial 2007.
- Yi Kang, Li Lun, and Jiang Lei for their help and advice during the preparation of this Cochrane review.



REFERENCES

References to studies included in this review

Akca 2004 {published data only}

Akca O, Lenhardt R, Fleischmann E, Treschan T, Greif R, Fleischhackl R, et al. Nitrous oxide increases the incidence of bowel distension in patients undergoing elective colon resection. *Acta Anaesthesiologica Scandinavica* 2004;**48**(7):894-8. [PUBMED: 15242436]

Alhashemi 1997 {published data only}

Alhashemi JA, Miller DR, O'Brien HV, Hull KA. Cost-effectiveness of inhalational, balanced and total intravenous anaesthesia for ambulatory knee surgery. *Canadian Journal of Anaesthesia* 1997;**44**(2):118-25. [PUBMED: 9043722]

Arellano 2000 {published data only}

Arellano RJ, Pole ML, Rafuse SE, Fletcher M, Saad YG, Friedlander M, et al. Omission of nitrous oxide from a propofolbased anesthetic does not affect the recovery of women undergoing outpatient gynecologic surgery. *Anesthesiology* 2000;**93**(2):332-9. [PUBMED: 10910478]

Badner 2000 {published data only}

Badner NH, Beattie WS, Freeman D, Spence JD. Nitrous oxideinduced increased homocysteine concentrations are associated with increased postoperative myocardial ischemia in patients undergoing carotid endarterectomy. *Anesthesia and Analgesia* 2000;**91**(5):1073-9. [PUBMED: 11049886]

Bloomfield 1988 {published data only}

Bloomfield E, Hilberman M, Brown P, Noe H, Gaydos J, Miller G, et al. Postoperative nausea and vomiting. A comparison of sufentanil, nitrous oxide, and isoflurane. *Cleveland Clinic Journal of Medicine* 1988;**55**(6):549-52. [PUBMED: 2976325]

Brodsky 2005 {published data only}

Brodsky JB, Lemmens HJ, Collins JS, Morton JM, Curet MJ, Brock-Utne JG. Nitrous oxide and laparoscopic bariatric surgery. *Obesity Surgery* 2005;**15**(4):494-6. [PUBMED: 15946427]

Chen 2013 {published data only}

Chen Y, Liu X, Cheng CH, Gin T, Leslie K, Myles P, et al. Leukocyte DNA damage and wound infection after nitrous oxide administration: a randomized controlled trial. *Anesthesiology* 2013;**118**(6):1322-31. [PUBMED: 23549382]

Deleu 2000 {published data only}

Deleu D, Louon A, Sivagnanam S, Sundaram K, Okereke P, Gravell D, et al. Long-term effects of nitrous oxide anaesthesia on laboratory and clinical parameters in elderly Omani patients: A randomized double-blind study. *Journal of Clinical Pharmacy and Therapeutics* 2000;**25**(4):271-7. [PUBMED: 10971777]

Eger 1990 {published data only}

Eger El 2nd, Lampe GH, Wauk LZ, Whitendale P, Cahalan MK, Donegan JH. Clinical pharmacology of nitrous oxide: an argument for its continued use. *Anesthesia and Analgesia* 1990;**71**(6):575-85. [PUBMED: 2240627]

ENIGMA II trial 2014 {published and unpublished data}

* Myles PS, Leslie K, Chan MT, Forbes A, Peyton PJ, Paech MJ, et al. The safety of addition of nitrous oxide to general anaesthesia in at-risk patients having major non-cardiac surgery (ENIGMA-II): a randomised, single-blind trial. *Lancet* 2014;**384**(9952):1446-54. [PUBMED: 25142708]

Myles PS, Leslie K, Peyton P, Paech M, Forbes A, Chan MT, et al. ANZCA Trials Group. Nitrous oxide and perioperative cardiac morbidity (ENIGMA-II) Trial: rationale and design. *American Heart Journal* 2009;**157**(3):488-94.e1. [PUBMED: 19249419]

ENIGMA trial 2007 {published and unpublished data}

Chan MT, Wan AC, Gin T, Leslie K, Myles PS. Chronic postsurgical pain after nitrous oxide anesthesia. *Pain* 2011;**152**(11):2514-20. [PUBMED: 21889262]

Graham AM, Myles PS, Leslie K, Chan MT, Paech MJ, Peyton P, et al. A cost-benefit analysis of the ENIGMA trial. *Anesthesiology* 2011;**115**(2):265-72. [PUBMED: 21681081]

* Myles PS, Leslie K, Chan MTV, Forbes A, Paech MJ, Peyton P, et al. Avoidance of nitrous oxide for patients undergoing major surgery: a randomized controlled trial. *Anesthesiology* 2007;**107**(2):221-31. [PUBMED: 17667565]

Fleischmann 2005 {published data only}

Fleischmann E, Lenhardt R, Kurz A, Herbst F, Fülesdi B, Greif R, et al. Outcomes Research Group. Nitrous oxide and risk of surgical wound infection: a randomised trial. *Lancet* 2005;**366**(9491):1101-7. [PUBMED: 16182898]

Gilani 2008 {published data only}

Gilani SM, Sofi K. Is nitrous oxide necessary for general anaesthesia?. *Journal of Ayub Medical College Abbottabad* 2008;**20**(4):149-52. [PUBMED: 19999230]

Jensen 1992 {published data only}

Jensen AG, Kalman SH, Nyström PO, Eintrei C. Anaesthetic technique does not influence postoperative bowel function: a comparison of propofol, nitrous oxide and isoflurane. *Canadian Journal of Anaesthesia* 1992;**39**(9):938-43. [PUBMED: 1451222]

Jensen 1993a {published data only}

Jensen AG, Prevedoros H, Kullman E, Anderberg B, Lennmarken C. Peroperative nitrous oxide does not influence recovery after laparoscopic cholecystectomy. *Acta Anaesthesiologica Scandinavica* 1993;**37**(7):683-6. [PUBMED: 8249558]

Jensen 1993b {published data only}

Jensen AG, Kalman SH, Eintrei C, Fransson SG, Morales O. Atelectasis and oxygenation in major surgery with either propofol with or without nitrous oxide or isoflurane anaesthesia. *Anaesthesia* 1993;**48**(12):1094-6. [PUBMED: 8285335]

Kozmary 1990 {published data only}

Kozmary SV, Lampe GH, Benefiel D, Cahalan MK, Wauk LZ, Whitendale P, et al. No finding of increased myocardial ischemia during or after carotid endarterectomy under anesthesia with nitrous oxide. *Anesthesia and Analgesia* 1990;**71**(6):591-6. [PUBMED: 2240629]

Krogh 1994 {published data only}

Krogh B, Jørn Jensen P, Henneberg SW, Hole P, Kronborg O. Nitrous oxide does not influence operating conditions or postoperative course in colonic surgery. *British Journal of Anaesthesia* 1994;**72**(1):55-7. [PUBMED: 8110552]

Lampe 1990 {published data only}

Lampe GH, Wauk LZ, Donegan JH, Pitts LH, Jackler RK, Litt LL, et al. Effect on outcome of prolonged exposure of patients to nitrous oxide. *Anesthesia and Analgesia* 1990;**71**(6):586-90. [PUBMED: 2240628]

Larsen 2000 {published data only}

Larsen B, Seitz A, Larsen R. Recovery of cognitive function after remifentanil-propofol anesthesia: a comparison with desflurane and sevoflurane anesthesia. *Anesthesia and Analgesia* 2000;**90**(1):168-74. [PUBMED: 10624999]

Lee 2005 {published data only}

Lee LH, Irwin MG, Lui SK. Intraoperative remifentanil infusion does not increase postoperative opioid consumption compared with 70% nitrous oxide. *Anesthesiology* 2005;**102**(2):398-402. [PUBMED: 15681957]

Leung 2006 {published data only}

Leung JM, Sands LP, Vaurio LE, Wang Y. Nitrous oxide does not change the incidence of postoperative delirium or cognitive decline in elderly surgical patients. *British Journal of Anaesthesia* 2006;**96**(6):754-60. [PUBMED: 16670110]

Lonie 1986 {published data only}

Lonie DS, Harper NJN. Nitrous oxide anaesthesia and vomiting. The effect of nitrous oxide anaesthesia on the incidence of vomiting following gynaecological laparoscopy. *Anaesthesia* 1986;**41**(7):703-7. [PUBMED: 2944432]

Mraovic 2008 {published data only}

Mraovic B, Simurina T, Sonicki Z, Skitarelic N, Gan TJ. The doseresponse of nitrous oxide in postoperative nausea in patients undergoing gynecologic laparoscopic surgery: a preliminary study. *Anesthesia and Analgesia* 2008;**107**(3):818-23. [PUBMED: 18713890]

Myles 2008a {published data only}

Myles PS, Chan MT, Kaye DM, McIlroy DR, Lau CW, Symons JA, et al. Effect of nitrous oxide anesthesia on plasma homocysteine and endothelial function. *Anesthesiology* 2008;**109**(4):657-63. [PUBMED: 18813045]

Paredi 1994 {published data only}

Paredi G, Sofi G, Bonazzi M, Bianchi de Grazia L, Giacomello R, Paladini C, et al. [Role of nitrous oxide on the incidence of postoperative emesis: Randomized, double blinded study]. Acta Anaesthesiologica Italica 1994;**45**:239-42. [EMBASE: 1995129835]

Pedersen 1993 {published data only}

Pedersen FM, Wilken-Jensen C, Knudsen F, Lindekaer AL, Svare EI. The influence of nitrous oxide on recovery of bowel function after abdominal hysterectomy. *Acta Anaesthesiologica Scandinavica* 1993;**37**(7):692-6. [PUBMED: 8249560]

Sengupta 1988 {published data only}

Sengupta P, Plantevin OM. Nitrous oxide and day-case laparoscopy: effects on nausea, vomiting and return to normal activity. *British Journal of Anaesthesia* 1988;**60**(5):570-3. [PUBMED: 2967712]

Short 1985 {published data only}

Short SM, Rutherfoord CF, Sebel PS. A comparison between isoflurane and alfentanil supplemented anaesthesia for short procedures. *Anaesthesia* 1985;**40**(12):1160-4. [PUBMED: 3936374]

Singh 2011 {published data only}

Singh GP, Prabhakar H, Bithal PK, Dash HH. A comparative evaluation of nitrous oxide-isoflurane vs isoflurane anesthesia in patients undergoing craniotomy for supratentorial tumors: A preliminary study. *Neurology India* 2011;**59**(1):18-24. [PUBMED: 21339653]

Sukhani 1994 {published data only}

Sukhani R, Lurie J, Jabamoni R. Propofol for ambulatory gynecologic laparoscopy: does omission of nitrous oxide alter postoperative emetic sequelae and recovery?. *Anesthesia and Analqesia* 1994;**78**(5):831-5. [PUBMED: 8160978]

Todd 1993 {published data only}

Todd MM, Warner DS, Sokoll MD, Maktabi MA, Hindman BJ, Scamman FL, et al. A prospective, comparative trial of three anesthetics for elective supratentorial craniotomy. Propofol/ fentanyl, isoflurane/nitrous oxide, and fentanyl/nitrous oxide. *Anesthesiology* 1993;**78**(6):1005-20. [PUBMED: 8512094]

Vanacker 1999 {published data only}

Vanacker BF. The impact of nitrous oxide on postoperative nausea and vomiting after desflurane anesthesia for breast surgery. *Acta anaesthesiologica Belgica* 1999;**50**(2):77-81. [PUBMED: 10418646]

Van Hemelrijck 1991 {published data only}

Van Hemelrijck J, Smith I, White PF. Use of desflurane for outpatient anesthesia. A comparison with propofol and nitrous oxide. *Anesthesiology* 1991;**75**(2):197-203. [PUBMED: 1830462]

Yoshimura 2014 {published data only}

Yoshimura T, Ueda K, Kakinuma A, Sawai J, Nakata Y. Bronchial blocker lung collapse technique: nitrous oxide for facilitating lung collapse during one-lung ventilation with a bronchial blocker. *Anesthesia and Analgesia* 2014;**118**(3):666-70. [PUBMED: 24557112]

References to studies excluded from this review

Antonini 1994 {published data only}

Antonini M, D'Errico RR, Della Rocca G, Oliva P, Coccia C, Pastore E. [Anesthesia in laparoscopic cholecystectomy: Evaluation of the use of nitrous oxide]. *Acta Anaesthesiologica Italica* 1994;**45**(2 Suppl):243-9. [EMBASE: 1995129836]

Atanassoff 1994 {published data only}

Atanassoff PG, Alon E, Weiss BM. Intercostal nerve block for lumpectomy: superior postoperative pain relief with bupivacaine. *Journal of Clinical Anesthesia* 1994;**6**(1):47-51. [PUBMED: 8142099]

Atassi 2005 {published data only}

Atassi K, Mangiapan G, Fuhrman C, Lasry S, Onody P, Housset B. Prefixed equimolar nitrous oxide and oxygen mixture reduces discomfort during flexible bronchoscopy in adult patients: a randomized, controlled, double-blind trial. *Chest* 2005;**128**(2):863-8. [PUBMED: 16100179]

Barr 1999 {published data only}

Barr G, Jakobsson JG, Owall A, Anderson RE. Nitrous oxide does not alter bispectral index: study with nitrous oxide as sole agent and as an adjunct to i.v. anaesthesia. *British Journal of Anaesthesia* 1999;**82**(6):827-30. [PUBMED: 10562773]

Bronco 2010 {published data only}

Bronco A, Ingelmo PM, Aprigliano M, Turella M, Sahillioğlu E, Bucciero M, et al. Xenon anaesthesia produces better early postoperative cognitive recovery than sevoflurane anaesthesia. *European Journal of Anaesthesiology* 2010;**27**(10):912-6. [PUBMED: 20523212]

Castéra 2001 {published data only}

Castéra L, Nègre I, Samii K, Buffet C. Patient-administered nitrous oxide/oxygen inhalation provides safe and effective analgesia for percutaneous liver biopsy: A randomized placebo-controlled trial. *American Journal of Gastroenterology* 2001;**96**(5):1553-7. [PUBMED: 11374698]

Cheong 2000 {published data only}

Cheong KF, Choy JM. Sevoflurane-fentanyl versus etomidatefentanyl for anesthetic induction in coronary artery bypass graft surgery patients. *Journal of Cardiothoracic Vascular Anesthesia* 2000;**14**(4):421-4. [PUBMED: 10972608]

Divatia 1996 {published data only}

Divatia JV, Vaidya JS, Badwe RA, Hawaldar RW. Omission of nitrous oxide during anesthesia reduces the incidence of postoperative nausea and vomiting. A meta-analysis. *Anesthesiology* 1996;**85**(5):1055-62. [PUBMED: 8916823]

Dover 1994 {published data only}

Dover SB, Plenderleith L, Moore MR, McColl KEL. Safety of general anaesthesia and surgery in acute hepatic porphyria. *Gut* 1994;**35**(8):1112-5. [PUBMED: 7926916]

Einarsson 1997 {published data only}

Einarsson S, Cerne A, Bengtsson A, Stenqvist O, Bengtson JP. Should nitrous oxide be discontinued before desflurane after

anaesthesia with desflurane/N2O?. *Acta Anaesthesiologica Scandinavica* 1997;**41**(10):1285-91. [PUBMED: 9422294]

Fredman 1998 {published data only}

Fredman B, Zohar E, Philipov A, Olsfanger D, Shalev M, Jedeikin R. The induction, maintenance, and recovery characteristics of spinal versus general anesthesia in elderly patients. *Journal of Clinical Anesthesia* 1998;**10**(8):623-30. [PUBMED: 9873961]

Gozdemir 2007 {published data only}

Gozdemir M, Sert H, Yilmaz N, Kanbak O, Usta B, Demircioglu RI. Remifentanil-propofol in vertebral disk operations: Hemodynamics and recovery versus desflurane-n(2)O inhalation anesthesia. *Advances in Therapy* 2007;**24**(3):622-31. [PUBMED: 17660173]

Haessler 1993 {published data only}

Haessler R, Schwender D, Leppmeier U, Klasing S, Rindfleisch F, Peter K. Anaesthesia for coronary artery bypass grafting: opioid-analgesia combined with either flunitrazepam, propofol or isoflurane. *Acta Anaesthesiologica Scandinavica* 1993;**37**(6):532-40. [PUBMED: 8213015]

Haraguchi 1995 {published data only}

Haraguchi N, Furusawa H, Takezaki R, Oi K. Inhalation sedation with sevoflurane: a comparative study with nitrous oxide. *Journal of Oral and Maxillofacial Surgery* 1995;**53**(1):24-6; discussion 26-7. [PUBMED: 7799117]

Heath 1996 {published data only}

Heath KJ, Sadler P, Winn JH, McFadzean WA. Nitrous oxide reduces the cost of intravenous anaesthesia. *European Journal* of Anaesthesiology 1996;**13**(4):369-72. [PUBMED: 8842658]

Holst 1993 {published data only}

Holst D, Anger C, Bauch HJ. [N₂O-supplemented intravenous anesthesia versus inhalation anesthesia. A comparative study of the sympathoadrenergic reaction and postoperative vigilance]. *Anästhesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie: AINS* 1993;**28**(1):18-22. [PUBMED: 8467026]

Ishii 1994 {published data only}

Ishii K, Kobayashi T, Kitajima T, Ogata H. [Neuromuscular blockade with vecuronium and its reversal with edrophonium during total intravenous anesthesia, neuroleptanalgesia and sevoflurane anesthesia]. *Masui. The Japanese Journal of Anesthesiology* 1994;**43**(8):1196-200. [PUBMED: 7933501]

Jastak 1973 {published data only}

Jastak JT, Gorretta C. Ketamine HCl as a continuousdrip anesthetic for outpatients. *Anesthesia and Analgesia* 1973;**52**(3):341-4. [PUBMED: 4735984]

Jellish 1996 {published data only}

Jellish WS, Lien CA, Jerrel Fontenot H, Hall R. The comparative effects of sevoflurane versus propofol in the induction and maintenance of anesthesia in adult patients. *Anesthesia and Analgesia* 1996;**82**(3):479-85. [PUBMED: 8623947]



Johnson 1997 {published data only}

Johnson GW, St John Gray H. Nitrous oxide inhalation as an adjunct to intravenous induction of general anaesthesia with propofol for day surgery. *European Journal of Anaesthesiology* 1997;**14**(3):295-9. [PUBMED: 9202917]

Kryshtalskyj 1990 {published data only}

Kryshtalskyj B, Direnfeld VN, Johnson TW. Use of low-dose ketamine hydrochloride in outpatient oral surgery. *Oral Surgery, Oral Medicine, and Oral Pathology* 1990;**69**(4):413-9. [PUBMED: 2326032]

Lim 1992 {published data only}

Lim BL, Low TC. Total intravenous anaesthesia versus inhalational anaesthesia for dental day surgery. *Anaesthesia and Intensive Care* 1992;**20**(4):475-8. [PUBMED: 1463176]

Losasso 1992 {published data only}

Losasso TJ, Muzzi DA, Dietz NM, Cucchiara RF. Fifty percent nitrous oxide does not increase the risk of venous air embolism in neurosurgical patients operated upon in the sitting position. *Anesthesiology* 1992;**77**(1):21-30. [PUBMED: 1609997]

Masood 2002 {published data only}

Masood J, Shah N, Lane T, Andrews H, Simpson P, Barua JM. Nitrous oxide (Entonox) inhalation and tolerance of transrectal ultrasound guided prostate biopsy: a double-blind randomized controlled study. *Journal of Urology* 2002;**168**(1):116-20; discussion 120. [PUBMED: 12050503]

Morimoto 1997 {published data only}

Morimoto Y, Matsumoto S, Nakamura M, Makino A, Tamura T, Oka H, et al. [Total intravenous anesthesia with propofol and fentanyl for laparoscopic cholecystectomy]. *Masui. The Japanese Journal of Anesthesiology* 1997;**46**(9):1242-5. [PUBMED: 9311219]

Nightingale 1992 {published data only}

Nightingale JJ, Lewis IH. Recovery from day-case anaesthesia: comparison of total i.v. anaesthesia using propofol with an inhalation technique. *British Journal of Anaesthesia* 1992;**68**(4):356-9. [PUBMED: 1642912]

Nishiyama 1998 {published data only}

Nishiyama T, Hanaoka K. [Anesthesia induction for laryngeal mask insertion--comparison among sevoflurane, isoflurane and propofol]. *Masui. The Japanese Journal of Anesthesiology* 1998;**47**(11):1320-4. [PUBMED: 9852695]

Ogg 1983 {published data only}

Ogg TW, Jennings RA, Morrison CG. Day-case anaesthesia for termination of pregnancy. Evaluation of a total intravenous anaesthetic technique. *Anaesthesia* 1983;**38**(11):1042-6. [PUBMED: 6638451]

Rocca 2000 {published data only}

Rocca G, Montecchi C, Baisi F, Monaco S, Romboli D, Gasparetto A. [N₂O-free sevoflurane anesthesia. Clinical evaluation]. *Minerva Anestesiologica* 2000;**66**(9):611-9. [PUBMED: 11070960]

Saïssy 2000 {published data only}

Saïssy JM. Simplified use of mixed propofol and alfentanil for anesthesia in remote locations. *Military Medicine* 2000;**165**(3):195-9. [PUBMED: 10741082]

Simpson 1977 {published data only}

Simpson P, Forsling M. The effects of halothane on plasma vasopressin during cardio-pulmonary bypass. *Clinical Endocrinology (Oxford)* 1977;**7**(1):33-9. [PUBMED: 328188]

Sinha 2006 {published data only}

Sinha PK, Neema PK, Unnikrishnan KP, Varma PK, Jaykumar K, Rathod RC. Effect of lung ventilation with 50% oxygen in air or nitrous oxide versus 100% oxygen on oxygenation index after cardiopulmonary bypass. *Journal of Cardiothoracic and Vascular Anesthesia* 2006;**20**(2):136-42. [PUBMED: 16616650]

Smith 1993 {published data only}

Smith I, Ding Y, White PF. Muscle pain after outpatient laparoscopy--influence of propofol versus thiopental and enflurane. *Anesthesia and Analgesia* 1993;**76**(6):1181-4. [PUBMED: 8498652]

Taki 2003 {published data only}

Taki K, Sugimura M, Morimoto Y, Hirose Y, Ueda J, Okada K, et al. [The influences of nitrous oxide inhalation during general anesthesia on postoperative nausea and vomiting]. *Journal of Japanese Dental Society of Anesthesiology* 2003;**31**(3):268-73. [EMBASE: 2003322122]

Towey 1979 {published data only}

Towey RM, Stanford BJ, Ballard RM, Gilbert JR. Morbidity of day-case gynaecological surgery. A comparison of thiopentone and Althesin. *British Journal of Anaesthesia* 1979;**51**(5):453-5. [PUBMED: 444346]

Van den Berg 1995 {published data only}

Van den Berg AA, Savva D, Honjol NM, Prabhu NV. Comparison of total intravenous, balanced inhalational and combined intravenous-inhalational anaesthesia for tympanoplasty, septorhinoplasty and adenotonsillectomy. *Anaesthesia and Intensive Care* 1995;**23**(5):574-82. [PUBMED: 8787257]

Vari 2010 {published data only}

Vari A, Gazzanelli S, Cavallaro G, De Toma G, Tarquini S, Guerra C, et al. Post-Operative Nausea and Vomiting (PONV) after thyroid surgery: A prospective, randomized study comparing totally intravenous versus inhalational anesthetics. *The American Surgeon* 2010;**76**(3):325-8. [PUBMED: 20349666]

Wesner 2005 {published data only}

Wesner L, Marone LK, Dennehy KC. Anesthesia for lower extremity bypass. *International Anesthesiology Clinics* 2005;**43**(1):93-109. [PUBMED: 15632519]

Yamakage 2001 {published data only}

Yamakage M, Chen X, Kamada Y, Tsujiguchi N, Namiki A. [Changes in sedative level during induction of anesthesia using a single volatile anesthetic]. *Masui. The Japanese Journal of Anesthesiology* 2001;**50**(4):383-6. [PUBMED: 11345750]



Yang 2004 {published data only}

Yang H, Choi PTL, McChesney J, Buckley N. Induction with sevoflurane-remifentanil is comparable to propofol-fentanylrocuronium in PONV after laparoscopic surgery. *Canadian Journal of Anaesthesia* 2004;**51**(7):660-7. [PUBMED: 15310632]

Zuurmond 1986 {published data only}

Zuurmond WW, van Leeuwen L. Alfentanil v. isoflurane for outpatient arthroscopy. *Acta Anaesthesiologica Scandinavica* 1986;**30**(4):329-31. [PUBMED: 3090845]

References to studies awaiting assessment

Adams 1994 {published data only}

Adams HA, Schmitz CS, Baltes-Götz B. [Endocrine stress reaction, hemodynamics and recovery in total intravenous and inhalation anesthesia. Propofol versus isoflurane]. *Der Anaesthesist* 1994;**43**(11):730-7. [PUBMED: 7840401]

Miralles Pardo 1991 {published data only}

Miralles Pardo FS, Robles García E, Moreno Cuesta J, Iranzo Reverter J, Sánchez Ortega JL, López Rodríguez F. [Intravenous perfusion of 2,6-diisopropylphenol (propofol) in the maintenance of emergency anesthesia]. *Revista Española de Anestesiología y Reanimación* 1991;**38**(3):162-6. [PUBMED: 1961960]

Moussa 1995 {published data only}

Moussa AM, Geaisa KN. Comparison of the recovery characteristics of propofol total intravenous anaesthesia and isoflurane inhalation anaesthesia for dental day surgery. *Egyptian Dental Journal* 1995;**41**(4):1451-5. [PUBMED: 9497696]

Rashchupkin 2011 {published data only}

Rashchupkin AB, Burov NE. [Low-flow xenon anesthesia in surgical patients with hypertension]. *Anesteziologiia i reanimatologiia* 2011;**2**(2):4-7. [PUBMED: 21692217]

Röpcke 2001 {published data only}

Röpcke H, Wartenberg HC, Konen-Bergmann M, Hoeft A. [The interaction of desflurane and nitrous oxide on EEG during surgery is additive]. *Anästhesiologie und Intensivmedizin* 2001;**42**(1):16-22. [EMBASE: 2001064587]

Schaffranietz 2000 {published data only}

Schaffranietz L, Rudolph C, Heinke W, Olthoff D. [Is the combination of nitrous oxide and hyperventilation in elective neurosurgical operations useful?]. *Anaesthesiologie und Reanimation* 2000;**25**(4):88-95. [PUBMED: 11132399]

Segatto 1993 {published data only}

Segatto A, Vincenti E, Valenti S, Sammons AW, De Bianchi E, Morossi M, et al. [TIVA with propofol vs thiopental-nitrous oxide anaesthesia for uterine cerclage (A prospective randomized clinical study on 200 pregnant patients)]. *Acta Anaesthesiologica Italica* 1993;**44**(Suppl 1):59-65. [EMBASE: 1994014491]

Shulunov 2002 {published data only}

Shulunov MV, Burov NE, Ibragimova GV. [Neurohumoral effect of xenon]. *Anesteziologiia i reanimatologiia* 2002;**3**:32-5. [PUBMED: 12221873]

Additional references

Apfel 2004

Apfel CC, Roewer N. [Postoperative nausea and vomiting]. *Der Anaesthesist* 2004;**53**(4):377-89. [PUBMED: 15190867]

Becker 2008

Becker DE, Rosenberg M. Nitrous oxide and the inhalation anesthetics. *Anesthesia Progress* 2008;**55**(4):124-30. [PUBMED: 19108597]

Chan 2011

Chan MT, Wan AC, Gin T, Leslie K, Myles PS. Chronic postsurgical pain after nitrous oxide anesthesia. *Pain* 2011;**152**(11):2514-20. [PUBMED: 21889262]

Chaparro 2013

Chaparro LE, Smith SA, Moore RA, Wiffen PJ, Gilron I. Pharmacotherapy for the prevention of chronic pain after surgery in adults. *Cochrane Database of Systematic Reviews* 2013, Issue 7. [DOI: 10.1002/14651858.CD008307.pub2]

Cheney 2007

Cheney FW. An early example of evidence-based medicine: hypoxemia due to nitrous oxide. *Anesthesiology* 2007;**106**(1):186-8. [PUBMED: 17197861]

Culley 2007

Culley DJ, Raghavan SV, Waly M, Baxter MG, Yukhananov R, Deth RC, et al. Nitrous oxide decreases cortical methionine synthase transiently but produces lasting memory impairment in aged rats. *Anesthesia and Analgesia* 2007;**105**(1):83-8. [PUBMED: 17578961]

de Vasconcellos 2013

de Vasconcellos K, Sneyd JR. Nitrous oxide: are we still in equipoise? A qualitative review of current controversies. *British Journal of Anaesthesia* 2013;**111**(6):877-85. [PUBMED: 23801743]

Eger 1965

Eger El 2nd, Saidman LJ. Hazards of nitrous oxide anaesthesia in bowel obstruction and pneumothorax. *Anesthesiology* 1965;**26**:61-6. [PUBMED: 14257336]

Egger 1997

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;**315**(7109):629–34. [PUBMED: 9310563]

Fernández-Guisasola 2010

Fernández-Guisasola J, Gómez-Arnau JI, Cabrera Y, del Valle SG. Association between nitrous oxide and the incidence of postoperative nausea and vomiting in adults: a systematic review and meta-analysis. *Anaesthesia* 2010;**65**(4):379-87. [PUBMED: 20151955]



Gruss 2004

Gruss M, Bushell TJ, Bright DP, Lieb WR, Mathie A, Franks NP. Two-pore-domain K+ channels are a novel target for the anesthetic gases xenon, nitrous oxide, and cyclopropane. *Molecular Pharmacology* 2004;**65**(2):443-52. [PUBMED: 14742687]

Guirguis 1990

Guirguis SS, Pelmear PL, Roy ML, Wong L. Health effects associated with exposure to anaesthetic gases in Ontario hospital personnel. *British Journal of Industrial Medicine* 1990;**47**(7):490-7. [PUBMED: 2383519]

Higgins 2002

Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis. *Statistics in Medicine* 2002;**21**(11):1539-58. [PUBMED: 12111919]

Higgins 2011

Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.

Imberger 2014

Imberger G, Orr A, Thorlund K, Wetterslev J, Myles P, Møller AM. Does anaesthesia with nitrous oxide affect mortality or cardiovascular morbidity? A systematic review with metaanalysis and trial sequential analysis. *British Journal of Anaesthesia* 2014;**112**(3):410-26. [PUBMED: 24408738]

Jevtović-Todorović 1998

Jevtović-Todorović V, Todorović SM, Mennerick S, Powell S, Dikranian K, Benshoff N, et al. Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin. *Nature Medicine* 1998;**4**(4):460-3. [PUBMED: 9546794]

Khan 2013

Khan FA, Ullah H. Pharmacological agents for preventing morbidity associated with the haemodynamic response to tracheal intubation. *Cochrane Database of Systematic Reviews* 2013, Issue 7. [DOI: 10.1002/14651858.CD004087.pub2]

Kripke 1987

Kripke BJ, Kupferman A, Luu KC. Suppression of chemotaxis to corneal inflammation by nitrous oxide. *Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi [Chinese Journal of Microbiology and Immunology]* 1987;**20**(4):302-10. [PUBMED: 3130236]

Lehmberg 2008

Lehmberg J, Waldner M, Baethmann A, Uhl E. Inflammatory response to nitrous oxide in the central nervous system. *Brain Research* 2008;**1246**:88-95. [PUBMED: 18929548]

Linde 1969

Linde HW, Bruce DL. Occupational exposure of anesthetists to halothane, nitrous oxide and radiation. *Anesthesiology* 1969;**30**(4):363-8. [PUBMED: 5773945]

Myles 2008b

Myles PS, Chan MT, Leslie K, Peyton P, Paech M, Forbes A. Effect of nitrous oxide on plasma homocysteine and folate in patients undergoing major surgery. *British Journal of Anaesthesia* 2008;**100**(6):780-6. [PUBMED: 18400808]

Parbrook 1967

Parbrook GD. Techniques of inhalational analgesia in the postoperative period. *British Journal of Anaesthesia* 1967;**39**(9):730-5. [PUBMED: 6051234]

Pasternak 2009

Pasternak JJ, McGregor DG, Lanier WL, Schroeder DR, Rusy DA, Hindman B, et al. IHAST Investigators. Effect of nitrous oxide use on long-term neurologic and neuropsychological outcome in patients who received temporary proximal artery occlusion during cerebral aneurysm clipping surgery. *Anesthesiology* 2009;**110**(3):563-73. [PUBMED: 19212259]

Perry 1983

Perry J, Chanarin I, Deacon R, Lumb M. Chronic cobalamin inactivation impairs folate polyglutamate synthesis in the rat. *The Journal of Clinical Investigation* 1983;**71**(5):1183-90. [PUBMED: 6853707]

RevMan 5.3 [Computer program]

The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

Rowland 1995

Rowland AS, Baird DD, Shore DL, Weinberg CR, Savitz DA, Wilcox AJ. Nitrous oxide and spontaneous abortion in female dental assistants. *American Journal of Epidemiology* 1995;**141**(6):531-8. [PUBMED: 7900720]

Schünemann 2009

Schünemann H, Brożek J, Oxman A (editors). GRADE handbook for grading quality of evidence and strength of recommendation. Version 3.2 [updated March 2009]. The GRADE Working Group, 2009. Available from www.cc-ims.net/ gradepro.

Stata 11.0 [Computer program]

StataCorp LP. Stata. Version 11.0. College Station: StataCorp LP, 2009.

Tramèr 1996

Tramèr M, Moore A, McQuay H. Omitting nitrous oxide in general anaesthesia: meta-analysis of intraoperative awareness and postoperative emesis in randomized controlled trials. *British Journal of Anaesthesia* 1996;**76**(2):186-93. [PUBMED: 8777095]

Yamakura 2000

Yamakura T, Borghese C, Harris RA. A transmembrane site determines sensitivity of neuronal nicotinic acetylcholine receptors to general anesthetics. *The Journal of Biological Chemistry* 2000;**275**(52):40879-86. [PUBMED: 11020384]

References to other published versions of this review

Yang 2011

Yang K, Jia WQ, Tian J, Ma B, Liu Y, Jia RH, et al. Nitrous oxidebased techniques versus nitrous oxide-free techniques for

CHARACTERISTICS OF STUDIES

Characteristics of included studies [ordered by study ID]

general anaesthesia. *Cochrane Database of Systematic Reviews* 2011, Issue 2. [DOI: 10.1002/14651858.CD008984]

* Indicates the major publication for the study

| Akca 2004 | | | | | | |
|--|--|---|--|--|--|--|
| Methods | Multi-centre RCT | | | | | |
| Participants | Setting: two Viennese | hospitals | | | | |
| | Inclusion criteria: ASA uled to last more than 2 | I-III patients, 18 to 80 years of age, scheduled for elective colon resection sched- 2 hours | | | | |
| Exclusion criteria: patients with bowel obstruction or having minor colon surgery (e.g. po isolated colostomy) | | | | | | |
| | Participant numbers: 344 randomly assigned; 344 analysed | | | | | |
| Interventions | Intervention: anaesth curonium (0.1 mg/kg) v rane (0.5 to 1.0% in 65% Control: anaesthetic m um (0.1 mg/kg) were us to 1.0% in air), vecuron | etic management was standardized. Sodium thiopental (3 to 5 mg/kg) and ve- were used for induction; anaesthesia subsequently was maintained with isoflu- % nitrous oxide), vecuronium, and remifentanil (0.2 mg/kg/min). nanagement was standardized. Sodium thiopental (3 to 5 mg/kg) and vecuroni- sed for induction; anaesthesia subsequently was maintained with isoflurane (0.5 nium, and remifentanil (0.2 mg/kg/min). | | | | |
| Outcomes | Other outcomes: Bowel distension | | | | | |
| Notes | _ | | | | | |
| Risk of bias | | | | | | |
| Bias | Authors' judgement | Support for judgement | | | | |
| Random sequence genera- tion (selection bias) | Low risk | Quote: "Patients were assigned to one of two groups using a reproducible set of computer-generated random numbers." | | | | |
| Allocation concealment (selection bias) | Low risk | Quote: "The assignments were kept in sealed, sequentially numbered opaque envelopes that were opened after induction of anaesthesia." | | | | |
| Blinding of participants and personnel (perfor- mance bias) All outcomes | Low risk | Quote: "Great care was exercised to prevent the surgeons from observing the administered gas mixture." | | | | |
| Blinding of outcome as- sessment (detection bias) Inhospital case fatality rate/length of stay | Unclear risk | _ | | | | |
| Blinding of outcome as- sessment (detection bias) Complications | Low risk | Quote: "The rater was blinded to anaesthesia management." | | | | |



| Akca 2004 (Continued) | | |
|---|----------|---|
| Incomplete outcome data (attrition bias) All outcomes | Low risk | No missing data. |
| Selective reporting (re- porting bias) | Low risk | All outcomes described in methods section reported. |
| Other bias | Low risk | No other potential sources of bias were detected. |

Alhashemi 1997

| Methods | Single-centre RCT | | | | | |
|---|---|---|--|--|--|--|
| Participants | Setting: the Ottawa Ge | eneral Hospital, Canada | | | | |
| | Inclusion criteria: ASA eral anaesthesia | I-II patients, scheduled to undergo arthroscopic knee surgery, and electing gen- | | | | |
| | Exclusion criteria: patient preference for regional anaesthesia; age < 20 or > 60 years; body mass index either < 20 or > 30 kg/m ² ; current or chronic use of benzodiazepines or other sedative-hypnotics; excessive alcohol intake; moderate or severe cardiac or respiratory disease; severe or uncontrolled hypertension; known allergy to any of the study medications; or chronic use of drugs known to interfere with the metabolism or clinical effects of the study medications | | | | | |
| | Participant numbers: 93 randomly assigned; 93 analysed | | | | | |
| Interventions | Intervention: patients received nitrous oxide 70% supplemented with isoflurane 0.5 to 1.0% or with intermittent boluses of 7 to 15 μg/kg iv alfentanil every 10 to 15 min. Control: patients received intermittent boluses of 7 to 15 μg/kg iv alfentanil every 10 to 15 min in conjunction with a continuous infusion of propofol. | | | | | |
| Outcomes | Other outcomes: Costs of anaesthesia ar | nd postoperative care | | | | |
| Notes | - | | | | | |
| Risk of bias | | | | | | |
| Bias | Authors' judgement | Support for judgement | | | | |
| Random sequence genera- tion (selection bias) | Low risk | Quote: "Patients were allocated according to a computer generated random- ization schedule." | | | | |
| Allocation concealment (selection bias) | Unclear risk | No details given. | | | | |
| Blinding of participants and personnel (perfor- mance bias) All outcomes | Unclear risk | No details given. | | | | |
| Blinding of outcome as- sessment (detection bias) Inhospital case fatality rate/length of stay | Unclear risk | _ | | | | |

Alhashemi 1997 (Continued)

| Blinding of outcome as- sessment (detection bias) Complications | Low risk | Quote: "Blinding was achieved by precluding the trained observer, who recorded all post-operative data, from gaining any knowledge of the intra-op- erative anaesthetic care." |
|---|----------|--|
| Incomplete outcome data (attrition bias) All outcomes | Low risk | No missing data. |
| Selective reporting (re- porting bias) | Low risk | All outcomes described in methods section reported. |
| Other bias | Low risk | No other potential sources of bias were detected. |

Arellano 2000

| Methods | Multi-centre RCT |
|---------------|---|
| Participants | Setting: Toronto General Hospital, Toronto Western Hospital, North York General Hospital and Women's College Hospital, Canada |
| | Inclusion criteria: ASA I-II patients, aged 18 to 55 years, undergoing termination of pregnancy and la- paroscopy |
| | Exclusion criteria: patients undergoing other ambulatory gynaecologic procedures; there was a history of psychiatric disease, narcotic/sedative use, drug abuse, or morbid obesity (> 30% above ideal body weight) |
| | Participant numbers: 1490 randomly assigned; 1417 analysed |
| Interventions | Intervention: for patients undergoing termination of pregnancy, they received fentanyl 0.7 mg/kg intravenously. After denitrogenation of the lungs with 100% oxygen, 20 mg lidocaine and 2.0 mg/kg propofol were infused intravenously over 40 s with further increments of propofol titrated to loss of lid reflex. Nitrous oxide and oxygen 65% to 35% were administered by mask. Anaesthesia was maintained with intermittent bolus doses of 20 mg propofol in response to clinical signs of light anaesthesia (movement, tearing, or phonation in response to surgical stimuli, or increases in blood pressure, pulse rate, or respiratory rate of ≥ 20%). For patients undergoing laparoscopy, they received fentanyl 1.5 mg/kg and 4-tubocurare 3 mg intravenously. After denitrogenation of the lungs with 100% oxygen, 20 mg lidocaine and 2 mg/kg propofol were infused intravenously over 40 s with further increments of propofol titrated to loss of lid reflex. After the administration of succinylcholine 1.5 mg/kg intravenously, subjects were intubated orally. After induction, patients were paralysed with 0.075 to 0.1 mg/kg vecuronium intravenously and mechanically ventilated. Patients received 55% nitrous oxide-35% oxygen and the anaesthesia was maintained with an infusion of propofol 100 to 200 µg/kg/min supplemented by intermittent bolus doses of 20 mg propofol in response to clinical signs of light anaesthesia (movement or tearing in response to surgical stimuli or increases in blood pressure, or pulse rate of ≥ 20%). At the end of surgery, neuromuscular blockade was reversed with atropine 0.02 mg/kg and neostigmine 0.04 mg/kg. Control: for patients undergoing termination of pregnancy, they received fentanyl 0.7 mg/kg intravenously. After denitrogenation of the lungs with 100% oxygen, 20 mg lidocaine and 2.0 mg/kg propofol were infused intravenously over 40 s with further increments of propofol titrated to loss of lid reflex. 100% oxygen vere administered by mask. Anaesthesia was maintained with intermittent bolus doses of 20 mg propofol in |



Arellano 2000 (Continued)

of propofol 100 to 200 μ g/kg/min supplemented by intermittent bolus doses of 20 mg propofol in response to clinical signs of light anaesthesia (movement or tearing in response to surgical stimuli or increases in blood pressure, or pulse rate of \geq 20%). At the end of surgery, neuromuscular blockade was reversed with atropine 0.02 mg/kg and neostigmine 0.04 mg/kg.

Outcomes Secondary outcomes: Severe nausea and vomiting: no specific definition

Notes

Risk of bias

| Bias | Authors' judgement | Support for judgement |
|---|--------------------|---|
| Random sequence genera- tion (selection bias) | Low risk | Quote: "Patients were randomly allocated by computer-generated random numbers in blocks of four, and stratification by hospital site and surgical pro- cedure." |
| Allocation concealment (selection bias) | Low risk | Sealed opaque envelopes were used. |
| Blinding of participants and personnel (perfor- mance bias) All outcomes | Low risk | Quote: "The personnel were not blinded to treatment allocation to ensure safe anaesthetic care. Biased administration of the aesthetics and unblinding of the research assistants were prevented by the following: (1) pre-enrolment training of anaesthesiologists to standardize anaesthetic administration; (2) random visits by the principal investigator to discuss the anaesthetic protocol with the anaesthesiologists; (3) ongoing review of the anaesthetic study sheets by the principal investigator; (4) restricting the research assistants from access to the operating rooms or patients' charts." |
| Blinding of outcome as- sessment (detection bias) Inhospital case fatality rate/length of stay | Unclear risk | _ |
| Blinding of outcome as- sessment (detection bias) Complications | Low risk | Quote: "Four research assistants blinded to treatment allocation postopera- tive data." |
| Incomplete outcome data (attrition bias) All outcomes | Low risk | Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups. |
| Selective reporting (re- porting bias) | Low risk | All outcomes described in methods section reported. |
| Other bias | Low risk | No other potential sources of bias were detected. |

Badner 2000

| Methods | Single-centre RCT | |
|--------------|--|--|
| Participants | Setting: McMaster University, Canada | |
| | Inclusion criteria: ASA I-III patients, age > 18 years, presenting for elective carotid endarterectomy | |



| Badner 2000 (Continued) | Exclusion criteria: patients were excluded if they had received an anaesthetic within 30 days before their scheduled surgery, if they were currently taking medications known to affect plasma homocysteine (vitamins B ₁₂ and B ₆ , folic acid, penicillamine, methotrexate, azaurodine, isoniazid, cycloserine, phenelzine, or procarbazine); if they were vitamin B ₁₂ or folate deficient, malnourished or cirrhotic; or if they had a pace-maker or left bundle branch block on electrocardiogram (ECG) Participant numbers: 90 randomly assigned; 86 analysed | | | |
|---|---|---|--|--|
| Interventions | Intervention: anaesthesia was maintained with opioid (fentanyl or sufentanil), isoflurane, and nitrous oxide/oxygen (inspired nitrous oxide 50%). Control: anaesthesia was maintained with opioid (fentanyl and sufentanil), isoflurane, and oxygen/air. | | | |
| Outcomes | Other outcomes: Myocardial ischaemia | | | |
| Notes | Four patients did not complete the 48-h study period, two required reoperation for hematoma forma- tion (both non-nitrous oxide), and two patients had Holter monitoring inappropriately discontinued (one from each group). | | | |
| Risk of bias | | | | |
| Bias | Authors' judgement | Support for judgement | | |
| Random sequence genera- tion (selection bias) | Low risk | Quote: "Patients were randomized using a computer-generated random num- ber table." | | |
| Allocation concealment (selection bias) | Unclear risk | No details given. | | |
| Blinding of participants and personnel (perfor- mance bias) All outcomes | Unclear risk | This was not reported. | | |
| Blinding of outcome as- sessment (detection bias) Inhospital case fatality rate/length of stay | Unclear risk | _ | | |
| Blinding of outcome as- sessment (detection bias) Complications | Low risk | Quote: "Myocardial ischemia was determined by a blinded technician." | | |
| Incomplete outcome data (attrition bias) All outcomes | Low risk | Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups. | | |
| Selective reporting (re- porting bias) | Low risk | All outcomes described in methods section reported. | | |
| Other bias | Low risk | No other potential sources of bias were detected. | | |

Bloomfield 1988

| Methods | Single-centre RCT |
|---------|-------------------|
| | |
| Bloomfield 1988 (Continued) | | |
|---|---|--|
| Participants | Setting: the University | of Colorado Health Science Center, USA |
| | Inclusion criteria: ASA | A I-II patients, aged 18 to 60 years |
| | Participant numbers: | 63 randomly assigned; 63 analysed |
| Interventions | Intervention: nitrous oxide/oxygen and 0.25% isoflurane with or without sufentanil Control: oxygen and 0.5% isoflurane with or without sufentanil | |
| Outcomes | 25 Other outcomes: | |
| | Non-severe nausea and | d vomiting |
| Notes | _ | |
| Risk of bias | | |
| Bias | Authors' judgement | Support for judgement |
| Random sequence genera- tion (selection bias) | Low risk | Quote: "Patients were allocated using random number tables." |
| Allocation concealment (selection bias) | Unclear risk | No details given. |
| Blinding of participants and personnel (perfor- mance bias) All outcomes | Unclear risk | This was not reported. |
| Blinding of outcome as- sessment (detection bias) Inhospital case fatality rate/length of stay | Unclear risk | _ |
| Blinding of outcome as- sessment (detection bias) Complications | Low risk | Quote: "Nausea and vomiting were recorded by an observer unaware of the anaesthetic technique used." |
| Incomplete outcome data (attrition bias) All outcomes | Low risk | No missing data. |
| Selective reporting (re- porting bias) | Low risk | All outcomes described in methods section reported. |
| Other bias | Low risk | No other potential sources of bias were detected. |

Brodsky 2005

| Methods | Single-centre RCT | |
|--------------|--|--|
| Participants | Setting: Stanford University Medical Center, USA | |
| | Inclusion criteria: patients undergoing either laparoscopic Roux-en-Y gastric bypass or gastric band- ing operations | |



_

| Brodsky 2005 (Continued) | Participant numbers: 50 randomly assigned; 50 analysed | | |
|--------------------------|--|--|--|
| Interventions | Intervention: the lungs of patients were ventilated with the volatile anaesthetic, oxygen (50%) and ni- trous oxide (50%). Control: the lungs of patients were ventilated with the volatile anaesthetic, oxygen (50%) and air. | | |
| Outcomes | Other outcomes: | | |
| | Quality of recovery | | |

Notes

Risk of bias

| Bias | Authors' judgement | Support for judgement |
|---|--------------------|--|
| Random sequence genera- tion (selection bias) | Low risk | Quote: "A randomization table was used to assign each patient to one of two groups." |
| Allocation concealment (selection bias) | Unclear risk | No details given. |
| Blinding of participants and personnel (perfor- mance bias) All outcomes | Unclear risk | This was not reported. |
| Blinding of outcome as- sessment (detection bias) Inhospital case fatality rate/length of stay | Unclear risk | _ |
| Blinding of outcome as- sessment (detection bias) Complications | Low risk | Quote: "The surgeon was blinded as to whether the patient was receiving air or nitrous oxide, was asked whether nitrous oxide was being used." |
| Incomplete outcome data (attrition bias) All outcomes | Low risk | No missing data. |
| Selective reporting (re- porting bias) | Low risk | All outcomes described in methods section reported. |
| Other bias | Low risk | No other potential sources of bias were detected. |

Chen 2013

| Methods | Single-centre RCT | | |
|--------------|---|--|--|
| Participants | Setting: Prince of Wales Hospital, Hong Kong, China | | |
| | Inclusion criteria: ASA I-IV patients, aged > 18 years, scheduled for elective open colorectal surgery | | |
| | Exclusion criteria: patients with ongoing infection and those with fever in the 24 h before surgery; patients with marked impairment of gaseous exchange; surgery for which primary wound closure; in the opinion of the attending anaesthesiologist that nitrous oxide administration was contraindicated | | |



| Participant numbers: 93 randomly assigned; 91 analysed |
|--|
| Intervention: anaesthesia was induced with propofol 1 to 2.5 mg/kg. Patients received sevoflurane targeted to achieve a bispectral index value between 40 and 60. Intraoperative analgesia was provided by remifentanil infusion 0.1 to 0.5 μg/kg/min and intravenous morphine 0.1 to 0.15 mg/kg, 30 min before completion. Muscle relaxation was facilitated by rocuronium. The lungs were ventilated through a tracheal tube using 70% nitrous oxide and 30% oxygen. Control: anaesthesia was induced with propofol 1 to 2.5 mg/kg. Patients received sevoflurane targeted to achieve a bispectral index value between 40 and 60. Intraoperative analgesia was provided by remifentanil infusion 0.1 to 0.5 μg/kg/min and intravenous morphine 0.1 to 0.15 mg/kg, 30 min before completion. Muscle relaxation was facilitated by rocuronium. The lungs were ventilated by remifentanil infusion 0.1 to 0.5 μg/kg/min and intravenous morphine 0.1 to 0.15 mg/kg, 30 min before completion. Muscle relaxation was facilitated by rocuronium. The lungs were ventilated through a tracheal tube using either 30% oxygen with 70% nitrogen or 80% oxygen with 20% nitrogen. |
| Primary outcomes: |
| Inhospital case fatality rate |
| Secondary outcomes: |
| Myocardial infarction: |
| The diagnosis of myocardial infarction required any one of the following criteria: |
| • 1. A typical rise in troponin or a typical fall in an increased troponin detected at its peak after surgery in a patient without a documented alternative explanation for an increased troponin measurement (e.g. pulmonary embolism). |
| This criterion also required that one of the following must also exist: |
| A. Ischaemic signs or symptoms (<i>i.e.</i>, chest, arm, neck, or jaw discomfort; shortness of breath; and pulmonary oedema); B. Development of pathologic Q waves present in any two contiguous leads that are ≥30 ms; C. ECG changes indicative of ischaemia (ST segment increase [≥2 mm in leads V1, V2, or V3; or ≥1 mm in the other leads], ST segment depression [≥1 mm], or symmetric inversion of T waves ≥1 mm) in at least two contiguous leads; D. Coronary artery intervention (<i>i.e.</i>, percutaneous coronary intervention or coronary artery bypass graft surgery); E. New or presumed new cardiac wall motion abnormality on echocardiography or new or presumed new fixed defect on radionuclide imaging. 2. Pathologic findings of an acute or healing myocardial infarction. 3. Development of new pathologic Q waves on an ECG if troponin levels were not obtained or were obtained at times that could have missed the clinical event. Pneumonia: The definition of pneumonia required any one of the following criteria: I. Rales or dullness to percussion on physical examinations of chest AND any of the following: A. New onset of purulent sputum or change in character of sputum; B. Isolation of organism from blood culture; C. Isolation of pathogen from specimen obtained by transtracheal aspirate, bronchial brushing, or biopsy. |
| |



| Chen 2013 (Continued) | |
|-----------------------|---|
| | 2. Chest radiography showing new or progressive infitrate, consolidation, cavitation, or pleural effusion AND any of the following: |
| | A. New onset of purulent sputum or change in character of sputum; |
| | B. Isolation of organism from blood culture; |
| | o. C. Isolation of pathogen from specimen obtained by transtracheal aspirate, bronchial brushing, or |

- C. Isolation of pathogen from specimen obtained by transtracheal aspirate, bronchial brushing, or biopsy;
- D. Isolation of virus or detection of viral antigen in respiratory secretions;
- E. Diagnostic single-antibody titer or four-fold increase in paired serum samples for pathogen;
- F. Histopathologic evidence of pneumonia.

Wound infection: diagnosed by ASEPSIS > 20

Length of hospital stay

Notes

Two patients were excluded after randomization because their surgeries were cancelled

Risk of bias

| Bias | Authors' judgement | Support for judgement |
|---|--------------------|---|
| Random sequence genera- tion (selection bias) | Low risk | Quote: "Patients were randomly allocated from a computer-generated list." |
| Allocation concealment (selection bias) | Low risk | The random sequence was accessed through an intranet system. |
| Blinding of participants and personnel (perfor- mance bias) All outcomes | Unclear risk | This was not reported. |
| Blinding of outcome as- sessment (detection bias) Inhospital case fatality rate/length of stay | Low risk | The outcome measurement is not likely to be influenced by lack of blinding. |
| Blinding of outcome as- sessment (detection bias) Complications | Low risk | Quote: "The complications were examined by ward medical staff who were un- aware of the allocated group identity." |
| Incomplete outcome data (attrition bias) All outcomes | Low risk | Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups. |
| Selective reporting (re- porting bias) | Low risk | All outcomes described in methods section reported. |
| Other bias | High risk | Fewer than 50 participants per arm. |

Deleu 2000

| Methods | Single-centre RCT | |
|--------------|---|--|
| Participants | Setting: a hospital in Sultanate of Oman | |
| | Inclusion criteria: patients aged 55 years or above undergoing ophthalmic surgery | |

| Deleu 2000 (Continued) | | | |
|---|--|---|--|
| | Exclusion criteria: patients had suffering from any major organ failure; patients had clinical signs or symptoms of cobalamin or folate deficiency; patients had macrocytosis (mean corpuscular volume lower than 96 fl) or anaemia (haematocrit higher than 0.30); or patients had cobalamin and/or folate substitution therapy during the preceding months | | |
| | Participant numbers: 69 randomly assigned; 51 analysed | | |
| Interventions | Intervention: patients were premedicated with midazolam 5 to 7.5 mg by mouth 1 h before being transferred to the operating theatre. Anaesthesia was induced and maintained nitrous oxide-based with propofol. Control: patients were premedicated with midazolam 5 to 7.5 mg by mouth 1 h before being transferred to the operating theatre. Anaesthesia was induced and maintained nitrous oxide-free with propofol. | | |
| Outcomes | Secondary outcomes: | | |
| | Stroke: new neurologic | al signs (paralysis, weakness or speech difficulties) that persisted for 24 hours | |
| Notes | 18 patients were either lost to follow-up (n = 6), had one or more laboratory values missing (n = 9) or had taken folic acid or cobalamin-containing vitamins during the interval between surgery and re-evaluation (n = 3). | | |
| Risk of bias | | | |
| Bias | Authors' judgement | Support for judgement | |
| Random sequence genera- tion (selection bias) | Unclear risk | Described as randomized but no further details. | |
| Allocation concealment (selection bias) | Unclear risk | No details given. | |
| Blinding of participants and personnel (perfor- mance bias) All outcomes | Unclear risk | Described as double-blind but no further details. | |
| Blinding of outcome as- sessment (detection bias) Inhospital case fatality rate/length of stay | Unclear risk | _ | |
| Blinding of outcome as- sessment (detection bias) Complications | Unclear risk | Described as double-blind but no further details. | |
| Incomplete outcome data (attrition bias) All outcomes | Unclear risk | Insufficient information. | |
| Selective reporting (re- porting bias) | Low risk | All outcomes described in methods section reported. | |
| Other bias | High risk | Fewer than 50 participants per arm. | |



| Eger 1990 | |
|---------------|--|
| Methods | Single-centre RCT |
| Participants | Setting: a hospital in San Francisco, USA |
| | Inclusion criteria: patients scheduled for elective total hip arthroplasty, carotid endarterectomy, or transsphenoidal hypophysectomy |
| | Participant numbers: 270 randomly assigned; 260 analysed |
| Interventions | Intervention: patients received isoflurane, thiopental, vecuronium and 60% nitrous oxide/40% oxygen. The concentration of isoflurane was determined by the attending anaesthesiologist. Fentanyl and edrophonium/atropine were administered at the anaesthesiologist's discretion. Ventilation was controlled, and total gas flows of 5 L/min were maintained throughout surgery. Control: patients received isoflurane, thiopental, vecuronium and 100% oxygen. The concentration of isoflurane was determined by the attending anaesthesiologist. Fentanyl and edrophonium/atropine were administered at the other maintained throughout surgery. |
| Outcomes | Primary outcomes: |
| | Inhospital case fatality rate |
| | Secondary outcomes: |
| | Pneumonia: based on chest x-ray |
| | Pulmonary atelectasis: based on chest x-ray |
| | Myocardial infarction: new abnormalities in postoperative creatine kinase isoenzymes or Q-wave de- velopment |
| | Wound infection: determined by the surgeon in the setting of suspected infection. |
| | Length of hospital stay |
| Notes | _ |
| Risk of bias | |
| Dies | Authorshindson on Connect for independent |

| Bias | Authors' judgement | Support for judgement |
|---|--------------------|--|
| Random sequence genera- tion (selection bias) | Unclear risk | Described as randomized but no further details. |
| Allocation concealment (selection bias) | Unclear risk | No details given. |
| Blinding of participants and personnel (perfor- mance bias) All outcomes | Unclear risk | This was not reported. |
| Blinding of outcome as- sessment (detection bias) Inhospital case fatality rate/length of stay | Low risk | Quote: "All data collection, analysis, and patient interviews were performed by medical personnel blinded to the anaesthetic regimen." |
| Blinding of outcome as- sessment (detection bias) Complications | Low risk | Quote: "All data collection, analysis, and patient interviews were performed by medical personnel blinded to the anaesthetic regimen." |

Eger 1990 (Continued)

| Incomplete outcome data (attrition bias) All outcomes | Unclear risk | Insufficient information. |
|---|--------------|---|
| Selective reporting (re- porting bias) | Low risk | All outcomes described in methods section reported. |
| Other bias | Low risk | No other potential sources of bias were detected. |

ENIGMA II trial 2014

| Methods | Multicentre RCT Setting: 45 participating centres from 10 countries Inclusion criteria: | | | |
|--------------|--|--|--|--|
| Participants | | | | |
| | | | | |
| | Adult males and females age ≥ 45 years, undergoing noncardiac surgery and general anaesthesia ex- pected to exceed two hours. | | | |
| | At increased risk of cardiac events, defined as any of History of coronary artery disease as defined by a history of any one of the following: i. angina ii. MI iii. segmental wall motion abnormality on echocardiography or a fixed defect on radionuclide imaging iv. a positive exercise stress test for cardiac ischaemia v. a positive radionuclide exercise, echocardiographic exercise, or pharmacological cardiovascular stress test for cardiac ischaemia vi. coronary revascularization (CABG or PTCA) vii. angiographic evidence of atherosclerotic stenosis > 50% of the diameter of any coronary artery viii. ECG with pathological Q waves in two contiguous leads; Least feilure. | | | |
| | b. Heart failure; | | | |
| | c. Cerebrovascular disease thought due to atherothrombotic disease; | | | |
| | d. Aortic or peripheral vascular disease; | | | |
| | e. Or three or more of the following risk factors: Age ≥ 70 years; | | | |
| | Any history of congestive heart failure; | | | |
| | Diabetes and currently on an oral hypoglycaemic agent or insulin therapy; | | | |
| | Current treatment for hypertension; | | | |
| | Preoperative serum creatinine > 175 μmol/L (> 2.0 mg/dL); | | | |
| | Current or previous high cholesterol ≥ 6.2 mmol/L (> 240 mg/dL); | | | |
| | History of a TIA (i.e. a transient focal neurological deficit that lasted less than 24 hours and thought to be vascular in origin); | | | |
| | • Emergency/urgent surgery (i.e. surgery which must be undertaken within 24 hours of acute pre- sentation to hospital); | | | |
| | High-risk type of surgery (i.e. intrathoracic or intraperitoneal). | | | |
| | Exclusion criteria: | | | |
| | 1. Having cardiac surgery. | | | |
| | 2. Marked impairment of gas-exchange expected to require FiO ₂ > 0.5 intraoperatively. | | | |
| | 3. Specific circumstances where nitrous oxide is contraindicated (e.g. volvulus, pulmonary hyperten- sion, raised intracranial pressure) or the anaesthetist plans to use supplemental oxygen (e.g. colorec- tal surgery). | | | |
| | 4. Nitrous oxide unavailable for use. | | | |
| | Participant numbers: 7112 randomly assigned; 6992 analysed | | | |

| Interventions | Intervention: 70% nitrous oxide |
|---------------|---------------------------------|
| | |



ENIGMA II trial 2014 (Continued)

Control: no nitrous oxide

Outcomes

Primary outcomes:

The primary endpoint is a composite of death and cardiovascular events (clinical and silent MI, cardiac failure, cardiac arrest, pulmonary embolism, and stroke) measured at 30 days after surgery.

Secondary outcomes:

Myocardial infarction:

- A typical rise of troponin or a typical fall of an elevated troponin with at least one value above the 99th percentile of the upper reference limit, detected at its peak-post surgery in a patient without a documented alternative explanation for an elevated troponin (e.g. pulmonary embolism). This criterion also requires that 1 of the following must also exist: a) ischaemic signs or symptoms (i.e., chest, arm, neck, or jaw discomfort; shortness of breath, pulmonary edema); b) development of pathologic Q waves present in any two contiguous leads that are > 30 milliseconds; c) ECG changes indicative of ischaemia (i.e. ST segment elevation [> 2 mm in leads V1, V2, or V3; or > 1 mm in the other leads], ST segment depression [> 1 mm], or symmetric inversion of T waves > 1 mm) in at least two contiguous leads; d) coronary artery intervention (i.e. PCI or CABG surgery); e) new or presumed new cardiac wall motion abnormality on echocardiography or new or presumed new fixed defect on radionuclide imaging.
- Pathologic findings of an acute or healing myocardial infarction.
- Development of new pathological Q waves on an ECG if troponin levels were not obtained or were obtained at times that could have missed the clinical event.

Wound infection

At least one of the following:

- Purulent drainage from the incision.
- · Positive microbial culture from the incision.
- Documentation of a wound infection in the medical record.

Stroke

• New cerebral infarction or haemorrhage on CT scan, MRI or documented new neurological signs (paralysis, weakness or speech difficulties) lasting more than 24 hours or leading to earlier death (confirmed by a copy of the autopsy report or in the medical record).

Severe nausea and vomiting

• At least two separate episodes of nausea or vomiting greater than six hours apart, or if requiring three or more doses of antiemetic medication, within three days after surgery.

Pulmonary embolism

• A high probability VQ scan, spiral CT or documented on pulmonary angiogram; or pathological findings (with autopsy).

Hospital stay

| Notes | ClinicalTrials.gov identifier: NCT00430989 | |
|-------------------------|--|---|
| Risk of bias | | |
| Bias | Authors' judgement | Support for judgement |
| Random sequence genera- | Low risk | Quote: "Randomization was done with a computer-generated code." |

ENIGMA II trial 2014 (Continued)

| Allocation concealment (selection bias) | Low risk | Quote: "Randomization sequence was accessed via an automated telephone voice-recognition service." |
|---|----------|--|
| Blinding of participants and personnel (perfor- mance bias) All outcomes | Low risk | Quote: "The attending anaesthetists were aware of the patients' group assign- ments, but the patients, their surgical team were not." |
| Blinding of outcome as- sessment (detection bias) Inhospital case fatality rate/length of stay | Low risk | Quote: "The postoperative interviewers, and endpoint adjudicators were un- aware of the patients' group assignments." |
| Blinding of outcome as- sessment (detection bias) Complications | Low risk | Quote: "The postoperative interviewers, and endpoint adjudicators were un- aware of the patients' group assignments." |
| Incomplete outcome data (attrition bias) All outcomes | Low risk | Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups. |
| Selective reporting (re- porting bias) | Low risk | Protocol was registered as NCT00430989 and outcomes were reported. |
| Other bias | Low risk | No other potential sources of bias were detected. |

ENIGMA trial 2007

| Methods | Multi-centre RCT | | |
|---------------|---|--|--|
| Participants | Setting: 19 hospitals from 6 countries | | |
| | Inclusion criteria: patients were aged 18 years or older, were scheduled to undergo general anaesthe- sia for surgery that included a skin incision and that was anticipated to exceed 2 h, and were expected to be in the hospital for at least 3 days after surgery | | |
| | Exclusion criteria: patients undergoing cardiac surgery, or thoracic surgery requiring one-lung ventila- tion; patients that the anaesthesiologist considered that nitrous oxide was contraindicated (e.g. a his- tory of post-operative emesis or if the anaesthesiologist wanted to use supplemental oxygen for col- orectal surgery) | | |
| | Participant numbers: 2050 randomly assigned; 2012 analysed | | |
| Interventions | Intervention: patients were administered a gas mixture of 70% nitrous oxide with 30% oxygen after in- duction of anaesthesia and until completion of surgery. Control: patients were administered a gas mixture of 80% oxygen with 20% nitrogen after induction of anaesthesia and until completion of surgery. | | |
| Outcomes | Primary outcomes: | | |
| | Inhospital case fatality rate | | |
| | Secondary outcomes: | | |
| | Pneumonia: radiologic infiltrate confirmed by chest x-ray or computed tomography, in association with at least one of the following: temperature greater than 38°C, leukocyte count greater than 12,000/mL, or positive sputum culture that was not heavily contaminated with oral flora or that corresponded with positive blood cultures | | |

ENIGMA trial 2007 (Continued)

| | Myocardial infarction: confirmed by ECG and/or troponin or CK-MB enzyme rise | | | |
|---|--|--|--|--|
| | Stroke: a new neurological deficit persisting for 24 hours, confirmed by neurologist assessment and/or computed tomography scan or magnetic resonance imaging Severe nausea and vomiting: at least 2 episodes > 6 hrs apart, or if requiring > 2 doses of antiemetic medication | | | |
| | | | | |
| | Venous thromboembo ultrasonography, V-Q s | Venous thromboembolism: symptomatic deep venous thrombosis, confirmed by venography, duplex ultrasonography, V-Q scan or spiral computed tomography, or autopsy | | |
| | Wound infection: if associated with purulent discharge or a positive microbial culture Length of hospital stay Length of ICU stay | | | |
| | | | | |
| | | | | |
| Notes | ClinicalTrials.gov identifier: NCT00164047 | | | |
| Risk of bias | | | | |
| Bias | Authors' judgement | Support for judgement | | |
| Random sequence genera- tion (selection bias) | Low risk | Quote: "Patients were randomly assigned using a computer-generated code." | | |
| Allocation concealment (selection bias) | Low risk | Quote: "The random sequence was accessed via an automated telephone voice recognition service." | | |
| Blinding of participants and personnel (perfor- mance bias) All outcomes | Low risk | Quote: "All research staff, including those responsible for postoperative data collection and outcome assessment, were precluded by protocol from accessing the anaesthetic record and so were blinded to group identity." | | |
| Blinding of outcome as- sessment (detection bias) Inhospital case fatality rate/length of stay | Low risk | Quote: "All research staff, including those responsible for postoperative data collection and outcome assessment, were precluded by protocol from accessing the anaesthetic record and so were blinded to group identity." | | |
| Blinding of outcome as- sessment (detection bias) Complications | Low risk | Quote: "All research staff, including those responsible for postoperative data collection and outcome assessment, were precluded by protocol from accessing the anaesthetic record and so were blinded to group identity." | | |
| Incomplete outcome data (attrition bias) All outcomes | Low risk | Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups. | | |
| Selective reporting (re- porting bias) | Low risk | Protocol was registered as NCT00164047 and outcomes were reported. | | |
| Other bias | Low risk | No other potential sources of bias were detected. | | |

Pulmonary atelectasis: confirmed by chest x-ray or computed tomography

Fleischmann 2005

Methods

Multi-centre RCT

| Fleischmann 2005 (Cor | ntinued) |
|-----------------------|---|
| Participants | Setting: three hospitals in Austria and Hungary |
| | Inclusion criteria: 418 ASA I-III patients, aged 18 to 80 years, scheduled for elective colon resection expected to last more than 2 h |
| | Exclusion criteria: patients with acute bowel obstruction or those having minor colon surgery (e.g. polypectomy, isolated colostomy); patients in whom the surgeon did not anticipate primary wound closure; patients with a history of fever or infection within 24 h of surgery |
| | Participant numbers: 418 randomly assigned; 408 analysed |
| Interventions | Intervention: anaesthetic management was standardized. Thiopental sodium (3 to 5 mg/kg) or propofol (2 to 3 mg/kg), fentanyl (1 to 3 μg/kg), and vecuronium (0.1 mg/kg) or rocuronium (0.6 mg/kg) were used for induction; anaesthesia was maintained with isoflurane (0.6%) in 65% nitrous oxide, with vecuronium or rocuronium. An infusion of remifentanil (0.2 μg/kg/min) was subsequently started. Control: anaesthetic management was standardized. Thiopental sodium (3 to 5 mg/kg) or propofol (2 to 3 mg/kg), fentanyl (1 to 3 μg/kg), and vecuronium (0.1 mg/kg) or rocuronium (0.6 mg/kg) were used for induction; anaesthesia was maintained with isoflurane (0.6%) in for subsequently started. Control: anaesthetic management was standardized. Thiopental sodium (3 to 5 mg/kg) or propofol (2 to 3 mg/kg), fentanyl (1 to 3 μg/kg), and vecuronium (0.1 mg/kg) or rocuronium (0.6 mg/kg) were used for induction; anaesthesia was maintained with isoflurane (0.6%) in nitrogen, with vecuronium or rocuronium. An infusion of remifentanil (0.2 μg/kg/min) was subsequently started. |
| Outcomes | Primary outcomes: |
| | Inhospital case fatality rate |
| | Secondary outcomes: |
| | Wound infection: pus was expressed from the surgical incision or aspirated from a loculated mass in- side the wound; the culture of pus was positive for pathogenic bacteria |
| | Length of hospital stay |
| Notes | The data cover sheets were lost for 4 patients; thus, their group assignment was unknown. Surgical complications occurred in 2 patients in the nitrous oxide group that required stopping the study. 4 patients in the nitrogen group were excluded from the analysis: 1 patient was excluded when the attending physician refused to allow the patient to participate; the other 3 patients that were excluded did not meet the inclusion criteria. |
| Risk of bias | |

| Bias | Authors' judgement | Support for judgement |
|---|--------------------|---|
| Random sequence genera- tion (selection bias) | Low risk | Quote: "The assignments were based on computer-generated random num- bers." |
| Allocation concealment (selection bias) | Low risk | Quote: "The random sequence was kept in sealed, sequentially numbered en- velopes until used." |
| Blinding of participants and personnel (perfor- mance bias) All outcomes | Low risk | Quote: "Patients were not informed of their group assignments." |
| Blinding of outcome as- sessment (detection bias) Inhospital case fatality rate/length of stay | Low risk | The outcome measurement is not likely to be influenced by lack of blinding. |
| Blinding of outcome as- sessment (detection bias) Complications | Low risk | Quote: "Surgical wounds were examined daily by a physician unaware of group assignment." |

Fleischmann 2005 (Continued)

| Incomplete outcome data (attrition bias) All outcomes | Low risk | Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups. |
|---|----------|---|
| Selective reporting (re- porting bias) | Low risk | All outcomes described in methods section reported. |
| Other bias | Low risk | No other potential sources of bias were detected. |

Gilani 2008

| Methods | Single-centre RCT | | | |
|---|--|--|--|--|
| Participants | Setting: King Fahad N | ational Guard Hospital, Saudi Arabia | | |
| | Inclusion criteria: patients above age of 18 years undergoing various elective and emergency surgical procedures under general anaesthesia | | | |
| | Exclusion criteria: pai | tients undergoing cardiac surgery or thoracic surgery | | |
| | Participant numbers: | Participant numbers: 200 randomly assigned; 200 analysed | | |
| Interventions | Intervention: general anaesthesia was maintained by 40% oxygen (FiO ₂ 0.4) with nitrous oxide and volatile anaesthetic sevoflurane (MAC 1.2-1.3) through oral endotracheal tube or laryngeal mask depending on the type of surgery. All patients received standard anaesthetic care and monitoring. Control: general anaesthesia was maintained by 40% oxygen (FiO ₂ 0.4) with air and volatile anaesthetic sevoflurane (MAC 1.2-1.3) through oral endotracheal tube or laryngeal mask depending on the type of surgery. All patients received standard anaesthetic care and monitoring. | | | |
| Outcomes | Other outcomes: | | | |
| | Postoperative pain | | | |
| Notes | _ | | | |
| Risk of bias | | | | |
| Bias | Authors' judgement | Support for judgement | | |
| Random sequence genera- tion (selection bias) | Unclear risk | Described as randomized but no further details. | | |
| Allocation concealment (selection bias) | Unclear risk | No details given. | | |
| Blinding of participants and personnel (perfor- mance bias) All outcomes | Unclear risk | This was not reported. | | |
| Blinding of outcome as- sessment (detection bias) Inhospital case fatality rate/length of stay | Unclear risk | _ | | |
| Blinding of outcome as- sessment (detection bias) | Unclear risk | This was not reported. | | |
| Nitrous oxide-based techniques | s versus nitrous oxide-free | techniques for general anaesthesia (Review) | | |

Copyright @ 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



Gilani 2008 (Continued) Complications

| - | | |
|---|----------|---|
| Incomplete outcome data (attrition bias) All outcomes | Low risk | No missing data. |
| Selective reporting (re- porting bias) | Low risk | All outcomes described in methods section reported. |
| Other bias | Low risk | No other potential sources of bias were detected. |

Jensen 1992

| Methods | Single-centre RCT | | |
|---------------|--|--|--|
| Participants | Setting: University Hospital Linköping, Linköping, Sweden | | |
| | Inclusion criteria: patients aged 18 to 85 years, scheduled for intraabdominal operations of the colon and rectum | | |
| | Participant numbers: 60 randomly assigned; 60 analysed | | |
| Interventions | Intervention: two anaesthetic protocols were used for induction and maintenance of anaesthesia. In protocol 1, patients received thiopentone 4 mg/kg and fentanyl 2 μg/kg intravenous for induction of anaesthesia; additional thiopentone was given if needed. During the operation the lungs were ventilated with isoflurane and 30% oxygen in nitrous oxide; fentanyl intravenous was added in amounts to ensure adequate anaesthesia. Whenever needed, the inhaled concentration of isoflurane was changed based on the use of precisely defined clinical signs of inadequate anaesthesia. In protocol 2, patients received a modified total intravenous anaesthesia; Propofol 2 mg/kg intravenous was given for induction of sleep and an infusion of propofol was given at a rate of 6 mg/kg/h for the first 30 min and then reduced to 4 mg/kg/h. Fentanyl was given for induction in a bolus dose of 2 μg/kg, followed by an infusion of 5 μg/kg/h. After 30 rain, this infusion rate was reduced to 2.5 μg/kg/h. During anaesthesia the lungs of these patents were ventilated with 30% oxygen in nitrous oxide. Whenever needed, the infusion rates of both propofol and fentanyl was changed based on the use of precisely defined clinical signs of inadequate anaesthesia. Control: patients received total intravenous anaesthesia, with sleep induction by propofol 2 mg/kg followed immediately by an initial infusion of 9 mg/kg/h of propofol, reduced to 6 mg/kg/h. The rate of fentanyl was given in a bolus dose of 2 μg/kg/h. The rate of fentanyl infusion was reduced after 30 min to 3.75 μg/kg/h. Ventilation was with oxygen in air to give an inspiratory fraction of oxygen of 0.3. Whenever needed, the infusion rates of both propofol and fentanyl was given in easesthesia. | | |
| Outcomes | Secondary outcomes: | | |
| | Pneumonia: no specific definition | | |
| | Pulmonary atelectasis: no specific definition | | |
| | Length of hospital stay | | |
| Notes | _ | | |
| Risk of bias | | | |
| Bias | Authors' judgement Support for judgement | | |

Jensen 1992 (Continued)

| Random sequence genera- tion (selection bias) | Unclear risk | Described as randomized but no further details. |
|---|--------------|---|
| Allocation concealment (selection bias) | Low risk | Quote: "A set of numbered envelopes was used." |
| Blinding of participants and personnel (perfor- mance bias) All outcomes | Unclear risk | The patients were blinded, but insufficient information on the personnel. |
| Blinding of outcome as- sessment (detection bias) Inhospital case fatality rate/length of stay | Low risk | The outcome measurement is not likely to be influenced by lack of blinding. |
| Blinding of outcome as- sessment (detection bias) Complications | Unclear risk | Insufficient information. |
| Incomplete outcome data (attrition bias) All outcomes | Low risk | No missing data. |
| Selective reporting (re- porting bias) | Low risk | All outcomes described in methods section reported. |
| Other bias | High risk | Fewer than 50 participants per arm. |

Jensen 1993a Methods Single-centre RCT Participants Setting: University Hospital Linköping, Linköping, Sweden Inclusion criteria: patients > 18 years, scheduled for laparoscopic cholecystectomy Participant numbers: 42 randomly assigned; 42 analysed for the outcome of pneumonia; 40 analysed for the outcome of length of hospital stay Interventions Intervention: patients received meperidine 1 mg/kg and atropine 6 µg/kg im for premedication approximately 45 min prior to anaesthetic induction. Anaesthesia was induced intravenously with fentanyl 2 µg/kg, and thiopental 4 to 6 mg/kg was administered until loss of eyelash reflex. Tracheal intubation was facilitated by the use of succinylcholine 1 mg/kg after pretreatment with vecuronium 1 mg. The patients received isoflurane with nitrous oxide in oxygen for maintenance of anaesthesia. An inspiratory fraction of oxygen of 0.3 was used. **Control:** patients received meperidine 1 mg/kg and atropine $6 \mu g/kg$ im for premedication approximately 45 min prior to anaesthetic induction. Anaesthesia was induced intravenously with fentanyl 2 μ g/kg, and thiopental 4 to 6 mg/kg was administered until loss of eyelash reflex. Tracheal intubation was facilitated by the use of succinylcholine 1 mg/kg after pretreatment with vecuronium 1 mg. The patients received isoflurane with air in oxygen for maintenance of anaesthesia. An inspiratory fraction of oxygen of 0.3 was used. Outcomes Secondary outcomes: Pneumonia: no specific definition



Jensen 1993a (Continued)

| | Length of hospital stay | , |
|---|-------------------------|--|
| Notes | _ | |
| Risk of bias | | |
| Bias | Authors' judgement | Support for judgement |
| Random sequence genera- tion (selection bias) | Unclear risk | Described as randomized but no further details. |
| Allocation concealment (selection bias) | Unclear risk | No details given. |
| Blinding of participants and personnel (perfor- mance bias) All outcomes | Unclear risk | Described as double-blind but no further details. |
| Blinding of outcome as- sessment (detection bias) Inhospital case fatality rate/length of stay | Low risk | The outcome measurement is not likely to be influenced by lack of blinding. |
| Blinding of outcome as- sessment (detection bias) Complications | Low risk | Quote: "Postoperative data was assessed by the postoperative ward staff and surgeon blinded to the anaesthetic technique." |
| Incomplete outcome data (attrition bias) All outcomes | Low risk | Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups. |

| Selective reporting (re- porting bias) | Low risk | All outcomes described in methods section reported. |
|---|-----------|---|
| Other bias | High risk | Fewer than 50 participants per arm. |

Jensen 1993b

| Methods | Single-centre RCT | |
|---------------|--|--|
| Participants | Setting: University Hospital Linköping, Linköping, Sweden | |
| | Inclusion criteria: patients scheduled for major operations on the intestines, and with an expected du ration of surgery of more than 1 h | |
| | Participant numbers: 42 randomly assigned; 42 analysed | |
| Interventions | Intervention: patients received flunitrazepam 0.5 to 1 mg by mouth as premedication 1 h before in- duction of anaesthesia. Two anaesthetic protocols were used for induction and maintenance of anaes- thesia. In protocol 1, patients received intravenous thiopentone 4 mg/kg and fentanyl 2 µg/kg for in- duction of anaesthesia. Fentanyl supplements were given as needed during the operation. Isoflurane (0.5 to 1.5%) in 70% nitrous oxide/30% oxygen was used for the maintenance of anaesthesia. In proto- col 2, propofol 2 mg/kg was used for induction, and anaesthesia was maintained using propofol at a rate of 6 mg/kg/h for the first 30 min and 4 mg/kg/h thereafter. At induction, fentanyl was given in a bo- lus dose of 2 µg/kg followed by an infusion rate of 5 µg/kg/h. After 30 min this was reduced to 2.5 µg/ kg/h. The lungs were ventilated with 30% oxygen in nitrous oxide. For all the patients, vecuronium 1 | |



Trusted evidence. Informed decisions. Better health.

| Jensen 1993b (Continued) | mg was given for precurarization followed by suxamethonium 1 mg/kg for tracheal intubation. Ventila- tion was adjusted to give an arterial carbon dioxide tension of 44.5 kPa. Control: patients received flunitrazepam 0.5 to 1 mg by mouth as premedication 1 h before induction of anaesthesia. Anaesthesia was induced with propofol 2 mg/kg and maintained by a total intravenous technique using propofol 9 mg/kg/h for the first 30 min, followed by propofol 6 mg/kg/h. Fentanyl was given in a bolus dose of 2 μg/kg, followed by an infusion of 7.5 μg/kg/h. The fentanyl infusion was also reduced after 30 min to 3.75 μg/kg/h. Oxygen in air was used for ventilation (FiO ₂ , 0.3). The patients re- ceived vecuronium 1 mg for precurarization followed by suxamethonium 1 mg/kg for tracheal intuba- tion. Ventilation was adjusted to give an arterial carbon dioxide tension of 44.5 kPa. | | |
|--|---|---|--|
| Outcomes | Secondary outcome: | | |
| | Pulmonary atelectasis: | defined by CT scans | |
| Notes | _ | | |
| Risk of bias | | | |
| Bias | Authors' judgement | Support for judgement | |
| Random sequence genera- tion (selection bias) | Unclear risk | Described as randomized but no further details. | |
| Allocation concealment (selection bias) | Unclear risk | No details given. | |

| Blinding of participants and personnel (perfor- mance bias) All outcomes | Unclear risk | This was not reported. |
|---|--------------|--|
| Blinding of outcome as- sessment (detection bias) Inhospital case fatality rate/length of stay | Unclear risk | _ |
| Blinding of outcome as- sessment (detection bias) Complications | Low risk | Quote: "The CT scans for the diagnosis of pulmonary atelectasis were reviewed blind to the anaesthetic given." |
| Incomplete outcome data (attrition bias) All outcomes | Low risk | No missing data. |
| Selective reporting (re- porting bias) | Low risk | All outcomes described in methods section reported. |
| Other bias | High risk | Fewer than 50 participants per arm. |

Kozmary 1990

| Methods | Single-centre RCT | |
|--------------|---|--|
| Participants | Setting: a hospital in California, USA | |
| | Inclusion criteria: patients scheduled for carotid endarterectomy or other surgery on the carotid artery | |



| Kozmary 1990 (Continued) | Participant numbers: | 70 randomly assigned; 70 analysed |
|---|--|--|
| Interventions | Intervention: patients received isoflurane, fentanyl (2 to 5 μg/kg), thiopental (2 to 5 mg/kg), vecuroni- um, and 60% nitrous oxide/40% oxygen. The patients were mechanically ventilated with tidal volumes of 10 mL/kg at a rate sufficient to produce an end-tidal carbon dioxide of 30 to 35 mmHg. Control: patients received isoflurane, fentanyl (2 to 5 μg/kg), thiopental (2 to 5 mg/kg), vecuronium, and 100% oxygen. The patients were mechanically ventilated with tidal volumes of 10 mL/kg at a rate sufficient to produce an end-tidal carbon dioxide of 30 to 35 mmHg. | |
| Outcomes | Secondary outcomes: | |
| | Myocardial infarction: o | defined by creatine kinase enzyme changes. |
| Notes | _ | |
| Risk of bias | | |
| Bias | Authors' judgement | Support for judgement |
| Random sequence genera- tion (selection bias) | Unclear risk | Described as randomized but no further details. |
| Allocation concealment (selection bias) | Unclear risk | No details given. |
| Blinding of participants and personnel (perfor- mance bias) All outcomes | Unclear risk | The patients were blinded, but insufficient information on the personnel. |
| Blinding of outcome as- sessment (detection bias) Inhospital case fatality rate/length of stay | Unclear risk | _ |
| Blinding of outcome as- sessment (detection bias) Complications | Low risk | Quote: "Experts unaware of the choice of anaesthetic analysed the data for di- agnosis of myocardial infarction." |
| Incomplete outcome data (attrition bias) All outcomes | Low risk | No missing data. |
| Selective reporting (re- porting bias) | Low risk | All outcomes described in methods section reported. |
| Other bias | High risk | Fewer than 50 participants per arm. |

Krogh 1994

| Methods | Single-centre RCT | |
|--------------|--|--|
| Participants | Setting: a hospital in Odense, Denmark | |
| | Inclusion criteria: ASA I-II patients scheduled for elective major colonic surgery | |



Krogh 1994 (Continued)

| | Participant numbers: 139 randomly assigned; 139 analysed | |
|---|---|---|
| Interventions | Intervention: premedication comprised diazepam 0.2 mg/kg orally. Anaesthesia was induced with fen- tanyl 2 to 5 μg/kg intravenous. Propofol was given as a bolus dose of 1 mg/kg. All patients breathed 100% oxygen during induction. The patient's lungs were ventilated with oxygen via a face mask until the trachea had been intubated. Tracheal intubation was facilitated by administration of pancuronium 0.1mg/kg. Anaesthesia was maintained with fentanyl 2 to 4 μg/kg/h and propofol 1 to 2 mg/kg/h. The lungs of the patients were ventilated with nitrous oxide in oxygen. The inspiratory oxygen concentra- tion was maintained at 30%. Neuromuscular block was maintained with pancuronium 1 to 2 mg if train- of-four showed one or two twitches. Before induction of anaesthesia, a lumbar extradural catheter was inserted and extradural bupivacaine given. Control: premedication comprised diazepam 0.2 mg/kg orally. Anaesthesia was induced with fen- tanyl 2 to 5 μg/kg intravenous. Propofol was given as a bolus dose of 1 mg/kg. All patients breathed 100% oxygen during induction. The patient's lungs were ventilated with oxygen via a face mask until the trachea had been intubated. Tracheal intubation was facilitated by administration of pancuronium 0.1mg/kg. Anaesthesia was maintained with fentanyl 2 to 4 μg/kg/h and propofol 4 to 6 mg/kg/h. The lungs of the patients were ventilated with oxygen and air. The inspiratory oxygen concentration was maintained at 30%. Neuromuscular block was maintained with pancuronium 1 to 2 mg if train-of-four showed one or two twitches. Before induction of anaesthesia, a lumbar extradural catheter was insert- ed and extradural bupivacaine given. | |
| Outcomes | Secondary outcomes: | |
| Notes | Length of hospital stay | |
| Risk of bias | | |
| Bias | Authors' iudgement | Support for judgement |
| Random sequence genera- tion (selection bias) | Unclear risk | Described as randomized but no further details. |
| Allocation concealment (selection bias) | Unclear risk | No details given. |
| Blinding of participants and personnel (perfor- mance bias) All outcomes | Unclear risk | This was not reported. |
| Blinding of outcome as- sessment (detection bias) Inhospital case fatality rate/length of stay | Low risk | The outcome measurement is not likely to be influenced by lack of blinding. |
| Blinding of outcome as- sessment (detection bias) Complications | Unclear risk | _ |
| Incomplete outcome data (attrition bias) All outcomes | Low risk | No missing data. |
| Selective reporting (re- porting bias) | Low risk | All outcomes described in methods section reported. |
| Other bias | Low risk | No other potential sources of bias were detected. |



Lampe 1990

| Methods | Single-centre RCT | | |
|---------------|--|--|--|
| Participants | Setting: a hospital in California, USA | | |
| | Inclusion criteria: patients presenting for elective resection of acoustic neuroma | | |
| | Participant numbers: 26 randomly assigned; 26 analysed | | |
| Interventions | Intervention: premedication (triazolam, and/or morphine, or none) and intraoperative fentanyl and edrophonium/atropine were administered at the discretion of the anaesthesiologist. Patients received thiopental and vecuronium and the lungs were ventilated with 50 to 60% nitrous oxide/30 to 40% oxygen and isoflurane. Inhaled isoflurane concentrations were adjusted to maintain clinically acceptable levels of anaesthesia as determined by the attending anaesthesiologist. Ventilation was controlled, and total gas flows of 5 L/min were maintained throughout surgery. Control: premedication (triazolam, and/or morphine, or none) and intraoperative fentanyl and edrophonium/atropine were administered at the discretion of the anaesthesiologist. Patients received thiopental and vecuronium and the lungs were ventilated with 100% oxygen and isoflurane. Inhaled isoflurane concentrations were adjusted to maintain clinically acceptable levels of anaesthesia as determined at the discretion of the anaesthesiologist. Patients received thiopental and vecuronium and the lungs were ventilated with 100% oxygen and isoflurane. Inhaled isoflurane concentrations were adjusted to maintain clinically acceptable levels of anaesthesia as determined by the attending anaesthesiologist. Ventilation was controlled, and total gas flows of 5 L/min were maintained throughout surgery. | | |
| Outcomes | Primary outcomes: | | |
| | Inhospital case fatality rate | | |
| | Secondary outcomes: | | |
| | Pneumonia: based on radiographic evidence and increased white blood cell count plus fever | | |
| | Pulmonary atelectasis: based on radiographic evidence | | |
| | Wound infection: as defined by the surgeon | | |
| | Length of hospital stay | | |
| Notes | | | |
| Risk of bias | | | |
| Bias | Authors' judgement Support for judgement | | |

| Bias | Authors' judgement | Support for judgement |
|---|--------------------|--|
| Random sequence genera- tion (selection bias) | Unclear risk | Described as randomized but no further details. |
| Allocation concealment (selection bias) | Unclear risk | No details given. |
| Blinding of participants and personnel (perfor- mance bias) All outcomes | Unclear risk | This was not reported. |
| Blinding of outcome as- sessment (detection bias) Inhospital case fatality rate/length of stay | Low risk | Quote: "All data collection (including patient interviews) and analyses were performed by individuals unaware of the patient's anaesthetic regimen." |

Lampe 1990 (Continued)

| Blinding of outcome as- sessment (detection bias) Complications | Low risk | Quote: "All data collection (including patient interviews) and analyses were performed by individuals unaware of the patient's anaesthetic regimen." |
|---|-----------|--|
| Incomplete outcome data (attrition bias) All outcomes | Low risk | No missing data. |
| Selective reporting (re- porting bias) | Low risk | All outcomes described in methods section reported. |
| Other bias | High risk | Fewer than 50 participants per arm. |

Larsen 2000

| Methods | Single-centre RCT | |
|--|---|--|
| Participants | Setting: University of Saarland, Germany | |
| | Inclusion criteria: ASA | I-II patients, aged 18–65 year, scheduled for elective operative procedures |
| | Exclusion criteria: a h or alcohol abuse; more or familial history of m who refused to give con | istory of a significant cardiac, pulmonary, hepatic, or renal disease; chronic drug bid obesity; disabling neuropsychiatric disorders; hypersensitivity to aesthetics alignant hyperthermia; women who were pregnant or breast-feeding; patients nsent 60 randomly assigned; 60 analysed |
| | | |
| Interventions | Intervention: before the induction of anaesthesia, all patients received fentanyl 2 μ g/kg IV, then breathed 100% oxygen for 3 min. Anaesthesia was induced with propofol 2 mg/kg IV. After loss of con- sciousness, patients received either desflurane at an endtidal concentration of 5% or sevoflurane 1.7% and rocuronium 0.6 mg/kg to facilitate endotracheal intubation. Maintenance of anaesthesia was pro- vided with the respective volatile anaesthetic (0.85 MAC concentration with nitrous oxide 65% in oxy- gen; the inspired concentration was adjusted to maintain mean arterial pressure within 20% of base- line values. Control: patients were infused with remifentanil at a rate of 0.5 μ g/kg/min until they felt dazed. There- after, anaesthesia was induced by propofol in a dose adequate for loss of eye-lash reflex, followed by rocuronium 0.6 mg/kg for tracheal intubation. After intubation, remifentanil infusion was reduced to 0.25 μ g/kg/min, and a propofol infusion was started at a rate of 3 mg/kg/min and maintained through- out surgery. During the maintenance of anaesthesia, patients were ventilated with a fresh gas flow of 2 L/min of oxygen 35% in air by using a semiclosed circle system. No inhaled anaesthetics were given. | |
| Outcomes | Other outcomes: | |
| | Quality of recovery | |
| Notes | _ | |
| Risk of bias | | |
| Bias | Authors' judgement | Support for judgement |
| Random sequence genera- tion (selection bias) | Unclear risk | Described as randomized but no further details. |



Larsen 2000 (Continued)

| Allocation concealment (selection bias) | Unclear risk | No details given. |
|---|--------------|---|
| Blinding of participants and personnel (perfor- mance bias) All outcomes | High risk | Quote: "The assignment of patients was single blinded." |
| Blinding of outcome as- sessment (detection bias) Inhospital case fatality rate/length of stay | Unclear risk | _ |
| Blinding of outcome as- sessment (detection bias) Complications | Low risk | Quote: "Observer was blinded to the anaesthesia the patients had received." |
| Incomplete outcome data (attrition bias) All outcomes | Low risk | No missing data. |
| Selective reporting (re- porting bias) | Low risk | All outcomes described in methods section reported. |
| Other bias | Low risk | No other potential sources of bias were detected. |

Lee 2005

| Methods | Single-centre RCT | | |
|---------------|--|--|--|
| Participants | Setting: University of Hong Kong, China | | |
| | Inclusion criteria: patients undergoing open colorectal surgery | | |
| | Exclusion criteria: patients were excluded from the study if they had known allergy to remifentanil or morphine, had abnormal preoperative renal or hepatic function, regularly took analgesics or had consumed any kind of opioid within the past 24 h, had a history of drug or alcohol abuse, were unable to use patient-controlled analgesia, were less than 18 yr old, or had a body weight that was not within 20% of ideal | | |
| | Participant numbers: 60 randomly assigned; 60 analysed | | |
| Interventions | Intervention: patients received isoflurane at an end tidal concentration of 0.5 to 1.5% (according to clinical requirement), delivered with 70% nitrous oxide in oxygen. Control: patients received isoflurane at an end tidal concentration of 0.5 to 1.5% (according to clinical requirement) delivered in an oxygen-air gas mixture and they also received an intravenous infusion of remifentanil at 0.05 to 0.5 µg/kg/min. | | |
| Outcomes | Other outcomes: | | |
| | Postoperative opioid consumption | | |
| Notes | _ | | |
| Risk of bias | | | |



Lee 2005 (Continued)

| Bias | Authors' judgement | Support for judgement |
|---|--------------------|--|
| Random sequence genera- tion (selection bias) | Low risk | Quote: "Randomization was based on computer-generated codes." |
| Allocation concealment (selection bias) | Low risk | Opaque envelopes were used. |
| Blinding of participants and personnel (perfor- mance bias) All outcomes | Unclear risk | This was not reported. |
| Blinding of outcome as- sessment (detection bias) Inhospital case fatality rate/length of stay | Unclear risk | _ |
| Blinding of outcome as- sessment (detection bias) Complications | Low risk | Nurses and acute pain team members who were not involved in the study and were unaware of the patients' intraoperative randomization conducted obser- vation and management in the postanaesthesia care unit and subsequently the ward. |
| Incomplete outcome data (attrition bias) All outcomes | Low risk | No missing data. |
| Selective reporting (re- porting bias) | Low risk | All outcomes described in methods section reported. |
| Other bias | Low risk | No other potential sources of bias were detected. |

Leung 2006

| Methods | Single-centre RCT | | |
|---------------|--|--|--|
| Participants | Setting: University of California, San Francisco Medical Centre, USA | | |
| | Inclusion criteria: consecutive men or women who were > 65 years of age, undergoing non-cardiac surgery, requiring general anaesthesia, who were expected to remain in the hospital after operation for > 48 h | | |
| | Exclusion criteria: patients who could not complete the neuropsychological testing such as those who were expected to remain intubated after operation; patients who not able to provide informed consent; surgical cases in which the use of nitrous oxide was contraindicated | | |
| | Participant numbers: 228 randomly assigned; 228 analysed | | |
| Interventions | Intervention: pre-medication was limited to fentanyl up to 2 µg/kg intravenous. During operation, mechanical ventilation was initiated to maintain normocarbia and oxygen saturation > 95%. Anaesthetists were requested to control intraoperative heart rate and blood pressure to within \pm 30% of preoperative baseline measurements. Intraoperative monitoring was not controlled by the study but was measured. Additional intravenous morphine sulfate or fentanyl was allowed to be titrated to maintain spontaneous ventilatory frequencies of 10 to 20 bpm and end-tidal CO ₂ between 45 and 55 mm Hg while the inhalational agents were discontinued at the conclusion of surgery. The intraoperative anaesthetic management was consisted of nitrous oxide with oxygen plus a potent inhalational agent. In order to | | |



| Leung 2006 (Continued) | | |
|---|---|---|
| | make the study clinical spired concentrations of Control: pre-medication chanical ventilation wa were requested to cont baseline measurement Additional intravenous neous ventilatory frequ inhalational agents we management was cons ically feasible, the stud of oxygen during surge | ly feasible, the study allowed the anaesthetists to adjust the percentages of in- of oxygen during surgery as clinically indicated. on was limited to fentanyl up to 2 μ g/kg intravenous. During operation, me- as initiated to maintain normocarbia and oxygen saturation > 95%. Anaesthetists trol intraoperative heart rate and blood pressure to within ± 30% of preoperative es. Intraoperative monitoring was not controlled by the study but was measured. morphine sulfate or fentanyl was allowed to be titrated to maintain sponta- uencies of 10 to 20 bpm and end-tidal CO ₂ between 45 and 55 mm Hg while the re discontinued at the conclusion of surgery. The intraoperative anaesthetic sisted of oxygen plus a potent inhalational agent. In order to make the study clin- y allowed the anaesthetists to adjust the percentages of inspired concentrations ry as clinically indicated. |
| Outcomes | Primary outcomes: | |
| | Inhospital case fatality | rate |
| | Secondary outcomes: | |
| | Length of hospital stay | |
| Notes | _ | |
| Risk of bias | | |
| Bias | Authors' judgement | Support for judgement |
| Random sequence genera- tion (selection bias) | Low risk | Quote: "A computerized random number list was created to designate the two anaesthetic group assignments." |
| Allocation concealment (selection bias) | Low risk | Quote: "The assignment of the anaesthetic group for each study patient was contained in a sealed envelope." |
| Blinding of participants and personnel (perfor- mance bias) All outcomes | Unclear risk | This was not reported. |
| Blinding of outcome as- sessment (detection bias) Inhospital case fatality rate/length of stay | Low risk | The outcome measurement is not likely to be influenced by lack of blinding. |
| Blinding of outcome as- sessment (detection bias) Complications | Unclear risk | _ |
| Incomplete outcome data (attrition bias) All outcomes | Low risk | No missing data. |
| Selective reporting (re- porting bias) | Low risk | All outcomes described in methods section reported. |
| Other bias | Low risk | No other potential sources of bias were detected. |



| Lonie 1986 | | | |
|---|--|---|--|
| Methods | Single-centre RCT | | |
| Participants | Setting: Manchester Royal Infirmary and St Mary's Hospital, UK | | |
| | Inclusion criteria: ASA | I-II patients who were scheduled for elective inpatient laparoscopy | |
| | Participant numbers: | 93 randomly assigned; 93 analysed | |
| Interventions | Intervention: nitrous of Control: 33% oxygen in | Intervention: nitrous oxide 67% in oxygen and 1.25% MAC end tidal enflurane (0.7%) Control: 33% oxygen in nitrogen and 1.25 MAC end tidal enflurane (2.1%) | |
| Outcomes | Other outcomes: | | |
| | Non-severe nausea and | d vomiting | |
| Notes | - | | |
| Risk of bias | | | |
| Bias | Authors' judgement | Support for judgement | |
| Random sequence genera- tion (selection bias) | Unclear risk | Described as randomized but no further details. | |
| Allocation concealment (selection bias) | Unclear risk | No details given. | |
| Blinding of participants and personnel (perfor- mance bias) All outcomes | Unclear risk | This was not reported. | |
| Blinding of outcome as- sessment (detection bias) Inhospital case fatality rate/length of stay | Unclear risk | _ | |
| Blinding of outcome as- sessment (detection bias) Complications | Low risk | Quote: "Patients were interviewed by a senior nurse who was unaware of which anaesthetic the patient had received." | |
| Incomplete outcome data (attrition bias) All outcomes | Low risk | No missing data. | |
| Selective reporting (re- porting bias) | Low risk | All outcomes described in methods section reported. | |
| Other bias | Low risk | No other potential sources of bias were detected. | |
| | | | |

Mraovic 2008

 Methods
 RCT

 Participants
 Setting: unknown

| Mraovic 2008 (Continued) | Inclusion criteria: 150 ASA I-II patients, between 19 and 75 years old, undergoing elective laparoscop- ic gynaecological surgery (removal of ovarian tumours and cysts, myomectomy, laparoscopic-assisted vaginal hysterectomy, and infertility surgery) | | |
|---|--|---|--|
| | Exclusion criteria: obesity (body mass index > 33 kg/m ²), pregnancy, breast-feeding, known hypersensitivity to drugs used in the study protocol, use of antiemetics, psychotropic drugs and steroids within 72 h before surgery; patients with known comorbidities that could increase the incidence of post-operative nausea and vomiting, i.e. diseases which impaired gastric motility (diabetes mellitus, chronic cholecystitis, gastric and intestinal disease, neuromuscular disorders, neuropathies, and liver dysfunction), vestibular disease, history of migraine headache, central nervous system injury, renal impairment, irregular menstrual cycle (duration of < 21 or > 35 days and/or variations between cycles > 4 days), alcoholism, and opioid addiction | | |
| | Participant numbers: | 150 randomly assigned; 137 analysed | |
| Interventions | Intervention: patients received 7.5 mg of midazolam by mouth 1 h before the surgery with no prophylactic antiemetics. After induction of anaesthesia with thiopental 5 mg/kg and fentanyl 1 to 2 μ g/kg, patients were manually ventilated with oxygen via facemask. Endotracheal intubation was facilitated with vecuronium 0.1 mg/kg IV. Patients then received either 50% nitrous oxide with oxygen or 70% nitrous oxide with oxygen. Anaesthesia was maintained with sevoflurane (end-tidal concentration approximately 1 MAC) and supplemental bolus doses of fentanyl intravenous (1 μ g/kg) to keep heart rate and arterial blood pressure within 20% of baseline values and additional vecuronium was administered to maintain 1 or 2 twitches on the train-of-four monitor. All patients received 10 mL/kg of crystalloids intraoperatively. Control: patients received 7.5 mg of midazolam by mouth 1 h before the surgery with no prophylactic antiemetics. After induction of anaesthesia with thiopental 5 mg/kg and fentanyl 1 to 2 μ g/kg, patients were manually ventilated with oxygen via facemask. Endotracheal intubation was facilitated with vecuronium 0.1 mg/kg IV. Patients then received air and oxygen, FiO ₂ 30%. Anaesthesia was maintained with sevoflurane (end-tidal concentration approximately 1 MAC) and supplemental bolus doses of fentanyl intravenous (1 μ g/kg) to keep heart rate and arterial blood pressure within 20% of baseline values and additional vecuronium 0.1 mg/kg IV. Patients then received air and oxygen, FiO ₂ 30%. Anaesthesia was maintained with sevoflurane (end-tidal concentration approximately 1 MAC) and supplemental bolus doses of fentanyl intravenous (1 μ g/kg) to keep heart rate and arterial blood pressure within 20% of baseline values and additional vecuronium was administered to maintain 1 or 2 twitches on the train-of-four monitor. All patients received 10 mL/kg of crystalloids intraoperatively. | | |
| Outcomes | Secondary outcomes: | | |
| | Severe nausea and vomiting: 2 or more episodes of vomiting and retching within a period of 30 min or total number of 3 or more emetic episodes during 24 h postoperatively. | | |
| Notes | 13 patients were excluded from the analysis. 4 patients were excluded in nitrous oxide-free group: 1 patient was treated with corticosteroids for urticaria at induction of anaesthesia, 1 patient had an anaesthesia time < 30 min, 2 patients had a protocol violation. 4 patients were excluded in nitrous ox- ide-based group 1: 1 patient had a conversion to laparotomy, 1 patient's anaesthesia time was < 30 min, and 2 patients had a protocol violation. 5 patients were excluded from the nitrous oxide-based group 2: 2 patients' surgery was converted to laparotomy, 1 patient each had severe hypotension after induction, which lasted more than 5 mins, acute coronary syndrome postoperatively, and anaesthesia time < 30 min. | | |
| Risk of bias | | | |
| Bias | Authors' judgement | Support for judgement | |
| Random sequence genera- tion (selection bias) | Low risk | Quote: "Patients were randomized by computer-generated random numbers." | |
| Allocation concealment (selection bias) | Unclear risk | No details given. | |
| Blinding of participants and personnel (perfor- mance bias) | Unclear risk | This was not reported. | |



Mraovic 2008 (Continued) All outcomes

| Blinding of outcome as- sessment (detection bias) Inhospital case fatality rate/length of stay | Unclear risk | _ |
|---|--------------|---|
| Blinding of outcome as- sessment (detection bias) Complications | Low risk | Quote: "Clinical nurses specifically trained for the study collected the data and were blinded to the anaesthesia technique used and randomizations." |
| Incomplete outcome data (attrition bias) All outcomes | Low risk | Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups. |
| Selective reporting (re- porting bias) | Low risk | All outcomes described in methods section reported. |
| Other bias | Low risk | No other potential sources of bias were detected. |

Myles 2008a

| Methods | Muli-centre RCT | |
|--|--|---|
| Participants | Setting: 2 hospitals from Australia and Hong Kong | |
| | Inclusion criteria: patients undergoing elective noncardiac surgery, with risk factors or a known histo- ry of coronary artery disease (hypertension, diabetes, age older than 60 years, or preexisting history of coronary artery disease) | |
| | Exclusion criteria: patients expected to require a high inspired oxygen concentration intraoperatively or with any relative contraindication to nitrous oxide (volvulus, pulmonary hypertension, increased intracranial pressure) | |
| | Participant numbers: 59 randomly assigned; 59 analysed | |
| Interventions | Intervention: patients had maintenance of general anaesthesia with nitrous oxide and FiO ₂ 0.3, and one of three other hypnotic agents (isoflurane, sevoflurane, or propofol) at the discretion of the anaesthesiologist. Control: patients had their anaesthesia maintained with FiO ₂ 0.8 or FiO ₂ 0.3, but without nitrous oxide. | |
| Outcomes | Secondary outcomes: | |
| | Length of hospital stay | |
| Notes | _ | |
| Risk of bias | | |
| Bias | Authors' judgement | Support for judgement |
| Random sequence genera- tion (selection bias) | Low risk | Quote: "Patients were randomly allocated via a computer-generated random list." |

Myles 2008a (Continued)

| Allocation concealment (selection bias) | Low risk | Quote: "The random sequence was concealed in opaque, sealed envelopes." |
|---|--------------|--|
| Blinding of participants and personnel (perfor- mance bias) All outcomes | Low risk | Quote: "Administration and group identity were concealed from the surgeon and research staff." |
| Blinding of outcome as- sessment (detection bias) Inhospital case fatality rate/length of stay | Low risk | The outcome measurement is not likely to be influenced by lack of blinding. |
| Blinding of outcome as- sessment (detection bias) Complications | Unclear risk | _ |
| Incomplete outcome data (attrition bias) All outcomes | Low risk | No missing data. |
| Selective reporting (re- porting bias) | High risk | Not all of the study's pre-specified primary outcomes (e.g. myocardial infarc- tion) had been reported. |
| Other bias | Low risk | No other potential sources of bias were detected. |

Paredi 1994

| Methods | Single-centre RCT | | |
|--|---|---|--|
| Participants | Setting: a hospital in It | taly | |
| | Inclusion criteria: ASA | I-II female patients, aged older than 18, undergoing total hysterectomy | |
| | Participant numbers: | 184 randomly assigned; 184 analysed | |
| Interventions | Intervention: enfluran Control: enflurane 2% | Intervention: enflurane 1.3% in nitrous oxide and oxygen Control: enflurane 2% in air and oxygen | |
| Outcomes | Secondary outcomes: | | |
| | Severe nausea and von | niting: no specific definition. | |
| Notes | _ | | |
| Risk of bias | | | |
| Bias | Authors' judgement | Support for judgement | |
| Random sequence genera- tion (selection bias) | Unclear risk | Described as randomized but no further details. | |
| Allocation concealment (selection bias) | Unclear risk | No details given. | |



Paredi 1994 (Continued)

| Blinding of participants and personnel (perfor- mance bias) All outcomes | High risk | Quote: "Participants and personnel had knowledge of nitrous oxide exposure." |
|---|--------------|---|
| Blinding of outcome as- sessment (detection bias) Inhospital case fatality rate/length of stay | Unclear risk | _ |
| Blinding of outcome as- sessment (detection bias) Complications | Low risk | Quote: "Nausea and vomiting were assessed by an investigator other than the anaesthetist or the surgeon." |
| Incomplete outcome data (attrition bias) All outcomes | Low risk | No missing data. |
| Selective reporting (re- porting bias) | Low risk | All outcomes described in methods section reported. |
| Other bias | Low risk | No other potential sources of bias were detected. |

Pedersen 1993

| Methods | Single-centre RCT | |
|---------------|--|--|
| Participants | Setting: Herlev hospital, Herlev, Denmark | |
| | Inclusion criteria: 44 ASA I-II patients, aged 30 to 65 years, scheduled for elective abdominal hysterec- tomy with or without salpingo oophorectomy | |
| | Exclusion criteria: patients with gastrointestinal disease of any kind, malignancy, or weight < 45 kg or > 90 kg; preoperative medication known to interfere with bowel function; contraindications against any of the anaesthetics used; insertion of a nasogastric tube; surgical complications; administration of lax-atives or enemas before the fourth day postoperatively (the operation day being day 0) | |
| | Participant numbers: 44 randomly assigned; 36 analysed | |
| Interventions | Intervention: diazepam 0.15 mg/kg administered orally 1 h before anaesthesia was used as premed- ication. Anaesthesia was induced with fentanyl 3 μg/kg and atracurium as precurarization followed by thiopentone 3 to 5 mg/kg. Intubation was facilitated by suxamethonium 1.5 mg/kg. Anaesthesia was maintained with fentanyl 2 μg/kg/h and isoflurane with nitrous oxide in 30% oxygen. Ventilation was adjusted to maintain end-tidal carbon dioxide tension between 4 and 4.5 kPa. After the disappearance of the effect of suxamethonium, neuromuscular block was achieved with a bolus of atracurium, 0.3 mg/ kg, and maintained with infusion of atracurium. Control: diazepam 0.15 mg/kg administered orally 1 h before anaesthesia was used as premedica- tion. Anaesthesia was induced with fentanyl 3 μg/kg and atracurium as precurarization followed by thiopentone 3 to 5 mg/kg. Intubation was facilitated by suxamethonium 1.5 mg/kg. Anaesthesia was maintained with fentanyl 2 μg/kg/h and isoflurane in 30% oxygen. Ventilation was adjusted to main- tain end-tidal carbon dioxide tension between 4 and 4.5 kPa. After the disappearance of the effect of suxamethonium, neuromuscular block was achieved with a bolus of atracurium, 0.3 mg/kg, and main- tain end-tidal carbon dioxide tension between 4 and 4.5 kPa. After the disappearance of the effect of suxamethonium, neuromuscular block was achieved with a bolus of atracurium, 0.3 mg/kg, and main- tained with infusion of atracurium. | |
| Outcomes | Secondary outcomes: | |
| | Severe nausea and vomiting: patient rated | |



Pedersen 1993 (Continued)

Notes

8 patients were excluded during the study: 3 patients because of per- or postoperative surgical complications, 1 patient because of the surgeon's wish for insertion of a nasogastric tube due to distension of the intestines (the patient received nitrous oxide), 3 patients due to erroneous administration of laxative on the second postoperative day and 1 patient because of severe gastrointestinal discomfort on the third day postoperatively requiring an enema (the patient received nitrous oxide).

Risk of bias

| Bias | Authors' judgement | Support for judgement |
|---|--------------------|---|
| Random sequence genera- tion (selection bias) | Unclear risk | Described as randomized but no further details. |
| Allocation concealment (selection bias) | Unclear risk | No details given. |
| Blinding of participants and personnel (perfor- mance bias) All outcomes | Low risk | Quote: "The mixture of gas administered was blinded for everyone other than the anaesthetist." |
| Blinding of outcome as- sessment (detection bias) Inhospital case fatality rate/length of stay | Unclear risk | _ |
| Blinding of outcome as- sessment (detection bias) Complications | Low risk | Quote: "Nausea and vomiting were assessed by an investigator other than the anaesthetist or the surgeon." |
| Incomplete outcome data (attrition bias) All outcomes | Unclear risk | Insufficient information. |
| Selective reporting (re- porting bias) | Low risk | All outcomes described in methods section reported. |
| Other bias | High risk | Fewer than 50 participants per arm. |

Sengupta 1988

| Methods | Single-centre RCT |
|---------------|---|
| Participants | Setting: a hospital in London, UK |
| | Inclusion criteria: 80 ASA I-II patients older than 18 years undergoing a standard anaesthetic tech- nique for day-case laparoscopy |
| | Exclusion criteria: patients with a history of excessive nausea and vomiting after previous anaesthet- ics |
| | Participant numbers: 80 randomly assigned; 64 analysed |
| Interventions | Intervention: patients were given fentanyl 1.5 μg/kg intravenous and anaesthesia was induced with propofol 2 mg/kg intravenous followed by vecuronium 0.06 mg/kg intravenous. The patients received an inspired gas mixture of 33% nitrous oxide and 1% enflurane in oxygen. |



| Sengupta 1988 (Continued) | Control: patients were given fentanyl 1.5 μ g/kg intravenous and anaesthesia was induced with propofol 2 mg/kg intravenous followed by vecuronium 0.06 mg/kg intravenous. The patients received an inspired gas mixture of 1% enflurane in oxygen. | | | |
|---|---|---|--|--|
| Outcomes | Secondary outcomes: | | | |
| | Severe nausea and von | Severe nausea and vomiting: patient rated | | |
| Notes | 16 patients had not ret | 16 patients had not returned questionnaires | | |
| Risk of bias | | | | |
| Bias | Authors' judgement | Support for judgement | | |
| Random sequence genera- tion (selection bias) | Unclear risk | Described as randomized but no further details. | | |
| Allocation concealment (selection bias) | Unclear risk | No details given. | | |
| Blinding of participants and personnel (perfor- mance bias) All outcomes | Unclear risk | This was not reported. | | |
| Blinding of outcome as- sessment (detection bias) Inhospital case fatality rate/length of stay | Unclear risk | _ | | |
| Blinding of outcome as- sessment (detection bias) Complications | Unclear risk | This was not reported. | | |
| Incomplete outcome data (attrition bias) All outcomes | Unclear risk | Insufficient information. | | |
| Selective reporting (re- porting bias) | Low risk | All outcomes described in methods section reported. | | |
| Other bias | High risk | Fewer than 50 participants per arm. | | |

| Short 1985 | |
|--------------|---|
| Methods | Single-centre RCT |
| Participants | Setting: a hospital in London, UK |
| | Inclusion criteria: ASA I-III patients scheduled for either minor gynaecological procedures such as di- latation and curettage, or urological procedures such as cysto-urethroscopy |
| | Exclusion criteria: surgery lasted less than 30 minutes; alternative anaesthetic techniques were re- quired; use of opioids for postoperative pain relief |
| | Participant numbers: 60 randomly assigned; 47 analysed |
| | |



| Interventions Intervention protocol 1, p | n: two anaesthetic pro patients received alfen | otocols were used for induction and maintenance of anaesthesia. In | |
|---|--|--|--|
| were given as clin given as clin lowed by up was satisfac Control: pai oxygen via a creased to 1 | Intervention: two anaesthetic protocols were used for induction and maintenance of anaesthesia. In protocol 1, patients received alfentanil 5 μg/kg over 1 minute, followed by methohexitone 1.5 mg/kg. The patients then breathed nitrous oxide and oxygen (FiO ₂ = 0.3). Supplements of alfentanil 2.5 μg/kg were given every 8 minutes until cessation of surgery, and increments of methohexitone 20 mg were given as clinically required. In protocol 2, patients received methohexitone 1.5 mg/kg as induction, followed by up to 5% isoflurane with 66% nitrous oxide in oxygen via a Magill system. When anaesthesia was satisfactory, the isoflurane concentration was decreased to 1.5 to 2%. Control: patients received methohexitone 1.5 mg/kg as induction, followed by up to 5% isoflurane in oxygen via a Magill system. When anaesthesia was satisfactory, the isoflurane the site isoflurane in oxygen via a Magill system. When anaesthesia was satisfactory to 2%. | | |
| Outcomes Secondary | outcomes: | | |
| Severe naus | ea and vomiting: no s | pecific definition | |
| Notes The results f minutes, or opioids for p | The results from 13 patients were excluded from the study because either surgery lasted more than 30 minutes, or alternative anaesthetic techniques were required, such as tracheal intubation or the use of opioids for postoperative pain relief. | | |
| Risk of bias | | | |
| Bias Authors' juo | lgement Support | for judgement | |
| Random sequence genera- Unclear risk tion (selection bias) | Described | l as randomized but no further details. | |
| Allocation concealment Unclear risk (selection bias) | No detail: | s given. | |
| Blinding of participants Unclear risk and personnel (perfor- mance bias) All outcomes | This was | not reported. | |
| Blinding of outcome as- sessment (detection bias) Inhospital case fatality rate/length of stay | _ | | |
| Blinding of outcome as- High risk sessment (detection bias) Complications | Quote: "T | he observer was aware of which anaesthetic had been used." | |
| Incomplete outcome data Unclear risk (attrition bias) All outcomes | Insufficie | nt information. | |
| Selective reporting (re- Low risk porting bias) | All outcor | nes described in methods section reported. | |
| Other bias High risk | Fewer tha | an 50 participants per arm. | |

Singh 2011

Methods

Single-centre RCT



Trusted evidence. Informed decisions. Better health.

| Participants | Setting: a hospital in New Delhi, India | | | | |
|--|--|--|--|--|--|
| | Inclusion criteria: 116 elective supratentorial | ASA I-II patients between 18 and 60 years of age, either gender, scheduled for tumour surgery, with anticipated duration of anaesthesia more than 4 hours | | | |
| | Exclusion criteria: pat those requiring postope plementation, history of ness/postoperative em | ients with history of smoking, patients with history of megaloblastic anaemia, erative mechanical ventilation, patients receiving vitamin B12/folic acid sup- of exposure to general anaesthesia in the last one month, history of motion sick- esis, evidence of pneumothorax/pneumocephalus, and bleeding disorders | | | |
| | Participant numbers: 116 randomly assigned; 87 analysed | | | | |
| Interventions | Intervention: patients were preoxygenated with 100% oxygen for 3 minutes. General anaesthesia was induced with fentanyl 2 mcg/kg and thiopentone 4 to 6 mg/kg and tracheal intubation facilitated with rocuronium 1 mg/kg. Additional dose of thiopentone 1 to 2 mg/kg was given before laryngoscopy and intubation to prevent the pressor response. Anaesthesia was maintained using 60% nitrous oxide and 40% oxygen as carrier gases, as well as isoflurane at end-tidal concentration of 0.7%. The flow rate of inhaled gas mixture was kept at 2 L/min in both the groups. Flow rate of nitrous oxide and oxygen were 1.2 and 0.8 L/min, respectively. Intermittent doses of fentanyl (1 mcg/kg) and vecuronium (0.01 mg/kg) were repeated as and when required. Use of other drugs and intravenous fluids was at the discretion of the attending anaesthesiologist. Control: patients were preoxygenated with 100% oxygen for 3 minutes. General anaesthesia was induced with fentanyl 2 mcg/kg and thiopentone 4 to 6 mg/kg and tracheal intubation facilitated with rocuronium 1 mg/kg. Additional dose of thiopentone 1 to 2 mg/kg was given before laryngoscopy and intubation to prevent the pressor response. Anaesthesia was maintained using 60% medical air and 40% oxygen as carrier gases, as well as isoflurane at end-tidal concentration of 1.2%. The flow rate of inhaled gas mixture was kept at 2 L/min in both the groups. Flow rates of medical air and 40% oxygen as carrier gases, as well as isoflurane at end-tidal concentration of 1.2%. The flow rate of inhaled gas mixture was kept at 2 L/min in both the groups. Flow rates of medical air and oxygen were 1.5 and 0.5 L/min, respectively. Intermittent doses of fentanyl (1 mcg/kg) and vecuronium (0.01 mg/kg) were repeated as and when required. Use of other drugs and intravenous fluids was at the discretion or the attending anaesthesiologist. | | | | |
| Outcomes | Secondary outcomes: | | | | |
| | Pneumonia: radiologic at least one of the follor mm ³ , or positive sputu | infiltrate confirmed by chest X-ray or computed tomography, in association with wing: temperature greater than 38°C, leukocyte count greater than 12000 cell/ m culture that corresponds with positive culture | | | |
| | Myocardial infarction: confirmed by a typical rise and fall in cardiac enzymes (troponin or CK-MB tion) with at least one of the following: typical ischaemic symptoms, new Q-wave or ST-segment of trocardiographic changes | | | | |
| Stroke: a new neurolo ment, and/or comput | | ical deficit persisting for 24 hours or longer, confirmed by neurologist assess- d tomography, or magnetic resonance imaging | | | |
| | Length of hospital stay | | | | |
| | Length of ICU stay | | | | |
| | 29 patients could not be tracheally extubated at the end of surgery (15 patients in nitrous oxide-based group and 14 in nitrous oxide-free group), so the data of these patients were excluded from final analysis. | | | | |
| Notes | 29 patients could not be group and 14 in nitrous sis. | s oxide-free group), so the data of these patients were excluded from final analy- | | | |
| Notes Risk of bias | 29 patients could not be group and 14 in nitrous sis. | s oxide-free group), so the data of these patients were excluded from final analy- | | | |
| Notes Risk of bias Bias | Authors' judgement | Support for judgement | | | |



Singh 2011 (Continued)

| Allocation concealment (selection bias) | Unclear risk | No details given. |
|---|--------------|--|
| Blinding of participants and personnel (perfor- mance bias) All outcomes | Low risk | Quote: "Attending anaesthesiologist was aware of the group identity (for safe administration of anaesthesia), but it was concealed from the surgeons." |
| Blinding of outcome as- sessment (detection bias) Inhospital case fatality rate/length of stay | Low risk | Quote: "Staff conducting the postoperative follow-ups (i.e., those responsible for postoperative data collection and outcome assessment) was blinded to the group identity." |
| Blinding of outcome as- sessment (detection bias) Complications | Low risk | Quote: "Staff conducting the postoperative follow-ups (i.e., those responsible for postoperative data collection and outcome assessment) was blinded to the group identity." |
| Incomplete outcome data (attrition bias) All outcomes | Low risk | Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups. |
| Selective reporting (re- porting bias) | Low risk | All outcomes described in methods section reported. |
| Other bias | High risk | Fewer than 50 participants per arm. |

Sukhani 1994

| Methods | Single-centre RCT |
|---------------|---|
| Participants | Setting: Loyola University Medical Center, USA |
| | Inclusion criteria: nonpregnant patients, 19 to 40 years of age, ASA I-II, scheduled for ambulatory gy- naecologic laparoscopy |
| | Exclusion criteria: patients were excluded from the study if they weighed more than 150% of their ideal body weight or had predisposing factors for delayed gastric emptying, such as diabetes, chronic cholecystitis, scleroderma, neuropathies, and neuromuscular disorders. Patients who demonstrated significant anxiety and who, in the anaesthesiologist's judgment, required preoperative anxiolytic therapy were also excluded |
| | Participant numbers: 70 randomly assigned; 70 analysed |
| Interventions | Intervention: patients were ventilated with a mixture of oxygen and nitrous oxide and the inspired oxygen concentration was maintained at 30%. Control: patients were ventilated with a mixture of oxygen and air and the inspired oxygen concentration was maintained at 30%. |
| Outcomes | Other outcomes: |
| | Quality of recovery |
| Notes | _ |
| Risk of bias | |



Sukhani 1994 (Continued)

| Bias | Authors' judgement | Support for judgement |
|---|--------------------|--|
| Random sequence genera- tion (selection bias) | Unclear risk | Described as randomized but no further details. |
| Allocation concealment (selection bias) | Unclear risk | No details given. |
| Blinding of participants and personnel (perfor- mance bias) All outcomes | High risk | Quote: "The patients were assigned using a non-blinded study design." |
| Blinding of outcome as- sessment (detection bias) Inhospital case fatality rate/length of stay | Unclear risk | _ |
| Blinding of outcome as- sessment (detection bias) Complications | Low risk | Quote: "Intermediate recovery variables were recorded by recovery room nurses and the attending anaesthesiologist blinded to anaesthetic technique." |
| Incomplete outcome data (attrition bias) All outcomes | Low risk | No missing data. |
| Selective reporting (re- porting bias) | Low risk | All outcomes described in methods section reported. |
| Other bias | Low risk | No other potential sources of bias were detected. |

Todd 1993

| Methods | Single-centre RCT | | |
|---------------|---|--|--|
| Participants | Setting: a hospital in Iowa, USA | | |
| | Inclusion criteria: ASA II-III patients, aged 18-75 years, scheduled for elective craniotomy for resection of a supratentorial mass lesion | | |
| | Exclusion criteria: patients with known aneurysms, arteriovenous malformations, or posterior fos- sa tumours; patients who suffered from severe ischaemic heart disease, congestive heart failure, re- nal or hepatic dysfunction, severe chronic respiratory disease, medically controlled hypertension, sta- ble angina, diabetes mellitus, or mild chronic obstructive lung disease; a rapid post-operative return to normal consciousness was unlikely due to the location or size of the lesion (e.g. large hypothalamic le- sions) or if postoperative sedation and mechanical ventilation were planned | | |
| | Participant numbers: 121 randomly assigned; 121 analysed | | |
| Interventions | Intervention: two anaesthetic protocols were used for induction and maintenance of anaesthesia. In protocol 1, anaesthesia was induced with 4 to 6 mg/kg thiopental, followed by 0.1 mg/kg vecuronium. Mask ventilation was begun with gradually increasing inspired concentrations of isoflurane in 60% nitrous oxide/balance oxygen, and continued for 10 min. The trachea was intubated, mechanical ventilation begun with nitrous oxide/oxygen (fraction of inspired oxygen 0.4), and the administered concentration of isoflurane was adjusted thereafter according to the judgment of the attending anaesthesiologist. In protocol 2, anaesthesia was induced with 4 to 6 mg/kg thiopental, followed by 0.1 mg/kg vecuronium. Mask ventilation was begun with 60% nitrous oxide/balance oxygen, and incremental dos- | | |



Todd 1993 (Continued)

Trusted evidence. Informed decisions. Better health.

pancuronium.

| | Control: anaesthesia was induced with 1 to 2 mg/kg propofol, followed by 0.1 mg/kg vecuronium. Simultaneously with the start of induction, a propofol infusion was begun at an initial rate of 200 μ g/kg / min. Manual mask ventilation with 40% oxygen (as an oxygen/air mixture) was begun, and incremental doses of fentanyl were given, with a target loading dose of 10 μ g/kg fentanyl to be given over 10 mins. The rate of fentanyl administration and the propofol infusion could be varied at the discretion of the attending anaesthesiologist. The patients' lungs mechanically ventilated with oxygen/air (FiO ₂ 0.4). A fentanyl infusion was started and maintained at a rate of 2 μ g/kg/h. The propofol infusion rate was varied according to clinical need. | | |
|---|--|---|--|
| Outcomes | Primary outcomes: | | |
| | Inhospital case fatality rate | | |
| | Secondary outcomes: Pneumonia: no specific definition | | |
| | | | |
| | Length of hospital stay | | |
| Notes | _ | | |
| Risk of bias | | | |
| Bias | Authors' judgement | Support for judgement | |
| Random sequence genera- tion (selection bias) | Unclear risk | Described as randomized but no further details. | |
| Allocation concealment (selection bias) | Low risk | Sealed envelopes were used. | |
| Blinding of participants and personnel (perfor- mance bias) All outcomes | Unclear risk | This was not reported. | |
| Blinding of outcome as- sessment (detection bias) Inhospital case fatality rate/length of stay | Low risk | The outcome measurement is not likely to be influenced by lack of blinding. | |
| Blinding of outcome as- sessment (detection bias) Complications | Unclear risk | This was not reported. | |
| Incomplete outcome data (attrition bias) All outcomes | Low risk | No missing data. | |
| Selective reporting (re- porting bias) | Low risk | All outcomes described in methods section reported. | |
| Other bias | Low risk | No other potential sources of bias were detected. | |
| | | | |

es of fentanyl were given, with a target loading dose of 10 μ g/kg fentanyl to be given over 10 min. This could be varied at the discretion of the anaesthesiologist. After 10 min, the trachea was intubated, and mechanical ventilation begun with 60% nitrous oxide/oxygen (fraction of inspired oxygen 0.4). An infusion of fentanyl was started at the rate of 2 μ g/kg/h, and paralysis was maintained with vecuronium or



Van Hemelrijck 1991

| Methods | Single-centre RCT | | | |
|---|--|---|--|--|
| Participants | Setting: A hospital in Missouri, USA | | | |
| | Inclusion criteria: 92 non-pregnant gynaecologic patients, 19 to 46 years of age, ASA I-II, scheduled for out-patient laparoscopic surgery | | | |
| | Participant numbers: 92 randomly assigned; 92 analysed | | | |
| Interventions | Intervention: all patients breathed 100% oxygen for 2 min after receiving a preinduction dose of fentanyl 1.5 μg/kg intravenous and dtubocurarine 3 mg intravenous. Three anaesthetic protocols were used for induction and maintenance of anaesthesia. In protocol 1, anaesthesia was induced with propofol 2.5 mg/kg administered over 2.5 minutes using a syringe-type infusion pump. After loss of consciousness, succinylcholine 1.5 mg/kg intravenous was administered to facilitate intubation. Anaesthesia was maintained with nitrous oxide 60% and a continuous infusion of propofol at an initial infusion rate of 160 μg/kg/min, which subsequently was titrated within the range of 50 to 200 μg/kg/min. The maintenance infusion rate of propofol was adjusted to maintain an adequate depth of anaesthesia, adjudged by clinical signs and hemodynamic responses. In protocol 2, anaesthesia was induced with propofol 2.5 mg/kg administered over 2.5 minutes using a syringe-type infusion pump. After loss of consciousness, succinylcholine 1.5 mg/kg intravenous was administered to facilitate intubation. Anaesthesia was maintained with desflurane 4 to 7% inspired concentration in combination with 60% nitrous oxide. The inspired desflurane concentration were adjusted to maintain an adequate depth of anaesthesia, adjudged by clinical signs and hemodynamic responses. In protocol 3, anaesthesia was induced by inhalation of desflurane with nitrous oxide 60% in oxygen. After loss of consciousness, succinylcholine 1.5 mg/kg intravenous was administered to facilitate intubation. Anaesthesia was maintained with desflurane 4 to 7% inspired concentration with 60% nitrous oxide. The inspired concentration in combination with 60% nitrous oxide. The inspired concentration in combination with 60% nitrous oxide. The inspired concentration in combination with 60% nitrous oxide. The inspired concentration in combination with 60% nitrous oxide. The inspired desflurane 4 to 7% inspired concentration were adjusted to maintain an adequate depth of anaesthesia, ad | | | |
| Outcomes | Secondary outcomes: | | | |
| | Severe nausea and vomiting: persistent nausea with repeated episodes of vomiting, requ ment | | | |
| Notes | _ | | | |
| Risk of bias | | | | |
| Bias | Authors' judgement | Support for judgement | | |
| Random sequence genera- tion (selection bias) | Unclear risk | Described as randomized but no further details. | | |
| Allocation concealment (selection bias) | Unclear risk | No details given. | | |
| Blinding of participants and personnel (perfor- mance bias) All outcomes | High risk | Quote: "The study used an open (non blinded) design." | | |
Van Hemelrijck 1991 (Continued)

| Blinding of outcome as- sessment (detection bias) Inhospital case fatality rate/length of stay | Unclear risk | _ |
|---|--------------|---|
| Blinding of outcome as- sessment (detection bias) Complications | Low risk | Quote: "The outcome was assessed by research nurse who was blinded to as to the anaesthetic treatment." |
| Incomplete outcome data (attrition bias) All outcomes | Low risk | No missing data. |
| Selective reporting (re- porting bias) | Low risk | All outcomes described in methods section reported. |
| Other bias | High risk | Fewer than 50 participants per arm. |

Vanacker 1999

| Methods | RCT |
|---------------|--|
| Participants | Inclusion criteria: 60 female in-patients (ASA I-II), aged 18 to 65 years, scheduled for breast surgery with a duration of 1 to 3 hours |
| | Exclusion criteria: patients had body weight 20% outside normal weight, history of motion sickness or of postoperative nausea and vomiting, pregnant or breastfeeding patients, history of alcohol or drug abuse, sensitivity to narcotics, impaired renal or hepatic function, recent (< 30 days) participation in another study |
| | Participant numbers: 30 randomly assigned; 30 analysed |
| Interventions | Intervention: patients were breathing 100% oxygen with a fresh gas flow of 7 L/min for 2 to 3 minutes. A standardized anaesthetic technique consisting of propofol for induction (2 mg/kg) followed by des- flurane with nitrous oxide for maintenance of anaesthesia was used in all patients. The concentration of anaesthetic given to the patients was based on previously determined MAC values and adjusted to the patient's needs as clinically indicated with the objective to maintain the heart rate and blood pres- sure within 20% of the baseline values. They received a pre-induction dose of fentanyl 2 µg/kg; addi- tional doses of fentanyl 1 µg/kg were given if there were signs of inadequate anaesthesia (i.e. move- ment, swallowing, tearing, salivation) despite changes in inhalation concentration. Muscle relaxation for intubation was achieved by a single dose of vecuronium 0.1 mg/kg. Mechanical ventilation was in- stituted in all patients and ventilatory settings were adjusted to achieve normocapnia; the fresh gas flow was reduced to 2 L/ min during maintenance of anaesthesia. At the end of surgery, desflurane and nitrous oxide were discontinued and the patients received 100% oxygen (7 L/min fresh gas flow). Control: patients were breathing 100% oxygen with a fresh gas flow of 7 L/min. for 2 to 3 minutes. A standardized anaesthetic technique consisting of propofol for induction (2 mg/kg) followed by desflu- rane for maintenance of anaesthesia was used in all patients. The concentration of anaesthetic given to the patients was based on previously determined MAC values and adjusted to the patient's needs as clinically indicated with the objective to maintain the heart rate and blood pressure within 20% of the baseline values. They received a pre-induction dose of fentanyl 2 µg/kg; additional doses of fentanyl 1 µg/kg were given if there were signs of inadequate anaesthesia (i.e. movement, swallowing, tearing, salivation) despite changes in inhalation concentration. Muscle relaxation for intubation was achieved by a singl |



Vanacker 1999 (Continued)

Outcomes

Secondary outcomes:

Severe nausea and vomiting: vomiting requiring at least three doses of antiemetic medication within 24 hours of surgery.

Notes **Risk of bias** Bias Authors' judgement Support for judgement Random sequence genera-Unclear risk Described as randomized but no further details. tion (selection bias) Allocation concealment Low risk Sealed envelopes were used. (selection bias) Unclear risk Blinding of participants This was not reported. and personnel (performance bias) All outcomes Unclear risk Blinding of outcome assessment (detection bias) Inhospital case fatality rate/length of stay Blinding of outcome as-Unclear risk This was not reported. sessment (detection bias) Complications Incomplete outcome data Low risk No missing data. (attrition bias) All outcomes Selective reporting (re-Low risk All outcomes described in methods section reported. porting bias) Other bias High risk Fewer than 50 participants per arm.

Yoshimura 2014

| Methods | Single-centre RCT |
|---------------|---|
| Participants | Setting: Teikyo University, Japan |
| | Inclusion criteria: Adult patients scheduled for elective thoracotomy or thoracoscopic surgery |
| | Exclusion criteria: Patients were excluded if pleural adhesion was anticipated during preoperative as- sessment or if they had evidence of bullae on their chest computed tomography scans |
| | Participant numbers: 50 randomly assigned; 50 analysed |
| Interventions | Intervention: patients received a gas mixture of oxygen and nitrous oxide (FiO ₂ = 0.5). Anaesthesia was induced with propofol (1 to 2 mg/kg), remifentanil (0.3 to 0.5 μ g/kg/min), and rocuronium (1 mg/kg) and was maintained with propofol infusion (120 to 200 μ g/kg/min) and intermittent boluses of rocuronium. |



Yoshimura 2014 (Continued)

Control: patients received 100% oxygen for three minutes for thorough denitrogenation. Anaesthesia was induced with propofol (1 to 2 mg/kg), remifentanil (0.3 to 0.5 μ g/kg/min), and rocuronium (1 mg/kg) and was maintained with propofol infusion (120 to 200 μ g/kg/min) and intermittent boluses of rocuronium.

| Outcomes | Other outcomes: | |
|---|---------------------|---|
| | Lung collapse score | |
| Notes | _ | |
| Risk of bias | | |
| Bias | Authors' judgement | Support for judgement |
| Random sequence genera- tion (selection bias) | Low risk | Quote: "Patients were allocated by random number." |
| Allocation concealment (selection bias) | Unclear risk | No details given. |
| Blinding of participants and personnel (perfor- mance bias) All outcomes | Unclear risk | This was not reported. |
| Blinding of outcome as- sessment (detection bias) Inhospital case fatality rate/length of stay | Unclear risk | _ |
| Blinding of outcome as- sessment (detection bias) Complications | Low risk | Quote: "Surgeons were blinded to the gas mixture and were instructed to as- sess the lung collapse scale." |
| Incomplete outcome data (attrition bias) All outcomes | Low risk | No missing data. |
| Selective reporting (re- porting bias) | Low risk | All outcomes described in methods section reported. |
| Other bias | Low risk | No other potential sources of bias were detected. |

Abbreviations: ASA: American Society of Anesthesiologists; ASEPSIS: Additional treatment, Serous discharge, Erythema, Purulent exudate, Separation of deep tissues, Isolation of bacteria, and duration of inpatient Stay; bpm: breaths per minute; CABG: Coronary Artery Bypass Grafting; CK-MB: Creatine Kinase, MB Form; CT: Computed Tomography; ECG: Electrocardiogram; h: hour(s); ICU: Intensive Care Unit; IM: intramuscular injection; IV: intravenous injection; kPa: kilopascals; MAC: Minimum Alveolar Concentration; N: number; PTCA: Percutaneous Transluminal Coronary Angioplasty; ST: ST-segment; TIA: Transient Ischaemic Attack; V-Q: Ventilation/Perfusion.

Characteristics of excluded studies [ordered by study ID]

| Study | Reason for exclusion |
|---------------|----------------------|
| Antonini 1994 | Not a RCT. |



| Study | Reason for exclusion |
|-------------------|--|
| Atanassoff 1994 | Not general anaesthesia. |
| Atassi 2005 | Nitrous oxide used in the control group. |
| Barr 1999 | Not a RCT. |
| Bronco 2010 | Nitrous oxide used in the control group. |
| Castéra 2001 | Not general anaesthesia. |
| Cheong 2000 | Nitrous oxide used in the control group. |
| Divatia 1996 | Not a RCT. |
| Dover 1994 | Not a RCT. |
| Einarsson 1997 | Nitrous oxide used in the control group. |
| Fredman 1998 | Nitrous oxide used in the control group. |
| Gozdemir 2007 | Nitrous oxide used in the control group. |
| Haessler 1993 | Nitrous oxide used in the control group. |
| Haraguchi 1995 | Not general anaesthesia. |
| Heath 1996 | Not general anaesthesia. |
| Holst 1993 | Nitrous oxide used in the control group. |
| Ishii 1994 | Nitrous oxide used in the control group. |
| Jastak 1973 | Non-adults involvement. |
| Jellish 1996 | Nitrous oxide used in the control group. |
| Johnson 1997 | Non-adults involvement. |
| Kryshtalskyj 1990 | Not general anaesthesia. |
| Lim 1992 | Non-adults involvement. |
| Losasso 1992 | Non-adults involvement. |
| Masood 2002 | Not general anaesthesia. |
| Morimoto 1997 | Not a RCT. |
| Nightingale 1992 | Non-adults involvement. |
| Nishiyama 1998 | Nitrous oxide used in the control group. |
| Ogg 1983 | Non-adults involvement. |
| Rocca 2000 | Non-adults involvement. |



| Study | Reason for exclusion |
|-------------------|--|
| Saïssy 2000 | Non-adults involvement. |
| Simpson 1977 | Nitrous oxide used in the control group. |
| Sinha 2006 | Nitrous oxide used in the control group. |
| Smith 1993 | Nitrous oxide used in the control group. |
| Taki 2003 | Non-adults involvement. |
| Towey 1979 | Non-adults involvement. |
| Van den Berg 1995 | Non-adults involvement. |
| Vari 2010 | Nitrous oxide used in the control group. |
| Wesner 2005 | Not a RCT. |
| Yamakage 2001 | Nitrous oxide used in the control group. |
| Yang 2004 | Nitrous oxide used in the control group. |
| Zuurmond 1986 | Nitrous oxide used in the control group. |

Characteristics of studies awaiting assessment [ordered by study ID]

Adams 1994

| Methods | RCT |
|---------------|--|
| Participants | 20 ASA 1 to 2 patients 18 to 60 years of age scheduled for orthopaedic surgery |
| Interventions | Intervention : intravenous combined with inhaled anaesthesia ventilated with 1.2 to 2.4 volume % isoflurane in nitrous oxide and oxygen Control : total intravenous anaesthesia ventilated with air and oxygen, FiO₂ 33% |
| Outcomes | Unknown |
| Notes | |

| Miralles Pardo 1991 | |
|---------------------|---|
| Methods | Controlled study |
| Participants | 20 ASA 1 to 2 patients |
| Interventions | Intervention : thiopental and nitrous oxide in oxygen |
| | Control : propofol |
| Outcomes | Unknown |



Miralles Pardo 1991 (Continued)

Notes

Moussa 1995

| Methods | Controlled study |
|---------------|--|
| Participants | Patients scheduled for dental day surgery |
| Interventions | Intervention : anaesthesia ventilated with nitrous oxide |
| | Control : total intravenous anaesthesia |
| Outcomes | Unknown |
| Notes | |

Rashchupkin 2011

| Methods | Controlled study |
|---------------|---|
| Participants | 60 patients undergoing open cholecystectomy |
| Interventions | Intervention : nitrous oxide |
| | Control : xenon |
| Outcomes | Unknown |
| Natas | |

Röpcke 2001

| Methods | RCT |
|---------------|---|
| Participants | 25 female patients during gynaecological laparotomies |
| Interventions | Intervention : sevoflurane in air and oxygen |
| | Control : sevoflurane in nitrous oxide and oxygen |
| Outcomes | Unknown |
| Notes | |

Schaffranietz 2000

Methods

Controlled study



Schaffranietz 2000 (Continued)

| Participants | 40 patients undergoing an elective craniotomy for brain tumour resection |
|---------------|--|
| Interventions | Intervention : general anaesthesia with nitrous oxide |
| | Control : general anaesthesia without nitrous oxide |
| Outcomes | Unknown |
| Notes | |

Segatto 1993

| Methods | RCT |
|---------------|---|
| Participants | 200 pregnant patients |
| Interventions | Intervention : thiopental-nitrous oxide anaesthesia |
| | Control : total intravenous anaesthesia |
| Outcomes | Unknown |
| Notes | Only title available |

Shulunov 2002

| Methods | Controlled study |
|---------------|---|
| Participants | 44 patients undergoing cholecystectomy |
| Interventions | Intervention : nitrous oxide and oxygen |
| | Control : xenon and oxygen |
| Outcomes | Unknown |
| Notes | |

Abbreviations; ASA: American Society of Anesthesiologists.

DATA AND ANALYSES

Comparison 1. Nitrous oxide-based versus nitrous oxide-free

| Outcome or subgroup title | No. of studies | No. of partici- pants | Statistical method | Effect size |
|---------------------------------|----------------|--------------------------|--|-------------------|
| 1 Inhospital case fatality rate | 8 | 10148 | Peto Odds Ratio (Peto, Fixed, 95% CI) | 0.87 [0.61, 1.26] |



Cochrane Database of Systematic Reviews

| Outcome or subgroup title | No. of studies | No. of partici- pants | Statistical method | Effect size |
|---|----------------|--------------------------|---|------------------------|
| 2 Pneumonia | 8 | 2699 | Odds Ratio (M-H, Fixed, 95% CI) | 1.68 [1.00, 2.81] |
| 3 Pulmonary atelectasis | 5 | 2400 | Odds Ratio (M-H, Fixed, 95% CI) | 1.57 [1.18, 2.10] |
| 4 Myocardial infarction | 6 | 9246 | Odds Ratio (M-H, Fixed, 95% CI) | 1.01 [0.84, 1.22] |
| 5 Stroke | 4 | 9142 | Odds Ratio (M-H, Fixed, 95% CI) | 1.47 [0.86, 2.53] |
| 6 Severe nausea and vomiting | 10 | 11045 | Odds Ratio (M-H, Random, 95% CI) | 1.44 [0.97, 2.15] |
| 7 Venous thromboembolism | 2 | 9004 | Odds Ratio (M-H, Fixed, 95% CI) | 0.73 [0.45, 1.20] |
| 8 Wound infection rate | 6 | 9789 | Odds Ratio (M-H, Random, 95% CI) | 1.22 [0.84, 1.78] |
| 9 Length of hospital stay | 6 | 1103 | Mean Difference (IV, Ran- dom, 95% CI) | 0.36 [-0.69, 1.40] |
| 10 Inhospital case fatality rate: type of surgery | 4 | 646 | Peto Odds Ratio (Peto, Fixed, 95% CI) | 0.64 [0.11, 3.88] |
| 10.1 Intra-abdominal surgery | 2 | 499 | Peto Odds Ratio (Peto, Fixed, 95% CI) | 0.41 [0.06, 3.03] |
| 10.2 Neurosurgery | 2 | 147 | Peto Odds Ratio (Peto, Fixed, 95% CI) | 4.45 [0.07, 287.21] |
| 11 Pneumonia: type of surgery | 6 | 427 | Odds Ratio (M-H, Fixed, 95% CI) | 1.29 [0.48, 3.48] |
| 11.1 Intra-abdominal surgery | 3 | 193 | Odds Ratio (M-H, Fixed, 95% CI) | 1.12 [0.33, 3.78] |
| 11.2 Neurosurgery | 3 | 234 | Odds Ratio (M-H, Fixed, 95% CI) | 1.71 [0.30, 9.81] |
| 12 Pulmonary atelectasis: type of surgery | 3 | 128 | Odds Ratio (M-H, Fixed, 95% CI) | 0.16 [0.02, 1.06] |
| 12.1 Intra-abdominal surgery | 2 | 102 | Odds Ratio (M-H, Fixed, 95% CI) | 0.16 [0.02, 1.06] |
| 12.2 Neurosurgery | 1 | 26 | Odds Ratio (M-H, Fixed, 95% Cl) | 0.0 [0.0, 0.0] |
| 13 Myocardial infarction: type of surgery | 3 | 212 | Odds Ratio (M-H, Fixed, 95% CI) | 1.24 [0.42, 3.67] |



Cochrane Database of Systematic Reviews

| Outcome or subgroup title | No. of studies | No. of partici- pants | Statistical method | Effect size |
|--|----------------|--------------------------|--|------------------------|
| 13.1 Intra-abdominal surgery | 1 | 91 | Odds Ratio (M-H, Fixed, 95% CI) | 2.07 [0.48, 8.93] |
| 13.2 Neurosurgery | 1 | 87 | Odds Ratio (M-H, Fixed, 95% CI) | 3.44 [0.14, 86.92] |
| 13.3 Vascular surgery | 1 | 34 | Odds Ratio (M-H, Fixed, 95% CI) | 0.25 [0.02, 2.74] |
| 14 Stroke: type of surgery | 2 | 138 | Odds Ratio (M-H, Fixed, 95% CI) | 2.46 [0.53, 11.48] |
| 14.1 Neurosurgery | 1 | 87 | Odds Ratio (M-H, Fixed, 95% CI) | 1.74 [0.28, 10.95] |
| 14.2 Ophthalmic surgery | 1 | 51 | Odds Ratio (M-H, Fixed, 95% CI) | 5.20 [0.24, 113.98] |
| 15 Severe nausea and vomiting: type of surgery | 8 | 2041 | Odds Ratio (M-H, Fixed, 95% CI) | 1.13 [0.72, 1.78] |
| 15.1 Day-case procedure/examination | 4 | 1624 | Odds Ratio (M-H, Fixed, 95% CI) | 0.65 [0.30, 1.41] |
| 15.2 Intra-abdominal surgery | 3 | 233 | Odds Ratio (M-H, Fixed, 95% CI) | 1.56 [0.65, 3.71] |
| 15.3 Breast surgery | 1 | 184 | Odds Ratio (M-H, Fixed, 95% CI) | 1.44 [0.70, 2.99] |
| 16 Wound infection rate: type of surgery | 3 | 525 | Odds Ratio (M-H, Random, 95% Cl) | 1.63 [0.28, 9.33] |
| 16.1 Intra-abdominal surgery | 2 | 499 | Odds Ratio (M-H, Random, 95% Cl) | 1.63 [0.28, 9.33] |
| 16.2 Neurosurgery | 1 | 26 | Odds Ratio (M-H, Random, 95% Cl) | 0.0 [0.0, 0.0] |
| 17 Length of hospital stay: type of surgery | 3 | 556 | Mean Difference (IV, Fixed, 95% CI) | -0.45 [-1.44, 0.54] |
| 17.1 Intra-abdominal surgery | 2 | 530 | Mean Difference (IV, Fixed, 95% CI) | -0.12 [-1.25, 1.00] |
| 17.2 Neurosurgery | 1 | 26 | Mean Difference (IV, Fixed, 95% CI) | -1.60 [-3.71, 0.51] |
| 18 Inhospital case fatality rate: concen- trations of inhaled nitrous oxide | 7 | 9920 | Peto Odds Ratio (Peto, Fixed, 95% CI) | 0.86 [0.60, 1.24] |
| 18.1 High-concentration nitrous oxide | 7 | 9920 | Peto Odds Ratio (Peto, Fixed, 95% CI) | 0.86 [0.60, 1.24] |



| Outcome or subgroup title | No. of studies | No. of partici- pants | Statistical method | Effect size |
|---|----------------|--------------------------|---|------------------------|
| 19 Stroke: concentrations of inhaled ni- trous oxide | 3 | 9091 | Odds Ratio (M-H, Fixed, 95% CI) | 1.39 [0.80, 2.42] |
| 19.1 High-concentration nitrous oxide | 3 | 9091 | Odds Ratio (M-H, Fixed, 95% CI) | 1.39 [0.80, 2.42] |
| 20 Severe nausea and vomiting: concen- trations of inhaled nitrous oxide | 8 | 10847 | Odds Ratio (M-H, Random, 95% CI) | 1.37 [0.89, 2.11] |
| 20.1 High-concentration nitrous oxide | 7 | 10691 | Odds Ratio (M-H, Random, 95% CI) | 1.34 [0.81, 2.19] |
| 20.2 Low-concentration nitrous oxide | 2 | 156 | Odds Ratio (M-H, Random, 95% CI) | 1.39 [0.53, 3.68] |
| 21 Length of hospital stay: concentra- tions of inhaled nitrous oxide | 5 | 875 | Mean Difference (IV, Ran- dom, 95% CI) | 0.45 [-1.03, 1.93] |
| 21.1 High-concentration nitrous oxide | 5 | 875 | Mean Difference (IV, Ran- dom, 95% CI) | 0.45 [-1.03, 1.93] |
| 22 Inhospital case fatality rate: tech- niques used in the nitrous oxide-free group | 6 | 1144 | Peto Odds Ratio (Peto, Fixed, 95% CI) | 1.33 [0.29, 6.00] |
| 22.1 Propofol-based maintenance of anaesthesia used in the nitrous ox-ide-free group | 1 | 121 | Peto Odds Ratio (Peto, Fixed, 95% CI) | 4.45 [0.07, 287.21] |
| 22.2 Volatile anaesthetic-based mainte- nance of anaesthesia used in the nitrous oxide-free group | 5 | 1023 | Peto Odds Ratio (Peto, Fixed, 95% CI) | 1.11 [0.22, 5.58] |
| 23 Pneumonia: techniques used in the nitrous oxide-free group | 7 | 687 | Odds Ratio (M-H, Fixed, 95% CI) | 1.13 [0.45, 2.86] |
| 23.1 Propofol-based maintenance of anaesthesia used in the nitrous ox-ide-free group | 2 | 181 | Odds Ratio (M-H, Fixed, 95% CI) | 0.50 [0.07, 3.61] |
| 23.2 Volatile anaesthetic-based mainte- nance of anaesthesia used in the nitrous oxide-free group | 5 | 506 | Odds Ratio (M-H, Fixed, 95% CI) | 1.42 [0.49, 4.06] |
| 24 Pulmonary atelectasis: techniques used in the nitrous oxide-free group | 4 | 388 | Odds Ratio (M-H, Fixed, 95% CI) | 0.32 [0.09, 1.12] |
| 24.1 Propofol-based maintenance of anaesthesia used in the nitrous ox-ide-free group | 2 | 102 | Odds Ratio (M-H, Fixed, 95% CI) | 0.16 [0.02, 1.06] |
| 24.2 Volatile anaesthetic-based mainte- nance of anaesthesia used in the nitrous oxide-free group | 2 | 286 | Odds Ratio (M-H, Fixed, 95% CI) | 0.70 [0.12, 4.29] |



| Outcome or subgroup title | No. of studies | No. of partici- pants | Statistical method | Effect size |
|---|----------------|--------------------------|--|------------------------|
| 25 Myocardial infarction: techniques used in the nitrous oxide-free group | 4 | 242 | Odds Ratio (M-H, Fixed, 95% CI) | 0.96 [0.37, 2.53] |
| 25.1 Volatile anaesthetic-based mainte- nance of anaesthesia used in the nitrous oxide-free group | 4 | 242 | Odds Ratio (M-H, Fixed, 95% CI) | 0.96 [0.37, 2.53] |
| 26 Stroke: techniques used in the ni- trous oxide-free group | 2 | 138 | Odds Ratio (M-H, Fixed, 95% CI) | 2.46 [0.53, 11.48] |
| 26.1 Propofol-based maintenance of anaesthesia used in the nitrous ox-ide-free group | 1 | 51 | Odds Ratio (M-H, Fixed, 95% CI) | 5.20 [0.24, 113.98] |
| 26.2 Volatile anaesthetic-based mainte- nance of anaesthesia used in the nitrous oxide-free group | 1 | 87 | Odds Ratio (M-H, Fixed, 95% CI) | 1.74 [0.28, 10.95] |
| 27 Severe nausea and vomiting: tech- niques used in the nitrous oxide-free group | 8 | 2041 | Odds Ratio (M-H, Fixed, 95% CI) | 1.13 [0.72, 1.78] |
| 27.1 Propofol-based maintenance of anaesthesia used in the nitrous ox-ide-free group | 1 | 1417 | Odds Ratio (M-H, Fixed, 95% CI) | 1.99 [0.18, 22.04] |
| 27.2 Volatile anaesthetic-based mainte- nance of anaesthesia used in the nitrous oxide-free group | 7 | 624 | Odds Ratio (M-H, Fixed, 95% CI) | 1.11 [0.70, 1.75] |
| 28 Wound infection rate: techniques used in the nitrous oxide-free group | 4 | 785 | Odds Ratio (M-H, Random, 95% CI) | 2.13 [0.44, 10.22] |
| 28.1 Volatile anaesthetic-based mainte- nance of anaesthesia used in the nitrous oxide-free group | 4 | 785 | Odds Ratio (M-H, Random, 95% CI) | 2.13 [0.44, 10.22] |
| 29 Length of hospital stay: techniques used in the nitrous oxide-free group | 5 | 1044 | Mean Difference (IV, Fixed, 95% CI) | 0.20 [-0.36, 0.75] |
| 29.1 Volatile anaesthetic-based mainte- nance of anaesthesia used in the nitrous oxide-free group | 5 | 1044 | Mean Difference (IV, Fixed, 95% CI) | 0.20 [-0.36, 0.75] |

Analysis 1.1. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 1 Inhospital case fatality rate.

| Study or subgroup | Nitrous ox- ide-based | Nitrous ox- ide-free | Peto Odds Ratio | | Weight | Peto Odds Ratio | | | |
|-------------------|-----------------------------|-------------------------|-----------------|-------|----------|-----------------|---------------|------------------------|---------------------|
| | n/N | n/N | | Peto, | Fixed, 9 | 5% CI | | | Peto, Fixed, 95% CI |
| Chen 2013 | 1/31 | 0/60 | | - | | • | \rightarrow | 0.77% | 18.83[0.3,1177.36] |
| Eger 1990 | 1/133 | 0/137 | 1 | | | - | | 0.86% | 7.61[0.15,383.92] |
| | Favours nitrous oxide-based | | 0.005 | 0.1 | 1 | 10 | 200 | Favours nitrous oxide- | free |



| Study or subgroup | Nitrous ox- ide-based | Nitrous ox- ide-free | | Peto Odds Ratio | | Weight | Peto Odds Ratio | |
|---|-------------------------------------|-------------------------|-------|-----------------|--------|---------------|--------------------------|---------------------|
| | n/N | n/N | | Peto, Fixed, | 95% CI | | l | Peto, Fixed, 95% CI |
| ENIGMA II trial 2014 | 42/3483 | 57/3509 | | -+- | | | 83.92% | 0.74[0.5,1.1] |
| ENIGMA trial 2007 | 9/1015 | 3/997 | | - | + | | 10.26% | 2.68[0.86,8.35] |
| Fleischmann 2005 | 0/206 | 3/202 | | -+ | | | 2.57% | 0.13[0.01,1.27] |
| Lampe 1990 | 0/13 | 0/13 | | | | | | Not estimable |
| Leung 2006 | 1/114 | 0/114 | | | - | \rightarrow | 0.86% | 7.39[0.15,372.38] |
| Todd 1993 | 1/81 | 0/40 | | | • | | 0.76% | 4.45[0.07,287.21] |
| | | | | | | | | |
| Total (95% CI) | 5076 | 5072 | | • | | | 100% | 0.87[0.61,1.26] |
| Total events: 55 (Nitrous oxide-based), 63 (Nitrous oxide-free) | | | | | | | | |
| Heterogeneity: Tau ² =0; Chi ² =12.12, d | f=6(P=0.06); I ² =50.489 | % | | | | | | |
| Test for overall effect: Z=0.72(P=0.47) | | | | | | | | |
| | Favours nit | rous oxide-based | 0.005 | 0.1 1 | 10 | 200 | Favours nitrous oxide-fr | ee |

Analysis 1.2. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 2 Pneumonia.

| Study or subgroup | Nitrous ox- ide-based | Nitrous ox- ide-free | Odds | Odds Ratio | | Odds Ratio | |
|---|--------------------------------|-------------------------|-----------|------------|---------|--------------------|--|
| | n/N | n/N | M-H, Fixe | d, 95% CI | | M-H, Fixed, 95% Cl | |
| Chen 2013 | 3/31 | 4/60 | | + | 10.68% | 1.5[0.31,7.17] | |
| Eger 1990 | 0/126 | 1/134 | + | | 6.28% | 0.35[0.01,8.72] | |
| ENIGMA trial 2007 | 30/1015 | 15/997 | | | 63.7% | 1.99[1.07,3.73] | |
| Jensen 1992 | 0/40 | 1/20 | + | <u> </u> | 8.5% | 0.16[0.01,4.12] | |
| Jensen 1993a | 1/21 | 0/21 | | | - 2.02% | 3.15[0.12,81.74] | |
| Lampe 1990 | 1/13 | 1/13 | | | 4% | 1[0.06,17.9] | |
| Singh 2011 | 1/41 | 0/46 | | | - 1.97% | 3.44[0.14,86.92] | |
| Todd 1993 | 1/81 | 0/40 | | | 2.84% | 1.51[0.06,37.88] | |
| | | | | | | | |
| Total (95% CI) | 1368 | 1331 | | ◆ | 100% | 1.68[1,2.81] | |
| Total events: 37 (Nitrous oxide-based | d), 22 (Nitrous oxide- | free) | | | | | |
| Heterogeneity: Tau ² =0; Chi ² =3.69, df= | =7(P=0.81); I ² =0% | | | | | | |
| Test for overall effect: Z=1.98(P=0.05) |) | | | | | | |
| Favours nitrous oxide-based 0.02 0.1 1 10 50 Favours nitrous oxide-free | | | | | | | |

Analysis 1.3. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 3 Pulmonary atelectasis.

| Study or subgroup | Nitrous ox- ide-based | Nitrous ox- ide-free | Odds Ratio | | | | Weight | Odds Ratio | |
|--|--------------------------|-------------------------|------------|----------|----------|----|--------|-------------------------|--------------------|
| | n/N | n/N | | M-H, Fiz | xed, 95% | CI | | | M-H, Fixed, 95% CI |
| Eger 1990 | 2/126 | 3/134 | | | + | | | 3.77% | 0.7[0.12,4.29] |
| ENIGMA trial 2007 | 127/1015 | 75/997 | | | -+- | | | 87.15% | 1.76[1.3,2.37] |
| Jensen 1992 | 1/40 | 1/20 | - | | | _ | | 1.71% | 0.49[0.03,8.22] |
| Jensen 1993b | 20/28 | 14/14 | - | + | + | | | 7.37% | 0.08[0,1.56] |
| Lampe 1990 | 0/13 | 0/13 | | | | | | | Not estimable |
| | | | | | | | | | |
| Total (95% CI) | 1222 | 1178 | | | • | | | 100% | 1.57[1.18,2.1] |
| Total events: 150 (Nitrous oxide-based), 93 (Nitrous oxide-free) | | | | | | | | | |
| | Favours nit | trous oxide-based | 0.01 | 0.1 | 1 | 10 | 100 | Favours nitrous oxide-f | ree |



| Study or subgroup | Nitrous ox- ide-based | Nitrous ox- ide-free | Odds Ratio | | | Weight Odds Ratio | | |
|--|------------------------------------|-------------------------|------------|-----|--------------|-------------------|-----|----------------------------|
| | n/N | n/N | | M-H | I, Fixed, 95 | 5% CI | | M-H, Fixed, 95% Cl |
| Heterogeneity: Tau ² =0; Chi ² =5.82, df | =3(P=0.12); I ² =48.429 | Ď | | | | | | |
| Test for overall effect: Z=3.1(P=0) | | | | | | 1 | 1 | |
| | Favours ni | rous oxide-based | 0.01 | 0.1 | 1 | 10 | 100 | Favours nitrous oxide-free |

Analysis 1.4. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 4 Myocardial infarction.

| Study or subgroup | Nitrous ox- ide-based | Nitrous ox- ide-free | Odds Ratio | Weight | Odds Ratio |
|---|---|-------------------------|--------------------|---------------------------|--------------------|
| | n/N | n/N | M-H, Fixed, 95% CI | | M-H, Fixed, 95% Cl |
| Chen 2013 | 4/31 | 4/60 | | 1.08% | 2.07[0.48,8.93] |
| Eger 1990 | 1/14 | 3/16 | | 1.18% | 0.33[0.03,3.64] |
| ENIGMA II trial 2014 | 215/3483 | 219/3509 | + | 93% | 0.99[0.81,1.2] |
| ENIGMA trial 2007 | 13/1015 | 7/997 | ++ | 3.17% | 1.83[0.73,4.62] |
| Kozmary 1990 | 1/18 | 3/16 | | 1.36% | 0.25[0.02,2.74] |
| Singh 2011 | 1/41 | 0/46 | + | - 0.21% | 3.44[0.14,86.92] |
| Total (95% CI) | 4602 | 4644 | • | 100% | 1.01[0.84,1.22] |
| Total events: 235 (Nitrous oxi | de-based), 236 (Nitrous oxic | le-free) | | | |
| Heterogeneity: Tau ² =0; Chi ² =5 | 5.26, df=5(P=0.39); I ² =4.89% | | | | |
| Test for overall effect: Z=0.15(| (P=0.88) | | | 1 | |
| | Favours ni | trous oxide-based | 0.01 0.1 1 10 10 | 0 Eavours nitrous oxide-f | roo |

Favours nitrous oxide-based Favours nitrous oxide-free

Analysis 1.5. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 5 Stroke.

| Study or subgroup | Nitrous ox- ide-based | Nitrous ox- ide-free | | Odds Ratio | | Weight | Odds Ratio | | |
|---|------------------------------------|-------------------------|------|------------|--------------|--------|---------------|--------------------------|--------------------|
| | n/N | n/N | | M-H | , Fixed, 95% | CI | | I | M-H, Fixed, 95% CI |
| Deleu 2000 | 2/26 | 0/25 | | - | | I | \rightarrow | 2.1% | 5.2[0.24,113.98] |
| ENIGMA II trial 2014 | 26/3483 | 19/3509 | | | | | | 85.38% | 1.38[0.76,2.5] |
| ENIGMA trial 2007 | 1/1015 | 1/997 | | | | | | 4.58% | 0.98[0.06,15.73] |
| Singh 2011 | 3/41 | 2/46 | | | + | | | 7.94% | 1.74[0.28,10.95] |
| Total (95% CI) | 4565 | 4577 | | | • | | | 100% | 1.47[0.86,2.53] |
| Total events: 32 (Nitrous oxide-b | oased), 22 (Nitrous oxide- | free) | | | | | | | |
| Heterogeneity: Tau ² =0; Chi ² =0.8 | , df=3(P=0.85); l ² =0% | | | | | | | | |
| Test for overall effect: Z=1.4(P=0 | 0.16) | | | | | | 1 | | |
| | Favours ni | trous oxide-based | 0.01 | 0.1 | 1 | 10 | 100 | Favours nitrous oxide-fr | ee |

Analysis 1.6. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 6 Severe nausea and vomiting.

| Study or subgroup | Nitrous ox- ide-based | Nitrous ox- ide-free | | Odds Ratio | | | | Weight | Odds Ratio |
|-------------------|--------------------------|-------------------------|------|------------|-----------|--------|-----|----------------------|---------------------|
| | n/N | n/N | | м-н, | Random, 9 | 95% CI | | | M-H, Random, 95% CI |
| Arellano 2000 | 2/710 | 1/707 | | | | | 1 | 2.52% | 1.99[0.18,22.04] |
| | Favours nit | rous oxide-based | 0.01 | 0.1 | 1 | 10 | 100 | Favours nitrous oxid | e-free |



| Study or subgroup | Nitrous ox- ide-based | Nitrous ox- ide-free | Odds Ratio | | | Weight | Odds Ratio | |
|---|----------------------------------|-------------------------|------------|------------|------------|---------------|-------------------------|---------------------|
| | n/N | n/N | | M-H, Rando | om, 95% Cl | | I | M-H, Random, 95% CI |
| ENIGMA II trial 2014 | 506/3483 | 378/3509 | | | • | | 27.23% | 1.41[1.22,1.62] |
| ENIGMA trial 2007 | 229/1015 | 104/997 | | | + | | 25.38% | 2.5[1.95,3.21] |
| Mraovic 2008 | 12/91 | 5/46 | | | • | | 8.88% | 1.25[0.41,3.78] |
| Paredi 1994 | 3/30 | 0/30 | | | | \rightarrow | 1.66% | 7.76[0.38,157.14] |
| Pedersen 1993 | 3/17 | 3/19 | | | + | | 4.38% | 1.14[0.2,6.6] |
| Sengupta 1988 | 5/33 | 3/31 | | | + | | 5.52% | 1.67[0.36,7.65] |
| Short 1985 | 0/40 | 2/11 | -+ | | | | 1.55% | 0.05[0,1.06] |
| Van Hemelrijck 1991 | 9/69 | 6/23 | | +- | - | | 8.3% | 0.43[0.13,1.36] |
| Vanacker 1999 | 21/91 | 16/93 | | _ | + | | 14.59% | 1.44[0.7,2.99] |
| Total (95% CI) | 5579 | 5466 | | | ◆ | | 100% | 1.44[0.97,2.15] |
| Total events: 790 (Nitrous oxide-based | d), 518 (Nitrous oxid | e-free) | | | | | | |
| Heterogeneity: Tau ² =0.15; Chi ² =26.68, | df=9(P=0); I ² =66.26 | % | | | | | | |
| Test for overall effect: Z=1.8(P=0.07) | | | | | | | | |
| | Favours nit | rous oxide-based | 0.01 | 0.1 1 | 10 | 100 | Favours nitrous oxide-f | free |

Analysis 1.7. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 7 Venous thromboembolism.

| Study or subgroup | Nitrous ox- ide-based | Nitrous ox- ide-free | | Odds Ratio | | | Weight | Odds Ratio | |
|---|-------------------------------|-------------------------|------|------------|---------------|----|--------|--------------------------|--------------------|
| | n/N | n/N | | M- | H, Fixed, 95% | CI | | | M-H, Fixed, 95% Cl |
| ENIGMA II trial 2014 | 18/3483 | 22/3509 | | | | | | 57.7% | 0.82[0.44,1.54] |
| ENIGMA trial 2007 | 10/1015 | 16/997 | | | | | | 42.3% | 0.61[0.28,1.35] |
| | | | | | | | | | |
| Total (95% CI) | 4498 | 4506 | | | • | | | 100% | 0.73[0.45,1.2] |
| Total events: 28 (Nitrous oxide-based) |), 38 (Nitrous oxide-f | ree) | | | | | | | |
| Heterogeneity: Tau ² =0; Chi ² =0.34, df= | 1(P=0.56); I ² =0% | | | | | | | | |
| Test for overall effect: Z=1.24(P=0.21) | | | | | | | | | |
| | Favours nit | rous oxide-based | 0.01 | 0.1 | 1 | 10 | 100 | Favours nitrous oxide-fr | ee |

Analysis 1.8. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 8 Wound infection rate.

| Study or subgroup | Nitrous ox- ide-based | Nitrous ox- ide-free | Odds Ratio | | | | Weight | Odds Ratio | |
|--|----------------------------------|-------------------------|------------|----------|---------|-------|--------|-------------------------|---------------------|
| | n/N | n/N | | M-H, Rai | ndom, 9 | 5% CI | | Ν | I-H, Random, 95% CI |
| Chen 2013 | 10/31 | 6/60 | | | | • | | 8.58% | 4.29[1.38,13.28] |
| Eger 1990 | 3/126 | 0/134 | | - | _ | | | 1.53% | 7.62[0.39,149.08] |
| ENIGMA II trial 2014 | 321/3483 | 311/3509 | | | • | | | 36.42% | 1.04[0.89,1.23] |
| ENIGMA trial 2007 | 106/1015 | 77/997 | | | - | | | 30.98% | 1.39[1.02,1.89] |
| Fleischmann 2005 | 31/206 | 40/202 | | - | • | | | 22.49% | 0.72[0.43,1.2] |
| Lampe 1990 | 0/13 | 0/13 | | | | | | | Not estimable |
| Total (95% CI) | 4874 | 4915 | | | • | | | 100% | 1.22[0.84,1.78] |
| Total events: 471 (Nitrous oxide-based | d), 434 (Nitrous oxid | e-free) | | | | | | | |
| Heterogeneity: Tau ² =0.09; Chi ² =12.49 | df=4(P=0.01); l ² =67 | .98% | | | | | | | |
| Test for overall effect: Z=1.04(P=0.3) | | | _1 | 1 | | | | | |
| | Favours nit | rous oxide-based | 0.005 | 0.1 | 1 | 10 | 200 | Favours nitrous oxide-f | ree |

Cochrane

Librarv

| Study or subgroup | Nitrous | oxide-based | Nitrou | s oxide-free | Mean Difference | Weight | Mean Difference |
|---|-------------|--|------------|---------------|-----------------|-------------|------------------|
| | Ν | Mean(SD) | Ν | Mean(SD) | Random, 95% Cl | | Random, 95% CI |
| Chen 2013 | 31 | 12.5 (10.3) | 30 | 9.7 (4.4) | + | 5.75% | 2.8[-1.15,6.75] |
| Chen 2013 | 31 | 12.5 (10.3) | 30 | 10.2 (12.3) | | 3.04% | 2.3[-3.4,8] |
| Eger 1990 | 126 | 8.1 (5) | 134 | 7.8 (4.4) | | 23.64% | 0.3[-0.85,1.45] |
| Fleischmann 2005 | 206 | 11.1 (4.9) | 202 | 11.6 (7.2) | | 23.06% | -0.5[-1.7,0.7] |
| Lampe 1990 | 13 | 7 (2.2) | 13 | 8.6 (3.2) | -+ | 14.06% | -1.6[-3.71,0.51] |
| Leung 2006 | 114 | 5.4 (3.5) | 114 | 4.8 (2.9) | - | 27.33% | 0.6[-0.23,1.43] |
| Myles 2008a | 25 | 16 (14) | 34 | 8.6 (3.7) | + | - 3.11% | 7.4[1.77,13.03] |
| Total *** | 546 | | 557 | | • | 100% | 0.36[-0.69,1.4] |
| Heterogeneity: Tau ² =0.86; Chi ² =13 | .43, df=6(P | =0.04); I ² =55.34 ⁰ | % | | | | |
| Test for overall effect: Z=0.67(P=0.9 | 5) | | | | | | |
| | | Favo | urs nitrou | s oxide-based | -10 -5 0 5 10 | Favours nit | ous oxide-free |

Analysis 1.9. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 9 Length of hospital stay.

10

Analysis 1.10. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 10 Inhospital case fatality rate: type of surgery.

| Study or subgroup | Nitrous ox- ide-based | Nitrous ox- ide-free | Peto | Peto Odds Ratio | | Weight | Peto Odds Ratio |
|---|--------------------------------------|-------------------------|-----------|-----------------|---------------|--------------------------|---------------------|
| | n/N | n/N | Peto, F | ixed, 95% CI | | I | Peto, Fixed, 95% CI |
| 1.10.1 Intra-abdominal surgery | | | | | | | |
| Chen 2013 | 1/31 | 0/60 | - | | \rightarrow | 18.84% | 18.83[0.3,1177.36] |
| Fleischmann 2005 | 0/206 | 3/202 | | + | | 62.6% | 0.13[0.01,1.27] |
| Subtotal (95% CI) | 237 | 262 | | | | 81.44% | 0.41[0.06,3.03] |
| Total events: 1 (Nitrous oxide-based), | 3 (Nitrous oxide-fre | e) | | | | | |
| Heterogeneity: Tau ² =0; Chi ² =4.26, df= | 1(P=0.04); I ² =76.51% | ò | | | | | |
| Test for overall effect: Z=0.87(P=0.39) | | | | | | | |
| | | | | | | | |
| 1.10.2 Neurosurgery | | | | | | | |
| Lampe 1990 | 0/13 | 0/13 | | | | | Not estimable |
| Todd 1993 | 1/81 | 0/40 | | + | | 18.56% | 4.45[0.07,287.21] |
| Subtotal (95% CI) | 94 | 53 | | | | 18.56% | 4.45[0.07,287.21] |
| Total events: 1 (Nitrous oxide-based), | 0 (Nitrous oxide-fre | e) | | | | | |
| Heterogeneity: Not applicable | | | | | | | |
| Test for overall effect: Z=0.7(P=0.48) | | | | | | | |
| | | | | | | | |
| Total (95% CI) | 331 | 315 | | | | 100% | 0.64[0.11,3.88] |
| Total events: 2 (Nitrous oxide-based), | , 3 (Nitrous oxide-fre | e) | | | | | |
| Heterogeneity: Tau ² =0; Chi ² =5.27, df= | 2(P=0.07); I ² =62.07% | b | | | | | |
| Test for overall effect: Z=0.48(P=0.63) | | | | | | | |
| Test for subgroup differences: Chi ² =1. | .02, df=1 (P=0.31), I ² = | =1.62% | | | | | |
| | Favours nit | rous oxide-based | 0.001 0.1 | 1 10 | 1000 | Favours nitrous oxide-fr | ee |

Analysis 1.11. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 11 Pneumonia: type of surgery.

| Study or subgroup | Nitrous ox- ide-based | Nitrous ox- ide-free | Odds Ratio | Weight | Odds Ratio |
|--|-------------------------------------|-------------------------|--------------------|----------------------------|--------------------|
| | n/N | n/N | M-H, Fixed, 95% Cl | | M-H, Fixed, 95% Cl |
| 1.11.1 Intra-abdominal surgery | | | | | |
| Chen 2013 | 3/31 | 4/60 | | 35.57% | 1.5[0.31,7.17] |
| Jensen 1992 | 0/40 | 1/20 | | 28.32% | 0.16[0.01,4.12] |
| Jensen 1993a | 1/21 | 0/21 | + | 6.73% | 3.15[0.12,81.74] |
| Subtotal (95% CI) | 92 | 101 | | 70.63% | 1.12[0.33,3.78] |
| Total events: 4 (Nitrous oxide-based), | 5 (Nitrous oxide-free | e) | | | |
| Heterogeneity: Tau ² =0; Chi ² =1.9, df=2 | P=0.39); I ² =0% | | | | |
| Test for overall effect: Z=0.18(P=0.86) | | | | | |
| | | | | | |
| 1.11.2 Neurosurgery | | | | | |
| Lampe 1990 | 1/13 | 1/13 | | 13.34% | 1[0.06,17.9] |
| Singh 2011 | 1/41 | 0/46 | | 6.58% | 3.44[0.14,86.92] |
| Todd 1993 | 1/81 | 0/40 | | 9.46% | 1.51[0.06,37.88] |
| Subtotal (95% CI) | 135 | 99 | | 29.37% | 1.71[0.3,9.81] |
| Total events: 3 (Nitrous oxide-based), | 1 (Nitrous oxide-free | e) | | | |
| Heterogeneity: Tau ² =0; Chi ² =0.32, df=2 | 2(P=0.85); I ² =0% | | | | |
| Test for overall effect: Z=0.6(P=0.55) | | | | | |
| | | | | | |
| Total (95% CI) | 227 | 200 | - | 100% | 1.29[0.48,3.48] |
| Total events: 7 (Nitrous oxide-based), | 6 (Nitrous oxide-free | e) | | | |
| Heterogeneity: Tau ² =0; Chi ² =2.3, df=5 | P=0.81); l ² =0% | | | | |
| Test for overall effect: Z=0.51(P=0.61) | | | | | |
| Test for subgroup differences: Chi ² =0. | 15, df=1 (P=0.7), I ² =0 | 9% | | | |
| | Eavours nit | rous oxido basad | 0.02 0.1 1 10 | 50 Eavours pitrous oxido f | roo |

Favours nitrous oxide-based 0.02 0.1 1 10 50 Favours nitrous oxide-free

Analysis 1.12. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 12 Pulmonary atelectasis: type of surgery.

| Study or subgroup | Nitrous ox- ide-based | Nitrous ox- ide-free | | Odds Ratio | | | Weight | Odds Ratio | |
|---|-------------------------------|-------------------------|------|------------|-------------|----|--------|------------------------|--------------------|
| | n/N | n/N | | M-H, Fi | ixed, 95% C | l | | | M-H, Fixed, 95% CI |
| 1.12.1 Intra-abdominal surgery | | | | | | | | | |
| Jensen 1992 | 1/40 | 1/20 | _ | • | | _ | | 18.83% | 0.49[0.03,8.22] |
| Jensen 1993b | 20/28 | 14/14 | ← | + | | | | 81.17% | 0.08[0,1.56] |
| Subtotal (95% CI) | 68 | 34 | - | | - | | | 100% | 0.16[0.02,1.06] |
| Total events: 21 (Nitrous oxide-based) | , 15 (Nitrous oxide-f | ree) | | | | | | | |
| Heterogeneity: Tau ² =0; Chi ² =0.79, df= | 1(P=0.37); I ² =0% | | | | | | | | |
| Test for overall effect: Z=1.9(P=0.06) | | | | | | | | | |
| | | | | | | | | | |
| 1.12.2 Neurosurgery | | | | | | | | | |
| Lampe 1990 | 0/13 | 0/13 | | | | | | | Not estimable |
| Subtotal (95% CI) | 13 | 13 | | | | | | | Not estimable |
| Total events: 0 (Nitrous oxide-based), | 0 (Nitrous oxide-free | e) | | | | | | | |
| Heterogeneity: Not applicable | | | | | | | | | |
| Test for overall effect: Not applicable | | | | | | | | | |
| | | | | | | | | | |
| | Favours nit | rous oxide-based | 0.01 | 0.1 | 1 | 10 | 100 | Favours nitrous oxide- | free |



| Study or subgroup | Nitrous ox- ide-based | Nitrous ox- ide-free | | Od | lds Rati | 0 | | Weight | Odds Ratio |
|---|---------------------------------|-------------------------|------|--------|----------|-------|-----|----------------------------|------------------|
| | n/N | n/N | | M-H, F | ixed, 95 | 5% CI | | M- | H, Fixed, 95% CI |
| Total (95% CI) | 81 | 47 | - | | | | | 100% | 0.16[0.02,1.06] |
| Total events: 21 (Nitrous oxide-base | d), 15 (Nitrous oxide- | free) | | | | | | | |
| Heterogeneity: Tau ² =0; Chi ² =0.79, d | f=1(P=0.37); I ² =0% | | | | | | | | |
| Test for overall effect: Z=1.9(P=0.06) | | | | | | | | | |
| Test for subgroup differences: Not a | pplicable | | | 1 | | | 1 | | |
| | Favours ni | trous oxide-based | 0.01 | 0.1 | 1 | 10 | 100 | Favours nitrous oxide-free | |

Analysis 1.13. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 13 Myocardial infarction: type of surgery.

| Study or subgroup | Nitrous ox- ide-based | Nitrous ox- ide-free | Odds Ratio | Weight | Odds Ratio |
|--|-------------------------------------|-------------------------|--------------------|----------------------------|--------------------|
| | n/N | n/N | M-H, Fixed, 95% CI | | M-H, Fixed, 95% CI |
| 1.13.1 Intra-abdominal surgery | | | | | |
| Chen 2013 | 4/31 | 4/60 | | 40.72% | 2.07[0.48,8.93] |
| Subtotal (95% CI) | 31 | 60 | | 40.72% | 2.07[0.48,8.93] |
| Total events: 4 (Nitrous oxide-based), 4 | 4 (Nitrous oxide-free |) | | | |
| Heterogeneity: Not applicable | | | | | |
| Test for overall effect: Z=0.98(P=0.33) | | | | | |
| 1.13.2 Neurosurgery | | | | | |
| Singh 2011 | 1/41 | 0/46 | | 7.81% | 3.44[0.14,86.92] |
| Subtotal (95% CI) | 41 | 46 | | 7.81% | 3.44[0.14,86.92] |
| Total events: 1 (Nitrous oxide-based), (|) (Nitrous oxide-free |) | | | |
| Heterogeneity: Not applicable | | | | | |
| Test for overall effect: Z=0.75(P=0.45) | | | | | |
| 1.13.3 Vascular surgery | | | | | |
| Kozmary 1990 | 1/18 | 3/16 | | 51.47% | 0.25[0.02,2.74] |
| Subtotal (95% CI) | 18 | 16 | | 51.47% | 0.25[0.02,2.74] |
| Total events: 1 (Nitrous oxide-based), 3 | 3 (Nitrous oxide-free |) | | | |
| Heterogeneity: Not applicable | | | | | |
| Test for overall effect: Z=1.13(P=0.26) | | | | | |
| Total (95% CI) | 90 | 122 | - | 100% | 1.24[0.42,3.67] |
| Total events: 6 (Nitrous oxide-based), | 7 (Nitrous oxide-free |) | | | |
| Heterogeneity: Tau ² =0; Chi ² =2.56, df=2 | (P=0.28); I ² =21.98% | | | | |
| Test for overall effect: Z=0.4(P=0.69) | | | | | |
| Test for subgroup differences: Chi ² =2.5 | 5, df=1 (P=0.28), l ² =2 | 21.48% | | | |
| | Fayours nitr | ous oxide-based | 0.01 0.1 1 10 | 100 Favours nitrous oxide- | free |

| Study or subgroup | Nitrous ox- ide-based | Nitrous ox- ide-free | | Odds Ratio | | | Weight | Odds Ratio |
|--|-------------------------------------|-------------------------|------|------------|-------------|---------------|---------------------------|--------------------|
| | n/N | n/N | | M-H, Fi | xed, 95% CI | | Ν | 1-H, Fixed, 95% CI |
| 1.14.1 Neurosurgery | | | | | | | | |
| Singh 2011 | 3/41 | 2/46 | | | | | 79.08% | 1.74[0.28,10.95] |
| Subtotal (95% CI) | 41 | 46 | | | | | 79.08% | 1.74[0.28,10.95] |
| Total events: 3 (Nitrous oxide-based), 2 | 2 (Nitrous oxide-free | 2) | | | | | | |
| Heterogeneity: Not applicable | | | | | | | | |
| Test for overall effect: Z=0.59(P=0.56) | | | | | | | | |
| | | | | | | | | |
| 1.14.2 Ophthalmic surgery | | | | | | | | |
| Deleu 2000 | 2/26 | 0/25 | | | • | \rightarrow | 20.92% | 5.2[0.24,113.98] |
| Subtotal (95% CI) | 26 | 25 | | | | | 20.92% | 5.2[0.24,113.98] |
| Total events: 2 (Nitrous oxide-based), (| 0 (Nitrous oxide-free | 2) | | | | | | |
| Heterogeneity: Not applicable | | | | | | | | |
| Test for overall effect: Z=1.05(P=0.29) | | | | | | | | |
| | | | | | | | | |
| Total (95% CI) | 67 | 71 | | - | | | 100% | 2.46[0.53,11.48] |
| Total events: 5 (Nitrous oxide-based), 2 | 2 (Nitrous oxide-free | e) | | | | | | |
| Heterogeneity: Tau ² =0; Chi ² =0.36, df=1 | (P=0.55); I ² =0% | | | | | | | |
| Test for overall effect: Z=1.15(P=0.25) | | | | | | | | |
| Test for subgroup differences: Chi ² =0.3 | 86, df=1 (P=0.55), I ² = | 0% | | | | | | |
| | Favours nit | rous oxide-based | 0.01 | 0.1 | 1 10 | 100 | Favours nitrous oxide-fre | e |

Analysis 1.14. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 14 Stroke: type of surgery.

Analysis 1.15. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 15 Severe nausea and vomiting: type of surgery.

| Study or subgroup | Nitrous ox- ide-based | Nitrous ox- ide-free | Odds Ratio | | | Weight | Odds Ratio | |
|--|----------------------------------|-------------------------|------------|-----------|------------|--------|-------------------------|--------------------|
| | n/N | n/N | | M-H, Fixe | ed, 95% CI | | | M-H, Fixed, 95% Cl |
| 1.15.1 Day-case procedure/examina | tion | | | | | | | |
| Arellano 2000 | 2/710 | 1/707 | | | | | 2.78% | 1.99[0.18,22.04] |
| Sengupta 1988 | 5/33 | 3/31 | | | + | | 7.29% | 1.67[0.36,7.65] |
| Short 1985 | 0/40 | 2/11 | -++ | | + | | 10.62% | 0.05[0,1.06] |
| Van Hemelrijck 1991 | 9/69 | 6/23 | | | + | | 21.75% | 0.43[0.13,1.36] |
| Subtotal (95% CI) | 852 | 772 | | - | • | | 42.43% | 0.65[0.3,1.41] |
| Total events: 16 (Nitrous oxide-based) | , 12 (Nitrous oxide-fi | ree) | | | | | | |
| Heterogeneity: Tau ² =0; Chi ² =5.55, df=3 | 3(P=0.14); I ² =45.9% | | | | | | | |
| Test for overall effect: Z=1.1(P=0.27) | | | | | | | | |
| | | | | | | | | |
| 1.15.2 Intra-abdominal surgery | | | | | | | | |
| Mraovic 2008 | 12/91 | 5/46 | | | • | | 16.02% | 1.25[0.41,3.78] |
| Paredi 1994 | 3/30 | 0/30 | | | | | 1.23% | 7.76[0.38,157.14] |
| Pedersen 1993 | 3/17 | 3/19 | | | • | | 6.48% | 1.14[0.2,6.6] |
| Subtotal (95% CI) | 138 | 95 | | • | | | 23.74% | 1.56[0.65,3.71] |
| Total events: 18 (Nitrous oxide-based) | , 8 (Nitrous oxide-fre | e) | | | | | | |
| Heterogeneity: Tau ² =0; Chi ² =1.37, df=2 | 2(P=0.5); I ² =0% | | | | | | | |
| Test for overall effect: Z=1(P=0.32) | | | | | | | | |
| | | | | | | | | |
| 1.15.3 Breast surgery | | | | | | | | |
| | Favours nit | ous oxide-based | 0.01 | 0.1 | 1 | 10 100 | Favours nitrous oxide-f | ree |



| Study or subgroup | Nitrous ox- ide-based | Nitrous ox- ide-free | | Odds Ratio | | Weight | | Odds Ratio | |
|--|-------------------------------------|-------------------------|------|------------|---------------|--------|-----|--------------------------|--------------------|
| | n/N | n/N | | M-H | l, Fixed, 95% | CI | | | M-H, Fixed, 95% Cl |
| Vanacker 1999 | 21/91 | 16/93 | | | +• - | | | 33.83% | 1.44[0.7,2.99] |
| Subtotal (95% CI) | 91 | 93 | | | - | | | 33.83% | 1.44[0.7,2.99] |
| Total events: 21 (Nitrous oxide-based) | , 16 (Nitrous oxide- | free) | | | | | | | |
| Heterogeneity: Not applicable | | | | | | | | | |
| Test for overall effect: Z=0.99(P=0.32) | | | | | | | | | |
| | | | | | | | | | |
| Total (95% CI) | 1081 | 960 | | | • | | | 100% | 1.13[0.72,1.78] |
| Total events: 55 (Nitrous oxide-based) | , 36 (Nitrous oxide- | free) | | | | | | | |
| Heterogeneity: Tau ² =0; Chi ² =9.22, df=7 | 7(P=0.24); I ² =24.05% | 6 | | | | | | | |
| Test for overall effect: Z=0.54(P=0.59) | | | | | | | | | |
| Test for subgroup differences: Chi ² =2.9 | 94, df=1 (P=0.23), I ² = | =31.86% | | | | | | | |
| | Favours nit | trous oxide-based | 0.01 | 0.1 | 1 | 10 | 100 | Favours nitrous oxide-fr | ee |

Analysis 1.16. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 16 Wound infection rate: type of surgery.

| Study or subgroup | Nitrous ox- ide-based | Nitrous ox- ide-free | | Odds Ratio | | Weight | Odds Ratio |
|--|---------------------------------|-------------------------|---------|--------------|--------|--------|---------------------|
| | n/N | n/N | M- | H, Random, 9 | 5% CI | M | I-H, Random, 95% CI |
| 1.16.1 Intra-abdominal surgery | | | | | | | |
| Chen 2013 | 10/31 | 6/60 | | | - | 45.87% | 4.29[1.38,13.28] |
| Fleischmann 2005 | 31/206 | 40/202 | | | | 54.13% | 0.72[0.43,1.2] |
| Subtotal (95% CI) | 237 | 262 | | | | 100% | 1.63[0.28,9.33] |
| Total events: 41 (Nitrous oxide-based) | , 46 (Nitrous oxide- | free) | | | | | |
| Heterogeneity: Tau ² =1.4; Chi ² =7.95, df | =1(P=0); I ² =87.42% | | | | | | |
| Test for overall effect: Z=0.55(P=0.58) | | | | | | | |
| | | | | | | | |
| 1.16.2 Neurosurgery | | | | | | | |
| Lampe 1990 | 0/13 | 0/13 | | | | | Not estimable |
| Subtotal (95% CI) | 13 | 13 | | | | | Not estimable |
| Total events: 0 (Nitrous oxide-based), | 0 (Nitrous oxide-fre | e) | | | | | |
| Heterogeneity: Not applicable | | | | | | | |
| Test for overall effect: Not applicable | | | | | | | |
| | | | | | | | |
| Total (95% CI) | 250 | 275 | | | | 100% | 1.63[0.28,9.33] |
| Total events: 41 (Nitrous oxide-based) | , 46 (Nitrous oxide- | free) | | | | | |
| Heterogeneity: Tau ² =1.4; Chi ² =7.95, df | =1(P=0); I ² =87.42% | | | | | | |
| Test for overall effect: Z=0.55(P=0.58) | | | | | | | |
| Test for subgroup differences: Not app | licable | | | | | | |
| | Favours ni | trous oxide-based | 0.005 0 | 1 1 | 10 200 | | ree |

Analysis 1.17. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 17 Length of hospital stay: type of surgery.

| Study or subgroup | Nitrous | oxide-based | Nitrou | s oxide-free | Mean Difference | Weight | Mean Difference |
|---|------------|-------------------------------|-------------|---------------|-----------------|--------------|-------------------|
| | Ν | Mean(SD) | Ν | Mean(SD) | Fixed, 95% CI | | Fixed, 95% CI |
| 1.17.1 Intra-abdominal surgery | | | | | | | |
| Chen 2013 | 31 | 12.5 (10.3) | 30 | 9.7 (4.4) | + | 6.29% | 2.8[-1.15,6.75] |
| Chen 2013 | 31 | 12.5 (10.3) | 30 | 10.2 (12.3) | | 3.02% | 2.3[-3.4,8] |
| Fleischmann 2005 | 206 | 11.1 (4.9) | 202 | 11.6 (7.2) | | 68.61% | -0.5[-1.7,0.7] |
| Subtotal *** | 268 | | 262 | | • | 77.93% | -0.12[-1.25,1] |
| Heterogeneity: Tau ² =0; Chi ² =3.17, d | f=2(P=0.2) | ; I ² =37.01% | | | | | |
| Test for overall effect: Z=0.22(P=0.83 | 3) | | | | | | |
| | | | | | | | |
| 1.17.2 Neurosurgery | | | | | | | |
| Lampe 1990 | 13 | 7 (2.2) | 13 | 8.6 (3.2) | | 22.07% | -1.6[-3.71,0.51] |
| Subtotal *** | 13 | | 13 | | | 22.07% | -1.6[-3.71,0.51] |
| Heterogeneity: Not applicable | | | | | | | |
| Test for overall effect: Z=1.49(P=0.14 | 1) | | | | | | |
| | | | | | | | |
| Total *** | 281 | | 275 | | • | 100% | -0.45[-1.44,0.54] |
| Heterogeneity: Tau ² =0; Chi ² =4.64, d | f=3(P=0.2) | ; I ² =35.3% | | | | | |
| Test for overall effect: Z=0.89(P=0.37 | 7) | | | | | | |
| Test for subgroup differences: Chi ² = | 1.46, df=1 | (P=0.23), I ² =31. | 6% | | | | |
| | | Favoi | urs nitrou: | s oxide-based | -10 -5 0 5 10 | Favours nitr | ous oxide-free |

Analysis 1.18. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 18 Inhospital case fatality rate: concentrations of inhaled nitrous oxide.

| Study or subgroup | High-concen- tration nitrous oxide-based | Nitrous ox- ide-free | | Peto Odds Ratio | | Weight | Peto Odds Ratio |
|--|--|-------------------------|----------|--------------------|--------|---------------------------|---------------------|
| | n/N | n/N | | Peto, Fixed, 95% C | .1 | I | Peto, Fixed, 95% Cl |
| 1.18.1 High-concentration nitrou | ıs oxide | | | | | | |
| Chen 2013 | 1/31 | 0/60 | | | | 0.78% | 18.83[0.3,1177.36] |
| Eger 1990 | 1/133 | 0/137 | | | • | 0.87% | 7.61[0.15,383.92] |
| ENIGMA II trial 2014 | 42/3483 | 57/3509 | | | | 84.65% | 0.74[0.5,1.1] |
| ENIGMA trial 2007 | 9/1015 | 3/997 | | + | _ | 10.35% | 2.68[0.86,8.35] |
| Fleischmann 2005 | 0/206 | 3/202 | | | | 2.59% | 0.13[0.01,1.27] |
| Lampe 1990 | 0/13 | 0/13 | | | | | Not estimable |
| Todd 1993 | 1/81 | 0/40 | _ | | > | 0.77% | 4.45[0.07,287.21] |
| Subtotal (95% CI) | 4962 | 4958 | | • | | 100% | 0.86[0.6,1.24] |
| Total events: 54 (High-concentration ide-free) | on nitrous oxide-based |), 63 (Nitrous ox- | | | | | |
| Heterogeneity: Tau ² =0; Chi ² =10.97, | df=5(P=0.05); I ² =54.42 | % | | | | | |
| Test for overall effect: Z=0.82(P=0.4 | 1) | | | | | | |
| | | | | | | | |
| Total (95% CI) | 4962 | 4958 | | + | | 100% | 0.86[0.6,1.24] |
| Total events: 54 (High-concentration ide-free) | on nitrous oxide-based | , 63 (Nitrous ox- | | | | | |
| Heterogeneity: Tau ² =0; Chi ² =10.97, | df=5(P=0.05); I ² =54.42 | % | | | | | |
| Test for overall effect: Z=0.82(P=0.4 | 1) | | | | | | |
| Favours | high-concentration nit | rous oxide-based | 0.01 0.1 | 1 | 10 100 | Favours nitrous oxide-fro | e |



Analysis 1.19. Comparison 1 Nitrous oxide-based versus nitrous oxidefree, Outcome 19 Stroke: concentrations of inhaled nitrous oxide.

| Study or subgroup | High-concen- tration nitrous oxide-based | Nitrous ox- ide-free | | | Odds Ratio | | | Weight | Odds Ratio |
|---|--|-------------------------|------|-----|--------------|----|-----|--------------------------|--------------------|
| | n/N | n/N | | M-H | , Fixed, 95% | CI | | | M-H, Fixed, 95% Cl |
| 1.19.1 High-concentration nitro | us oxide | | | | | | | | |
| ENIGMA II trial 2014 | 26/3483 | 19/3509 | | | | | | 87.21% | 1.38[0.76,2.5] |
| ENIGMA trial 2007 | 1/1015 | 1/997 | | | | | | 4.68% | 0.98[0.06,15.73] |
| Singh 2011 | 3/41 | 2/46 | | - | + | | | 8.11% | 1.74[0.28,10.95] |
| Subtotal (95% CI) | 4539 | 4552 | | | • | | | 100% | 1.39[0.8,2.42] |
| Total events: 30 (High-concentrati ide-free) | on nitrous oxide-based |), 22 (Nitrous ox- | | | | | | | |
| Heterogeneity: Tau ² =0; Chi ² =0.12, | df=2(P=0.94); I ² =0% | | | | | | | | |
| Test for overall effect: Z=1.17(P=0. | 24) | | | | | | | | |
| | | | | | | | | | |
| Total (95% CI) | 4539 | 4552 | | | • | | | 100% | 1.39[0.8,2.42] |
| Total events: 30 (High-concentrati ide-free) | on nitrous oxide-based |), 22 (Nitrous ox- | | | | | | | |
| Heterogeneity: Tau ² =0; Chi ² =0.12, | df=2(P=0.94); I ² =0% | | | | | | | | |
| Test for overall effect: Z=1.17(P=0. | 24) | | | | | | | | |
| Favours | s high-concentration nit | trous oxide-based | 0.01 | 0.1 | 1 | 10 | 100 | Favours nitrous oxide-fr | ee |

Analysis 1.20. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 20 Severe nausea and vomiting: concentrations of inhaled nitrous oxide.

| Study or subgroup | High-concen- tration nitrous oxide-based | Nitrous ox- ide-free | Odds Ratio | Weight | Odds Ratio |
|--|--|-------------------------|---------------------|-------------------------------------|---------------------|
| | n/N | n/N | M-H, Random, 95% Cl | | M-H, Random, 95% Cl |
| 1.20.1 High-concentration ni | trous oxide | | | | |
| Arellano 2000 | 2/710 | 1/707 | | 2.93% | 1.99[0.18,22.04] |
| ENIGMA II trial 2014 | 506/3483 | 378/3509 | - | 29.63% | 1.41[1.22,1.62] |
| ENIGMA trial 2007 | 229/1015 | 104/997 | + | 27.76% | 2.5[1.95,3.21] |
| Mraovic 2008 | 6/45 | 5/46 | | 8.46% | 1.26[0.36,4.47] |
| Pedersen 1993 | 3/17 | 3/19 | | 5.07% | 1.14[0.2,6.6] |
| Short 1985 | 0/40 | 2/11 | ↓ | 1.81% | 0.05[0,1.06] |
| Van Hemelrijck 1991 | 9/69 | 6/23 | | 9.5% | 0.43[0.13,1.36] |
| Subtotal (95% CI) | 5379 | 5312 | • | 85.16% | 1.34[0.81,2.19] |
| Total events: 755 (High-concer oxide-free) | tration nitrous oxide-based | d), 499 (Nitrous | | | |
| Heterogeneity: Tau ² =0.19; Chi ² | =25.48, df=6(P=0); I ² =76.45 | % | | | |
| Test for overall effect: Z=1.14(P | 9=0.25) | | | | |
| 1.20.2 Low-concentration nit | rous oxide | | | | |
| Mraovic 2008 | 6/46 | 5/46 | + | 8.47% | 1.23[0.35,4.35] |
| Sengupta 1988 | 5/33 | 3/31 | | 6.37% | 1.67[0.36,7.65] |
| Subtotal (95% CI) | 79 | 77 | - | 14.84% | 1.39[0.53,3.68] |
| Total events: 11 (High-concent ide-free) | ration nitrous oxide-based) | , 8 (Nitrous ox- | | | |
| Heterogeneity: Tau ² =0; Chi ² =0. | 09, df=1(P=0.76); l ² =0% | | | | |
| Test for overall effect: Z=0.67(P | =0.51) | | | | |
| Favo | ours high-concentration nit | rous oxide-based | 0.01 0.1 1 10 | ¹⁰⁰ Favours nitrous oxid | e-free |



| Study or subgroup | High-concen- tration nitrous oxide-based | Nitrous ox- ide-free | | Odds Ratio | | | Weight | Odds Ratio | |
|--|--|-------------------------|------|------------|------------|------|--------|----------------------------|-----------------|
| | n/N | n/N | | м-н, | Random, 95 | % CI | | М-Н, | Random, 95% CI |
| | | | | | | | | | |
| Total (95% CI) | 5458 | 5389 | | | • | | | 100% | 1.37[0.89,2.11] |
| Total events: 766 (High-concentr oxide-free) | ration nitrous oxide-based | l), 507 (Nitrous | | | | | | | |
| Heterogeneity: Tau ² =0.16; Chi ² =2 | 25.63, df=8(P=0); I ² =68.79 | % | | | | | | | |
| Test for overall effect: Z=1.43(P=0 | 0.15) | | | | | | | | |
| Test for subgroup differences: Ch | ni²=0.01, df=1 (P=0.94), I²= | 0% | | | | | | | |
| Favou | rs high-concentration nit | rous oxide-based | 0.01 | 0.1 | 1 | 10 | 100 | Favours nitrous oxide-free | |

Analysis 1.21. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 21 Length of hospital stay: concentrations of inhaled nitrous oxide.

| Study or subgroup | High-co nitrous | oncentration oxide-based | Nitrou | s oxide-free | Mean Difference | Weight | Mean Difference |
|---|--------------------|--------------------------------|------------|---------------|-----------------|-------------|------------------|
| | N | Mean(SD) | Ν | Mean(SD) | Random, 95% Cl | | Random, 95% CI |
| 1.21.1 High-concentration nitrou | ıs oxide | | | | | | |
| Chen 2013 | 31 | 12.5 (10.3) | 30 | 10.2 (12.3) | | 5.65% | 2.3[-3.4,8] |
| Chen 2013 | 31 | 12.5 (10.3) | 30 | 9.7 (4.4) | | 10.03% | 2.8[-1.15,6.75] |
| Eger 1990 | 126 | 8.1 (5) | 134 | 7.8 (4.4) | | 29.2% | 0.3[-0.85,1.45] |
| Fleischmann 2005 | 206 | 11.1 (4.9) | 202 | 11.6 (7.2) | | 28.75% | -0.5[-1.7,0.7] |
| Lampe 1990 | 13 | 7 (2.2) | 13 | 8.6 (3.2) | • | 20.58% | -1.6[-3.71,0.51] |
| Myles 2008a | 25 | 16 (14) | 34 | 8.6 (3.7) | | 5.78% | 7.4[1.77,13.03] |
| Subtotal *** | 432 | | 443 | | | 100% | 0.45[-1.03,1.93] |
| Heterogeneity: Tau ² =1.61; Chi ² =12 | .34, df=5(P | =0.03); l ² =59.479 | 6 | | | | |
| Test for overall effect: Z=0.6(P=0.5 | 5) | | | | | | |
| | | | | | | | |
| Total *** | 432 | | 443 | | | 100% | 0.45[-1.03,1.93] |
| Heterogeneity: Tau ² =1.61; Chi ² =12 | .34, df=5(P | =0.03); l ² =59.479 | <i>/</i> o | | | | |
| Test for overall effect: Z=0.6(P=0.5 | 5) | | | | | | |
| | Favours h | igh-concentrati | on nitrou | s oxide-based | -4 -2 0 2 4 | Favours nit | rous oxide-free |

Analysis 1.22. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 22 Inhospital case fatality rate: techniques used in the nitrous oxide-free group.

| Study or subgroup | Nitrous ox- ide-based | Intravenous combined with inhaled anaesthesia | | Peto Odds Ratio | | | Weight | Peto Odds Ratio | |
|--|--------------------------|--|-------|-----------------|---------|-------|--------|---------------------|-----------------------|
| | n/N | n/N | | Peto, F | ixed, 9 | 5% CI | | | Peto, Fixed, 95% Cl |
| 1.22.1 Propofol-based maintenance oxide-free group | e of anaesthesia us | ed in the nitrous | | | | | | | |
| Todd 1993 | 1/81 | 0/40 | | | | • | | 13.08% | 4.45[0.07,287.21] |
| Subtotal (95% CI) | 81 | 40 | | | | | | 13.08% | 4.45[0.07,287.21] |
| Total events: 1 (Nitrous oxide-based), haled anaesthesia) | 0 (Intravenous com | bined with in- | | | | | | | |
| Heterogeneity: Not applicable | | | | | | | | | |
| Test for overall effect: Z=0.7(P=0.48) | | | | | | | | | |
| | | | 1 | | | | 1 | | |
| | Favours ni | trous oxide-based | 0.001 | 0.1 | 1 | 10 | 1000 | Favours intravenous | combined with inhaled |



| Study or subgroup | Nitrous ox- ide-based | Intravenous combined with inhaled anaesthesia | | Peto | Odds F | latio | | Weight | Peto Odds Ratio |
|--|--------------------------------------|--|-------|---------|-----------------|-------|---------------|---------------------|-----------------------|
| | n/N | n/N | | Peto, F | ixed, 9 | 5% CI | | | Peto, Fixed, 95% Cl |
| 1.22.2 Volatile anaesthetic-based the nitrous oxide-free group | d maintenance of ana | esthesia used in | | | | | | | |
| Chen 2013 | 1/31 | 0/60 | | - | | + | \rightarrow | 13.27% | 18.83[0.3,1177.36] |
| Eger 1990 | 1/133 | 0/137 | | _ | | + | | 14.77% | 7.61[0.15,383.92] |
| Fleischmann 2005 | 0/206 | 3/202 | | | | | | 44.1% | 0.13[0.01,1.27] |
| Lampe 1990 | 0/13 | 0/13 | | | | | | | Not estimable |
| Leung 2006 | 1/114 | 0/114 | | | | + | | 14.77% | 7.39[0.15,372.38] |
| Subtotal (95% CI) | 497 | 526 | | - | \blacklozenge | ► | | 86.92% | 1.11[0.22,5.58] |
| Total events: 3 (Nitrous oxide-base haled anaesthesia) | ed), 3 (Intravenous com | bined with in- | | | | | | | |
| Heterogeneity: Tau ² =0; Chi ² =7.02, | df=3(P=0.07); I ² =57.29% | 6 | | | | | | | |
| Test for overall effect: Z=0.13(P=0.9 | 9) | | | | | | | | |
| | | | | | | | | | |
| Total (95% CI) | 578 | 566 | | - | \blacklozenge | ► | | 100% | 1.33[0.29,6] |
| Total events: 4 (Nitrous oxide-base haled anaesthesia) | ed), 3 (Intravenous com | bined with in- | | | | | | | |
| Heterogeneity: Tau ² =0; Chi ² =7.4, d | f=4(P=0.12); I ² =45.92% | | | | | | | | |
| Test for overall effect: Z=0.37(P=0.7 | 71) | | | | | | | | |
| Test for subgroup differences: Chi ² | =0.37, df=1 (P=0.54), I ² | =0% | | | | | | | |
| | Favours ni | trous oxide-based | 0.001 | 0.1 | 1 | 10 | 1000 | Favours intravenous | combined with inhaled |

Analysis 1.23. Comparison 1 Nitrous oxide-based versus nitrous oxidefree, Outcome 23 Pneumonia: techniques used in the nitrous oxide-free group.

| Study or subgroup | Nitrous ox- ide-based | Intravenous combined with inhaled anaesthesia | Odds | Ratio | Weight | Odds Ratio |
|--|-------------------------------|--|------------|------------|---------------------------------|-----------------------|
| | n/N | n/N | M-H, Fixe | ed, 95% CI | | M-H, Fixed, 95% CI |
| 1.23.1 Propofol-based maintenance oxide-free group | of anaesthesia us | ed in the nitrous | | | | |
| Jensen 1992 | 0/40 | 1/20 | ← • | <u> </u> | 23.42% | 0.16[0.01,4.12] |
| Todd 1993 | 1/81 | 0/40 | | +• | 7.82% | 1.51[0.06,37.88] |
| Subtotal (95% CI) | 121 | 60 | | | 31.24% | 0.5[0.07,3.61] |
| Total events: 1 (Nitrous oxide-based), haled anaesthesia) | 1 (Intravenous com | bined with in- | | | | |
| Heterogeneity: Tau ² =0; Chi ² =0.92, df=1 | L(P=0.34); I ² =0% | | | | | |
| Test for overall effect: Z=0.69(P=0.49) | | | | | | |
| 1.23.2 Volatile anaesthetic-based mathematics of the network of th | aintenance of ana | esthesia used in | | | | |
| Chen 2013 | 3/31 | 4/60 | | | 29.42% | 1.5[0.31,7.17] |
| Eger 1990 | 0/126 | 1/134 | + | | 17.31% | 0.35[0.01,8.72] |
| Jensen 1993a | 1/21 | 0/21 | | + | - 5.57% | 3.15[0.12,81.74] |
| Lampe 1990 | 1/13 | 1/13 | | • | 11.03% | 1[0.06,17.9] |
| Singh 2011 | 1/41 | 0/46 | | + | - 5.44% | 3.44[0.14,86.92] |
| Subtotal (95% CI) | 232 | 274 | | | 68.76% | 1.42[0.49,4.06] |
| Total events: 6 (Nitrous oxide-based), haled anaesthesia) | 6 (Intravenous com | bined with in- | | | | |
| Heterogeneity: Tau ² =0; Chi ² =1.31, df=4 | 4(P=0.86); I ² =0% | | | | | |
| | Favours ni | trous oxide-based | 0.02 0.1 | 1 10 50 | Favours intravenous anaesthesia | combined with inhaled |



| Study or subgroup | Nitrous ox- ide-based | Intravenous combined with inhaled anaesthesia | | | Odds Rati | 0 | | Weight | Odds Ratio |
|--|------------------------------------|--|------|-----|-------------|-------|----|------------------------------------|-----------------------|
| | n/N | n/N | - | M-I | l, Fixed, 9 | 5% CI | | | M-H, Fixed, 95% Cl |
| Test for overall effect: Z=0.65(P=0.52) | | | | | | | | | |
| | | | | | | | | | |
| Total (95% CI) | 353 | 334 | | | - | | | 100% | 1.13[0.45,2.86] |
| Total events: 7 (Nitrous oxide-based) <u>;</u> haled anaesthesia) | , 7 (Intravenous con | nbined with in- | | | | | | | |
| Heterogeneity: Tau ² =0; Chi ² =2.9, df=6 | 6(P=0.82); I ² =0% | | | | | | | | |
| Test for overall effect: Z=0.26(P=0.8) | | | | | | | | | |
| Test for subgroup differences: Chi ² =0. | .84, df=1 (P=0.36), l ² | 2=0% | | | | | | | |
| | Favours n | itrous oxide-based | 0.02 | 0.1 | 1 | 10 | 50 | Favours intravenous anaesthesia | combined with inhaled |

Analysis 1.24. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 24 Pulmonary atelectasis: techniques used in the nitrous oxide-free group.

| Study or subgroup | Nitrous ox- ide-based | Intravenous combined with inhaled anaesthesia | | c | Odds Ratio | | | Weight | Odds Ratio |
|---|-------------------------------------|--|------|------|--------------|----|-----|------------------------------------|-----------------------|
| | n/N | n/N | | м-н, | Fixed, 95% C | 1 | | | M-H, Fixed, 95% Cl |
| 1.24.1 Propofol-based maintenanc oxide-free group | e of anaesthesia us | ed in the nitrous | | | | | | | |
| Jensen 1992 | 1/40 | 1/20 | - | | • | _ | | 13.31% | 0.49[0.03,8.22] |
| Jensen 1993b | 20/28 | 14/14 | - | - | | | | 57.38% | 0.08[0,1.56] |
| Subtotal (95% CI) | 68 | 34 | - | | | | | 70.69% | 0.16[0.02,1.06] |
| Total events: 21 (Nitrous oxide-based haled anaesthesia) | d), 15 (Intravenous c | ombined with in- | | | | | | | |
| Heterogeneity: Tau ² =0; Chi ² =0.79, df | =1(P=0.37); I ² =0% | | | | | | | | |
| Test for overall effect: Z=1.9(P=0.06) | | | | | | | | | |
| 1.24.2 Volatile anaesthetic-based r the nitrous oxide-free group | naintenance of ana | esthesia used in | | | | | | 20.210/ | |
| Eger 1990 | 2/126 | 3/134 | | | | | | 29.31% | 0.7[0.12,4.29] |
| Lampe 1990 | 0/13 | 0/13 | | | | | | | Not estimable |
| Subtotal (95% CI) | 139 | 147 | | | | | | 29.31% | 0.7[0.12,4.29] |
| Total events: 2 (Nitrous oxide-based) haled anaesthesia) |), 3 (Intravenous con | nbined with in- | | | | | | | |
| Heterogeneity: Tau ² =0; Chi ² =0, df=0(| P<0.0001); l ² =100% | | | | | | | | |
| Test for overall effect: Z=0.38(P=0.7) | | | | | | | | | |
| Total (95% CI) | 207 | 181 | | | | | | 100% | 0.32[0.09,1.12] |
| Total events: 23 (Nitrous oxide-based haled anaesthesia) | d), 18 (Intravenous c | ombined with in- | | | | | | | |
| Heterogeneity: Tau ² =0; Chi ² =1.63, df | =2(P=0.44); I ² =0% | | | | | | | | |
| Test for overall effect: Z=1.78(P=0.07) |) | | | | | | | | |
| Test for subgroup differences: Chi ² =1 | 1.24, df=1 (P=0.27), l ² | 2=19.25% | | 1 | | | | | |
| | Favours n | itrous oxide-based | 0.01 | 0.1 | 1 | 10 | 100 | Favours intravenous anaesthesia | combined with inhaled |

Analysis 1.25. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 25 Myocardial infarction: techniques used in the nitrous oxide-free group.

| Study or subgroup | Nitrous ox- ide-based | Intravenous combined with inhaled anaesthesia | Odd | s Ratio | Weight | Odds Ratio |
|--|---------------------------------------|--|----------|------------|---|-----------------------|
| | n/N | n/N | M-H, Fix | ed, 95% CI | | M-H, Fixed, 95% Cl |
| 1.25.1 Volatile anaesthetic-base the nitrous oxide-free group | ed maintenance of ana | esthesia used in | | | | |
| Chen 2013 | 4/31 | 4/60 | _ | | 28.16% | 2.07[0.48,8.93] |
| Eger 1990 | 1/14 | 3/16 | | | 30.85% | 0.33[0.03,3.64] |
| Kozmary 1990 | 1/18 | 3/16 | | | 35.59% | 0.25[0.02,2.74] |
| Singh 2011 | 1/41 | 0/46 | | + | - 5.4% | 3.44[0.14,86.92] |
| Subtotal (95% CI) | 104 | 138 | | | 100% | 0.96[0.37,2.53] |
| Total events: 7 (Nitrous oxide-bas haled anaesthesia) | ed), 10 (Intravenous cor | mbined with in- | | | | |
| Heterogeneity: Tau ² =0; Chi ² =3.62 | , df=3(P=0.31); l ² =17.1% | | | | | |
| Test for overall effect: Z=0.08(P=0 | .94) | | | | | |
| | | | | | | |
| Total (95% CI) | 104 | 138 | | | 100% | 0.96[0.37,2.53] |
| Total events: 7 (Nitrous oxide-bas haled anaesthesia) | ed), 10 (Intravenous cor | mbined with in- | | | | |
| Heterogeneity: Tau ² =0; Chi ² =3.62 | , df=3(P=0.31); l ² =17.1% | | | | | |
| Test for overall effect: Z=0.08(P=0 | .94) | | | | | |
| | Favours ni | trous oxide-based 0 | 0.01 0.1 | 1 10 | ¹⁰⁰ Favours intravenous anaesthesia | combined with inhaled |

Analysis 1.26. Comparison 1 Nitrous oxide-based versus nitrous oxidefree, Outcome 26 Stroke: techniques used in the nitrous oxide-free group.

| Study or subgroup | Nitrous ox- ide-based | Intravenous combined with inhaled anaesthesia | | C | dds Ratio | | Weight | Odds Ratio |
|--|--------------------------|--|------|------|---------------|---------------------------------------|------------------------------------|-----------------------|
| | n/N | n/N | | м-н, | Fixed, 95% CI | | | M-H, Fixed, 95% CI |
| 1.26.1 Propofol-based maintenance oxide-free group | of anaesthesia us | ed in the nitrous | | | | | | |
| Deleu 2000 | 2/26 | 0/25 | | _ | • | \longrightarrow | 20.92% | 5.2[0.24,113.98] |
| Subtotal (95% CI) | 26 | 25 | | _ | | | 20.92% | 5.2[0.24,113.98] |
| Total events: 2 (Nitrous oxide-based), haled anaesthesia) | 0 (Intravenous com | bined with in- | | | | | | |
| Heterogeneity: Not applicable | | | | | | | | |
| Test for overall effect: Z=1.05(P=0.29) | | | | | | | | |
| 1.26.2 Volatile anaesthetic-based m the nitrous oxide-free group | aintenance of ana | esthesia used in | | | | | | |
| Singh 2011 | 3/41 | 2/46 | | - | | _ | 79.08% | 1.74[0.28,10.95] |
| Subtotal (95% CI) | 41 | 46 | | - | | - | 79.08% | 1.74[0.28,10.95] |
| Total events: 3 (Nitrous oxide-based), haled anaesthesia) | 2 (Intravenous con | bined with in- | | | | | | |
| Heterogeneity: Not applicable | | | | | | | | |
| Test for overall effect: Z=0.59(P=0.56) | | | | | | | | |
| Total (95% CI) | 67 | 71 | | | - | - | 100% | 2.46[0.53,11.48] |
| Total events: 5 (Nitrous oxide-based), haled anaesthesia) | 2 (Intravenous com | bined with in- | | | | · · · · · · · · · · · · · · · · · · · | | |
| | Favours ni | trous oxide-based | 0.01 | 0.1 | 1 | 10 100 | Favours intravenous anaesthesia | combined with inhaled |

| Study or subgroup | Nitrous ox- ide-based | Intravenous combined with inhaled anaesthesia | | C | dds Ra | tio | | Weight Odds Ratio |
|--|--------------------------------|--|------|------|--------|--------|-----|---|
| | n/N | n/N | | м-н, | Fixed, | 95% CI | | M-H, Fixed, 95% Cl |
| Heterogeneity: Tau ² =0; Chi ² =0.36, df | =1(P=0.55); I ² =0% | | | | | | | |
| Test for overall effect: Z=1.15(P=0.25 |) | | | | | | | |
| Test for subgroup differences: Chi ² =0 | 0.36, df=1 (P=0.55), I | ² =0% | | | | | | |
| | Favours r | nitrous oxide-based | 0.01 | 0.1 | 1 | 10 | 100 | Favours intravenous combined with inhaled anaesthesia |

Analysis 1.27. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 27 Severe nausea and vomiting: techniques used in the nitrous oxide-free group.

| Study or subgroup | Nitrous ox- ide-based | Intravenous combined with inhaled anaesthesia | | Odd | s Ratio | | Weight | Odds Ratio |
|--|-------------------------------------|--|------|----------|------------|-----|------------------------------------|-----------------------|
| | n/N | n/N | | M-H, Fix | ed, 95% CI | | | M-H, Fixed, 95% CI |
| 1.27.1 Propofol-based maintenance oxide-free group | of anaesthesia use | d in the nitrous | | | | | | |
| Arellano 2000 | 2/710 | 1/707 | | | + + | - | 2.78% | 1.99[0.18,22.04] |
| Subtotal (95% CI) | 710 | 707 | | | | - | 2.78% | 1.99[0.18,22.04] |
| Total events: 2 (Nitrous oxide-based), haled anaesthesia) | 1 (Intravenous comb | vined with in- | | | | | | |
| Heterogeneity: Not applicable | | | | | | | | |
| Test for overall effect: Z=0.56(P=0.57) | | | | | | | | |
| 1.27.2 Volatile anaesthetic-based m the nitrous oxide-free group | aintenance of anae | sthesia used in | | | | | | |
| Mraovic 2008 | 12/91 | 5/46 | | | + | | 16.02% | 1.25[0.41,3.78] |
| Paredi 1994 | 3/30 | 0/30 | | | + | | 1.23% | 7.76[0.38,157.14] |
| Pedersen 1993 | 3/17 | 3/19 | | | + | | 6.48% | 1.14[0.2,6.6] |
| Sengupta 1988 | 5/33 | 3/31 | | | +• | | 7.29% | 1.67[0.36,7.65] |
| Short 1985 | 0/40 | 2/11 | ← | + | + | | 10.62% | 0.05[0,1.06] |
| Van Hemelrijck 1991 | 9/69 | 6/23 | | +- | + | | 21.75% | 0.43[0.13,1.36] |
| Vanacker 1999 | 21/91 | 16/93 | | - | ⊣∎ | | 33.83% | 1.44[0.7,2.99] |
| Subtotal (95% CI) | 371 | 253 | | | • | | 97.22% | 1.11[0.7,1.75] |
| Total events: 53 (Nitrous oxide-based) haled anaesthesia) | , 35 (Intravenous co | mbined with in- | | | | | | |
| Heterogeneity: Tau ² =0; Chi ² =8.99, df=6 | 6(P=0.17); I ² =33.26% | | | | | | | |
| Test for overall effect: Z=0.44(P=0.66) | | | | | | | | |
| Total (95% CI) | 1081 | 960 | | | | | 100% | 1.13[0.72.1.78] |
| Total events: 55 (Nitrous oxide-based) haled anaesthesia) | , 36 (Intravenous co | mbined with in- | | | | | | |
| Heterogeneity: Tau ² =0; Chi ² =9.22, df= | 7(P=0.24); I ² =24.05% | | | | | | | |
| Test for overall effect: Z=0.54(P=0.59) | | | | | | | | |
| Test for subgroup differences: Chi ² =0.2 | 22, df=1 (P=0.64), I ² = | 0% | | | | | | |
| | Favours nit | ous oxide-based | 0.01 | 0.1 | 1 10 | 100 | Favours intravenous anaesthesia | combined with inhaled |

Analysis 1.28. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 28 Wound infection rate: techniques used in the nitrous oxide-free group.

| Study or subgroup | Nitrous ox- ide-based | Intravenous combined with inhaled anaesthesia | | O | dds Ratio | • | | Weight | Odds Ratio |
|--|---|--|-------|--------|-----------|-------|-----|------------------------------------|-------------------------|
| | n/N | n/N | | M-H, R | andom, 9 | 5% CI | | | M-H, Random, 95% CI |
| 1.28.1 Volatile anaesthetic-base the nitrous oxide-free group | ed maintenance of ana | esthesia used in | | | | | | | |
| Chen 2013 | 10/31 | 6/60 | | | | | | 37.78% | 4.29[1.38,13.28] |
| Eger 1990 | 3/126 | 0/134 | | | | • | | 17.48% | 7.62[0.39,149.08] |
| Fleischmann 2005 | 31/206 | 40/202 | | | | | | 44.74% | 0.72[0.43,1.2] |
| Lampe 1990 | 0/13 | 0/13 | | | | | | | Not estimable |
| Subtotal (95% CI) | 376 | 409 | | | - | | | 100% | 2.13[0.44,10.22] |
| Total events: 44 (Nitrous oxide-ba haled anaesthesia) | ased), 46 (Intravenous co | ombined with in- | | | | | | | |
| Heterogeneity: Tau ² =1.36; Chi ² =9 | 0.77, df=2(P=0.01); l ² =79. | 53% | | | | | | | |
| Test for overall effect: Z=0.95(P=0 |).34) | | | | | | | | |
| | | | | | | | | | |
| Total (95% CI) | 376 | 409 | | | - | | | 100% | 2.13[0.44,10.22] |
| Total events: 44 (Nitrous oxide-ba haled anaesthesia) | ased), 46 (Intravenous co | ombined with in- | | | | | | | |
| Heterogeneity: Tau ² =1.36; Chi ² =9 | 0.77, df=2(P=0.01); l ² =79. | 53% | | | | | | | |
| Test for overall effect: Z=0.95(P=0 |).34) | | | | | | | | |
| | Favours ni | trous oxide-based | 0.005 | 0.1 | 1 | 10 | 200 | Favours intravenous anaesthesia | s combined with inhaled |

Analysis 1.29. Comparison 1 Nitrous oxide-based versus nitrous oxide-free, Outcome 29 Length of hospital stay: techniques used in the nitrous oxide-free group.

| Study or subgroup | Favou oxio | ırs nitrous le-based | Intrave bine haled a | enous com- d with in- anaesthesia | Mean Difference | Weight | Mean Difference |
|---|---------------|--------------------------|----------------------------|---|-----------------|-----------------------------|-----------------------------------|
| | N | Mean(SD) | Ν | Mean(SD) | Fixed, 95% CI | | Fixed, 95% CI |
| 1.29.1 Volatile anaesthetic-based n trous oxide-free group | naintena | ance of anaesth | esia used | l in the ni- | | | |
| Chen 2013 | 31 | 12.5 (10.3) | 30 | 10.2 (12.3) | | 0.96% | 2.3[-3.4,8] |
| Chen 2013 | 31 | 12.5 (10.3) | 30 | 9.7 (4.4) | | 1.99% | 2.8[-1.15,6.75] |
| Eger 1990 | 126 | 8.1 (5) | 134 | 7.8 (4.4) | - # - | 23.63% | 0.3[-0.85,1.45] |
| Fleischmann 2005 | 206 | 11.1 (4.9) | 202 | 11.6 (7.2) | | 21.71% | -0.5[-1.7,0.7] |
| Lampe 1990 | 13 | 7 (2.2) | 13 | 8.6 (3.2) | -+ | 6.99% | -1.6[-3.71,0.51] |
| Leung 2006 | 114 | 5.4 (3.5) | 114 | 4.8 (2.9) | | 44.72% | 0.6[-0.23,1.43] |
| Subtotal *** | 521 | | 523 | | • | 100% | 0.2[-0.36,0.75] |
| Heterogeneity: Tau ² =0; Chi ² =7.2, df=5 | (P=0.21) | ; I ² =30.56% | | | | | |
| Test for overall effect: Z=0.69(P=0.49) | | | | | | | |
| Total *** | 521 | | 523 | | • | 100% | 0.2[-0.36,0.75] |
| Heterogeneity: Tau ² =0; Chi ² =7.2, df=5 | (P=0.21) | ; I ² =30.56% | | | | | |
| Test for overall effect: Z=0.69(P=0.49) | | | | | | | |
| | | Favou | irs nitrous | oxide-based | -10 -5 0 5 10 | Favours intr inhaled ana | avenous combined with esthesia |



APPENDICES

Appendix 1. CENTRAL, the Cochrane Library

#1MeSH descriptor: [Nitrous Oxide] explode all trees #2(laughing gas or nitrous oxide or dinitrogen monoxide or dinitrogen oxide or factitious air or hyponitrous acid anhydride or nitrogen protoxide or N2O):ti,ab #3#1 or #2 #4MeSH descriptor: [Anesthesia, General] explode all trees #5general an?esth*:ti,ab #6surg*:ti,ab #7MeSH descriptor: [General Surgery] explode all trees #8(#4 or #5) and (#6 or #7) and #3

Appendix 2. MEDLINE (Ovid SP)

#1 exp Nitrous oxide/ or (laughing gas or nitrous oxide or dinitrogen monoxide or dinitrogen oxide or factitious air or hyponitrous acid anhydride or nitrogen protoxide or N2O).ti,ab.

#2 (General anesthesia/ or general an?esthesia.mp.) and (General surgery/ or surg*.mp.)

#3 ((randomized controlled trial or controlled clinical trial).pt. or randomized.ab. or placebo.ab. or clinical trials as topic.sh. or randomly.ab. or trial.ti.) not (animals not (humans and animals)).sh.

#4 #1 and #2 and #3

Appendix 3. EMBASE (Ovid SP)

#1 exp nitrous oxide/ or (laughing gas or nitrous oxide or dinitrogen monoxide or dinitrogen oxide or factitious air or hyponitrous acid anhydride or nitrogen protoxide or N2O).ti,ab.

#2 (general anesthesia/ or general an?esthesia.ti,ab.) and (general surgery/ or surg*.ti,ab.)

#3 (placebo.sh. or controlled study.ab. or random*.ti,ab. or trial*.ti,ab. or ((singl* or doubl* or trebl* or tripl*) adj3 (blind* or mask*)).ti,ab.) not (animals not (humans and animals)).sh.

#4 #1 and #2 and #3

Appendix 4. ISI Web of Science

TS=(laughing gas or nitrous oxide or dinitrogen monoxide or dinitrogen oxide or factitious air or hyponitrous acid anhydride or nitrogen protoxide or N2O) and TS=((general an?esth*) and surg*) and TS=(random* or (trial* SAME (control* or clinical)) or placebo* or multicenter* or prospective or ((blind* or mask*) SAME (single or double or triple or treble)))

Appendix 5. Data extraction form

Study selection form

First author

Journal/Conference proceedings etc

Year

Study eligibility

| RCT | Relevant partic- ipants (age over 18 years, having standard general anaesthesia) | Relevant interven- tions (nitrous ox- ide-based through- out duration of anaesthesia com- pared with nitrous oxide-free) | Relevant outcomes: Inhospital case fatality rate, pulmonary complications (pneumonia and pulmonary atelectasis), heart complica- tions (myocardial infarction), neurological complications (stroke), other complications (venous thromboembolism, wound infection rate and severe nausea and vomiting), length of stay (length of hospital stay and length of ICU stay) |
|-----|--|--|--|
| | | | |



(Continued)

Yes/No/Unclear

Yes/No/Unclear

Yes/No/Unclear

Yes/No/Unclear

Issue relates to selective reporting - when study authors may have taken measurements for particular outcomes, but not reported these within the paper(s). Review authors should contact study authors for information on possible non-reported outcomes and reasons for exclusion from publication. Study should be listed in 'Studies awaiting assessment' section until clarified. If no clarification is received after three attempts, the review authors should exclude the study.

Do not proceed if any of the above answers are "No". If study is to be included in the 'Excluded studies' section of the review, record below the information to be inserted into 'Table of excluded studies' section.

References to trial

Check other references identified in searches. If there are further references to this trial link the papers now and list below. All references to a trial should be linked under one Study ID in RevMan 5.3.

| Code each paper | Author(s) | Journal/Conference proceedings Year etc |
|------------------------|--------------------------------|--|
| A | The paper listed above | |
| В | Further papers | |
| Participants and tria | l characteristics | |
| Participant and tria | l characteristics | |
| Characteristics | | Further details |
| Age (mean, median, | range, etc) | |
| Number of participa | nts in each intervention group | |
| Sex of participants (| numbers/%, etc) | |
| Disease status/type, | etc? (if applicable) | |
| ASA physical status of | classification | |
| Type of surgery | | |
| Single centre/multi- | centre | |
| Country/Countries | | |
| | | |



(Continued)

Number of participants who were analysed

Trial design (e.g. parallel/cross-over*)

Other

Abbreviations: ASA: American Society of Anesthesiologists.

Details of intervention

Groups

Details of intervention

Nitrous oxide based group(concentration of inhaled N2O, O2 separately, duration of inhaled N2O)

Nitrous oxide-free group (inhaled gas, concentration of inhaled O₂)

Methodological quality

Allocation of intervention

| State here method used to generate allocation and reasons for grading | Grade (circle) |
|---|-----------------------------|
| Comment on allocation by review authors or included study quote concerning allocation | Adequate (random) |
| | Inadequate (e.g. alternate) |
| | Unclear |
| Concealment of allocation | |
| State here method used to generate allocation and reasons for grading | Grade (circle) |
| Comment on allocation by review authors or included study quote concerning allocation | Adequate (random) |
| | Inadequate (e.g. alternate) |
| | Unclear |
| Blinding | |
| Person responsible for participants' care | Yes/No |
| Participant | Yes/No |
| Outcome assessor | Yes/No |
| Other (please specify) | Yes/No |



(Continued)

Intention-to-treat

All participants entering trial

15% or fewer excluded

More than 15% excluded

Not analysed as "intention-to-treat"

Unclear

Were withdrawals described? Yes/No/Unclear

Discuss if appropriate

| Code of pa- per | Outcomes | Unit of mea- surement | N ₂ O-based group | | N ₂ O-free group | | Details if outcome only de- scribed in text |
|--------------------|---------------------------|--------------------------|------------------------------|------|-----------------------------|------|--|
| | | | n | Mean | n | Mean | |
| econdary ou | tcomes | | | | | | |
| | Duration of hospital stay | | | | | | Yes/No |
| | Duration of ICU stay | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |



| For dichotomous data | | | | | |
|----------------------|-------------------------------|---|--|--|--|
| Code of paper | Outcomes | N ₂ O-based group(n) n = number of partici- pants, not number of events | N ₂ O-free group(n) n = number of partici- pants, not number of events | | |
| Primary outcomes | | | | | |
| | Inhospital case fatality rate | | | | |
| Secondary outcom | es | | | | |
| | Pneumonia | | | | |
| | Pulmonary atelectasis | | | | |
| | Myocardial infarction | | | | |
| | Stroke | | | | |
| | Severe nausea and vomiting | | | | |
| | Venous thromboembolism | | | | |
| | Wound infection rate | | | | |
| | | | | | |

Other information which you feel is relevant to the results

Indicate if: any data were obtained from the primary study author; if results were estimated from graphs etc; or calculated by you using a formula (this should be stated and the formula given). In general if results not reported in paper(s) are obtained this should be made clear here to be cited in review.

CONTRIBUTIONS OF AUTHORS

Rao Sun (RS), Wen Qin Jia (WQJ), KeHu Yang (KHY), Jin Hui Tian (JHT), Bin Ma (BM), Yali Liu (YL), Run H Jia (RHJ), Peng Zhang (PZ), Xiao F Luo (XFL), Akira Kuriyama (AK):

- KHY and WQJ conceived the review.
- KHY and JHT coordinated the review.
- BM and YL undertook manual searches of the literature.
- WQJ and RS screened search results.
- WQJ, JHT, and RS organized retrieval of papers.
- WQJ and RS screened retrieved papers against the inclusion criteria.
- RS and BM appraised the quality of the papers.
- RS, WQJ, and AK: abstracted data from papers.
- RS, PZ, and AK wrote to authors of papers for additional information.
- WQJ, RS, PZ, and AK provided additional data about papers.



- YL and BM obtained and screened data on unpublished studies.
- RS and JHT performed data management for the review.
- XFL and RS entered data into RevMan 5.3.
- XFL and RS performed statistical analyses using RevMan 5.3.
- XFL and RS performed statistical analyses using Stata 11.0.
- RS, JHT, and WQJ performed other statistical analyses without RevMan 5.3.
- JHT and RS performed double entry of data: person one: JHT; person two: RS.
- WQJ and RS interpreted the data.
- RS and XFL assessed statistical inferences.
- KHY, RS, and RHJ wrote the review.
- KHY secured funding for the review.
- JHT and WQJ performed previous work that was the foundation of the present review.
- KHY is guarantor for this Cochrane review.
- KHY and RS were responsible for reading and checking the review before submission.

DECLARATIONS OF INTEREST

Rao Sun: none known. Wen Qin Jia: none known. KeHu Yang: none known. Jin Hui Tian: none known. Bin Ma: none known. Yali Liu: none known. Run H Jia: none known. Peng Zhang: none known. Xiao F Luo: none known. Akira Kuriyama: none known.

SOURCES OF SUPPORT

Internal sources

• Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, China.

External sources

• No sources of support supplied

DIFFERENCES BETWEEN PROTOCOL AND REVIEW

Authors: we have changed the author list from the published protocol (Yang 2011). Rao Sun and Akira Kuriyama joined the review author team.

Types of interventions: we replaced 'total intravenous anaesthesia' and 'inhaled anaesthesia' with the more precise descriptions of 'propofol-based maintenance of anaesthesia' and 'volatile anaesthetic-based maintenance of anaesthesia', respectively.

Data collection and analysis: we used the most recent of the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011) for 'Risk of bias' assessment, and we generated 'Risk of bias' tables. We also used RevMan 5.3 for statistical analyses.

Selection of studies: the full texts we obtained provided sufficient information for us to determine their eligibility. Therefore, we did not correspond with the original study investigators.

Measures of treatment effect: the data expressed as median and the interquartile range values may be skewed. To avoid introducing potential bias, we only pooled the data expressed as mean and standard deviation for length of stay.

Assessment of reporting biases: we conducted Egger's test to examine asymmetry of the funnel plot.

Data synthesis: where we did not conduct meta-analysis, we described the findings of the included studies qualitatively. We stated the implementation of GRADE methods and the selection of outcomes in the 'Summary of findings' tables.

Subgroup analysis and investigation of heterogeneity: we stated the details of grouping in the subgroup analysis.

Nitrous oxide-based techniques versus nitrous oxide-free techniques for general anaesthesia (Review) Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



Sensitivity analysis: we conducted sensitivity analyses based on the percentages of withdrawals (above 10% versus below 10%) of the included RCTs.

INDEX TERMS

Medical Subject Headings (MeSH)

Anesthesia, General [*adverse effects] [methods]; Anesthetics, Inhalation [*adverse effects]; Myocardial Infarction [etiology]; Nausea [etiology]; Nitrous Oxide [*adverse effects]; Pneumonia [etiology]; Pulmonary Atelectasis [etiology]; Randomized Controlled Trials as Topic; Stroke [etiology]; Surgical Wound Infection [etiology]; Venous Thromboembolism [etiology]; Vomiting [etiology]

MeSH check words

Adult; Humans